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Short abstract 
Cancer survival is poorer in rural NSW but specialist cancer surgical services are 
predominately located in the Sydney region. The aim of this thesis is to examine whether 
increasing distance from cancer surgical services affects access to those services and 
ultimately cancer survival after adjusting for patient, cancer and treatment factors. The first 
objective was to explore and discuss the literature as well as methodological issues 
associated with measuring distance and cancer survival. The second objective was to 
determine the influence of actual distance to surgical services on cancer survival for patients 
with bladder cancer and distance to the closest specialist service for patients with ovarian 
and lung cancer. Factors known to mediate survival were also investigated, including 
whether advanced or unknown stage cancer or the patient not receiving surgery were 
associated with increasing distance to a specialist hospital and whether these influenced the 
hospital of treatment. The method used was population based data linkage for patients 
diagnosed between 2000 and 2008 (data obtained from the NSW Central Cancer Registry 
database and linked to hospitalisations in the Admitted Patients Data Collection) and 
followed to the end of 2008. Distance was measured in kilometres from a person’s home to 
their hospital of surgery (bladder cancer) or the closest specialist hospital (ovarian and lung 
cancer) by using geographical coordinates based on address information and the “Great 
Circle Distance Calculator”.   Associations were modelled using logistic and multinomial 
logistic regression and the hazard of death was modelled using Cox regression and the 
survival time parametric method (stpm2). 
Results The hazard of death decreased with distance to hospital of surgery for people with 
bladder cancer who had a cystectomy but not for people who had another type of surgical 
resection. People with ovarian and lung cancer who lived further from specialist surgical 
hospitals were much more likely to attend general hospitals for their care than people who 
lived near a specialist hospital. People admitted to general hospitals were more likely to have 
advanced or unknown stage cancer at diagnosis and to have limited or no surgery. Treatment 
in a specialist hospital and surgery were the best predictors of survival in women with 
 xiii 
ovarian cancer. The same was true for people with lung cancer. With increasing distance, 
people with lung cancer who attended specialist hospitals had less advanced cancer 
suggesting greater selection for operability. 
Understanding the factors that impede referral to and attendance at specialist surgical 
hospitals for NSW residents particularly those who live remotely is essential if everyone is 
to have the best chance of cancer survival regardless of where they live. 
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Long abstract 
In 2012, 30 per cent of the Australian population and cancer patients lived in rural and 
remote areas. The challenge for people diagnosed with cancer particularly those who live in 
rural and remote locations is that medical specialists and specialist surgical hospitals are 
predominantly located in cities. Centralisation of services is important to ensure a 
concentration of clinical expertise and surgical volume both known to be associated with 
cancer survival. Distance from treatment is an access measure that takes into account the 
distance from a person’s home to appropriate affordable treatment and ultimately whether 
that person receives treatment. Previous studies of distance to treatment on cancer survival 
had limitations. Many were not population-based with limited or no stage information and 
did not take account of the hospital of treatment or include surgery. Adjustment for a 
number of patient, tumour and treatment factors known to influence cancer survival was also 
not possible because the information was not available. 
Most studies of distance and cancer survival assumed that people who were diagnosed with 
cancer died from it because cause of death information was not available to them or was of 
poor quality. Linkage of cancer registry data to hospital data and the ability to measure 
distance, stage at diagnosis and cause of death for people in NSW provides a comprehensive 
population-based dataset to enable the investigation of the impact of distance to specialist 
care. The aim of this thesis is to examine whether increasing distance from cancer surgical 
services affects access to those services and ultimately cancer survival after adjusting for 
patient, cancer and treatment factors. This issue was examined for three cancer types, 
namely bladder, lung and ovarian cancers 
Chapter 1 
Chapter 1 reviews the current literature on distance from the patients home to treatment for 
any health condition and then specifically for cancer treatment. This chapter examines 
literature on why distance to treatment is important, particularly, in the current policy 
framework of specialisation and centralisation of services. An individual’s health problem 
and the availability of services determine whether a person needs to travel to access that 
service. 
 xv 
There are a number of ways of measuring distance to health services. Previous health related 
studies using straight-line distance to treatment and outcome are discussed. When a patient’s 
health problem is an emergency, for example in the case of acute myocardial infarction 
(AMI), longer time to care significantly influences a patient’s survival because urgent 
immediate care and, therefore, proximity to services is important. 
Increasing distance from treatment may affect whether a person with cancer refuses or has 
the suboptimal alternative because it involves less travel. For example, radiotherapy requires 
daily visits for a number of weeks. The recommended treatment for women with early stage 
breast cancer is a lumpectomy and radiotherapy, with mastectomy recommended for women 
whose cancer has spread beyond the breast. However, a number of registry studies report 
that women with early stage breast cancer are more likely to have a mastectomy with 
increasing distance to radiotherapy so that they do not have to attend radiotherapy. 
Distance to treatment can also depend on the type of cancer and the range of treatments 
available. Surgical services are often located in cities because of the policy framework that 
supports the centralisation and specialisation of surgical services. 
Surgery (both the likelihood and the type )depends on the stage of cancer at the time of 
diagnosis and is often the definitive treatment for cancers where the primary tumour has not 
spread beyond the organ of origin. In this thesis three cancer sites: bladder, ovarian and lung 
cancer are examined in detail. Stage at diagnosis, whether patients undergo surgery and 
whether treatment occurs in specialist hospital is examined to determine what impact these 
factors have on cancer survival. Therefore, these issues are emphasised in this review. 
Literature associated with patient, tumour and treatment factors that could confound the 
relationship between distance and survival is examined. International and Australian best 
practice clinical guidelines for bladder, ovarian and lung cancers are also reviewed. 
Finally, specific aims of this thesis are outlined. The first two questions of interest are 
methodological and underpin subsequent analyses. Firstly, how valid is the measure of 
distance in NSW? Secondly, does it matter whether we use cause specific or relative survival 
 xvi 
methods? What effect do different methods of allocating cause of death have on our survival 
estimates? 
The remaining aims relate to the three cancers of interest with the questions influenced by 
what is already known about their cancer survival. Bladder cancer survival in NSW is poorer 
in women than it is in men. However, unknown is whether distance from the patient's home 
to where they have surgery (cystectomy or resection) explains this survival difference. 
Survival from ovarian cancer in NSW is influenced by stage at diagnosis and histological 
subtype, but also unknown is whether distance to specialist care influences access to that 
care, a woman’s likelihood of having surgery or ultimately survival. 
Surgery is the recommended treatment for people who are diagnosed with non small cell 
lung cancer and survival is higher when the tumour is localised to the lung. Therefore, does 
distance from the nearest accessible specialist hospital increase the likelihood of presenting 
with a tumour of advanced or unknown stage? Or the likelihood of having no surgery? 
Moreover, how do both of these factors affect survival from lung cancer after adjustment for 
patient, cancer and treatment factors? 
Chapter 2 
The objective of this chapter is to present the methods used to geocode the longitude and 
latitude coordinates of a person’s residential address at the time they were diagnosed with 
cancer as it appears on the NSW Central Cancer Registry. The quality checks undertaken to 
consider the validity of allocating geographic areas and distance using these geocodes is 
discussed. Historically, the patient address at diagnosis in the NSW Cancer Registry 
allocates a defined geographic region based on the Australian Standard Geographical 
Classification (ASGC) using an Australian Bureau of Statistics (ABS) National Locality 
Index (NLI) coder. A comparison of the number of people with cancer determined using the 
LGA for the census period 2001 is undertaken. Little difference between the numbers of 
cancer patients derived from the historical method compared to the new geocode derived 
LGA occurred. This shows that the new method produced similar results. In addition, mean 
distance from each LGA to Royal Prince Alfred Hospital (RPA), by period of diagnosis and 
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by Area Health Service of Residence (AHS) provided further evidence that distance in 
kilometres was calculated correctly. 
Chapter 3 
This chapter investigates relative, net and cause specific cancer survival methods for breast, 
prostate, colorectal and lung cancer at each month from diagnosis up to 12 months and then 
each year up to 8 years to determine the impact that different methods have on cancer 
survival. This was necessary to ensure that differences in survival results were true and not 
due to methodological artefact  
Survival estimates using different methods were compared in the New South Wales Central 
Cancer Registry (CCR) and a UK registry, the Northern and Yorkshire cancer registry 
(NYCR), which has a similar population size to NSW. Many studies of straight-line distance 
to cancer treatment were conducted in northern England using this registry. It is important to 
know whether different methods of measuring survival and allocating the cause of death 
affect the reporting of cancer survival. 
The cause of cancer death for cases in the NYCR is allocated using similar rules to the CCR. 
Differences in five year age adjusted survival estimates between NSW and Northern and 
Yorkshire (NY) were calculated. Survival estimates in NSW were found to be similar at 
each period from diagnosis regardless of survival method used and for each cancer site 
investigated. A four-percentage point difference in survival estimates for bowel cancer at 
five years was explained by the differences in the cause of death allocation. Differences in 
registry practices and implications associated with the cause of cancer death allocation are 
discussed. Cause specific is an acceptable alternative to the relative method for reporting 
cancer survival. The method is also easier to implement because life tables are not required 
making the adjustment of patient, tumour and treatment factors easier to model. Cancer 
survival in NSW was 5-11% higher than in NY at five years (depending on cancer site). 
Higher survival in NSW is real and not artefact due to differences in survival methods or 
differences in the allocation of the cause of death between registries. 
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Chapter 4 
This chapter addresses whether increasing distance from the patient's home to where they 
have surgery (cystectomy or resection) is associated with poorer survival and whether this 
factor explained the previously observed poorer survival in women relative to men. This 
study included an analysis of linked data population cancer registry and hospital data for 
6,880 people diagnosed with bladder cancer between 2000 and 2008. Distance was 
measured in kilometres from the person’s home to their hospital of surgery or their first 
hospital if they had no surgery. 
The estimated five year, cause specific survival from bladder cancer was 56 per cent for 
women diagnosed in NSW in 2000-08 and 68 per cent in men (P<0.0001). This poorer 
survival in women was observed regardless of whether they had a cystectomy or resection 
(including endoscopic destruction) or had no specific therapy. 
Adjustment for a wide range of other variables associated with survival had little impact on 
women’s higher risk of death from bladder cancer following cystectomy.  
The higher risk of death in women relative to men undergoing a cystectomy reduced after 
adjusting for the following factors summary stage, age at diagnosis, distance from treatment 
facility and, the presence of haematuria, country of birth and time to cystectomy. 
Patients who had a cystectomy had a greater hazard of death if they lived within 25 
kilometres of a treatment facility than if they lived further from the hospital: 26 to 75 km 
(Hazard Ratio (HR) 0.61 95% Confidence Interval (CI) 0.43-0.88), 76 to 125 km (HR 0.50 
95%CI 0.29-0.88) or 125 km or further away. Specialty of hospital was not investigated 
because there are no Australian guidelines that recommend treatment in them. The reduction 
in death is consistent with patients experiencing better survival because they travelled 
further to a hospital in Sydney. Examination of interactions between sex and other covariates 
found a possibly meaningful interaction of sex with a history of cystitis in influencing death 
after cystectomy (HR was 1.55, 95%CI 1.15-2.10) in women with a history of cystitis. No 
such interaction was evident in women who underwent resection. Poorer survival in women 
diagnosed with bladder cancer remains unexplained. 
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Chapter 5 
In contrast, this chapter considers an area of cancer surgical care where patients should be 
treated in specialist centres by gynaecological oncologists but can also be treated in general 
hospitals by gynaecologists or general surgeons. The questions of interest include 
1. Does distance from, and access to the closest Gynaecology Oncology Service affect 
ovarian cancer survival? 
2. What are the characteristics of women treated in public hospitals? and 
3. What factors influence the likelihood of surgery? These questions are important because 
guidelines recommend that all women should be referred to a gynaecological oncologist if 
they are to have the best survival outcomes. 
Access to a gynaecological oncology service (GOS) was measured in kilometres from a 
woman’s geocoded address to the geocoded address of the closest public GOS hospital. 
Flexible parametric survival, Cox proportional hazards and logistic regression models were 
fitted to examine whether better access to a GOS was associated with a better outcome. 
There were 3,749 women diagnosed with ovarian cancer between 2000 and 2008. The 
aspects of care that most strongly reduced a woman’s hazard of dying from epithelial 
ovarian cancer were treatment in a GOS hospital (HR 0.68 95%CI 0.56-0.83), or private 
general hospital and having appropriate surgery (HR 0.35 95%CI 0.28-0.43). Women were 
more likely to attend a GOS hospital the nearer they lived to one and more likely to have 
appropriate surgery if they were treated in GOS hospitals. 
Thus, distance was an important factor in determining whether women would receive the 
best care for their ovarian cancer. With increasing distance to a specialist centre, women 
who attended specialist hospitals had less advanced cancer suggesting greater selection for 
operability. Understanding what factors impede referral of women with ovarian cancer to 
gynaecological oncology services, particularly when women live remotely from such 
services, is important. 
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Chapter 6 
• what the research questions are,  
• why they are important,  
• how the research questions were answered, what was found and  
what the implications are. Having some consistent structure to these sections would add 
greatly to the clarity, and this may require a substantial rewriting of the Long Abstract. 
The next three chapters focus on exploring issues of distance to the closest specialist hospital 
in 11,147 people diagnosed with non small cell lung cancer in NSW between 2000 and 2008 
and admitted to hospital within 12 months of diagnosis. This chapter focuses on the question 
"Are patients who live further from the nearest accessible specialist hospital (NASH) more 
likely to have advanced or unknown stage non small cell lung cancer (NSCLC) at 
diagnosis”? This is important because appropriate staging is necessary before surgery can be 
considered and because treatment options are limited when patients present with advanced 
disease. 
Distance from the patient's home to the NASH was measured in kilometres. Two groups of 
potential predictor variables were considered for inclusion in multivariate models based on 
temporality: (1) those variables that were plausibly associated with and antecedent to stage 
at diagnosis; and (2) variables not antecedent to stage but likely to be associated with 
accuracy and completeness of clinical determination of stage and its reporting to the CCR. 
People diagnosed with NSCLC and treated in general hospitals had 40% to 60% higher odds 
of advanced stage cancer than people treated in specialist hospitals that lived 0-39 km from 
the NASH. The opposite was true for people who attended a specialist hospital. In people 
with unknown stage at diagnosis, distance from the NASH, hospital of treatment and the 
odds of unknown stage showed a similar pattern to that observed for advanced stage. With 
increasing distance to a specialist centre, people who attended specialist hospitals had less 
advanced or unknown stage cancer suggesting greater selection for operability. 
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Chapter 7 
This chapter asks the question 
Does increasing distance from the NASH determine whether 3,240 people diagnosed with 
localised NSCLC are admitted to a specialist or general hospital within 12 months of their 
date of diagnosis and do they miss out on potentially curative surgery? This is important 
because guidelines recommend curative surgery for all patients with localised NSCLC and 
curative surgery improves survival. 
Cancer registry, hospital and death records were linked. Distance from, the patient's home to 
the NASH was measured in kilometres. People diagnosed with localised NSCLC were 30 
times more likely to be admitted to a general hospital when they lived 100+ kilometres from 
the NASH. People treated in specialist hospitals (public or private), were more likely to have 
surgery with increasing distance when treated in a specialist hospital, confirming that with 
increasing distance from the NASH people were selected depending on their suitability for 
surgery. 
Chapter 8 
While the previous chapter addressed the likelihood of having NSCLC removed surgically, 
Chapter 8 addresses the question 
Is survival for people with NSCLC poorer with increasing distance to the NASH and do 
factors predictive of survival vary by stage at diagnosis? This is an important question 
because survival is influenced by stage at diagnosis as is the likelihood of undergoing 
curative surgery. Therefore, stratifying by stage and examining surgery while adjusting for 
other factors is important to better understand the factors influencing distance. 
This analysis included 3,240 people with localised NSCLC, 2,435 regional stage and 3,540 
people with distant stage hospitalised within 12 months of their date of diagnosis. Distance 
from the person’s home to the NASH was measured in kilometres. Cox proportional hazards 
models examined predictors of death for people diagnosed with NSCLC. People who had a 
surgical resection for their cancer, which admission to a specialist hospital made more likely, 
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were much less likely to die. People were less likely to have a resection the further they 
lived from the NASH. However, people who lived distant from the NASH and who were 
admitted to a specialist hospital were more likely to have a resection and were less likely to 
die. These patterns varied little with lung cancer stage. 
Greater distance to the NASH can affect a person’s outcome by reducing the likelihood of 
them being treated in a specialist hospital. Research is needed into health service barriers to 
referral of people with NSCLC to enable them to obtain specialist care, increasing their 
likelihood of surgery and, therefore, reducing their likelihood of death. 
Chapter 9 
Chapter 9 provides an overall discussion of common findings in relation to cancer survival 
in NSW and the impact of distance from and access to cancer surgical services for people 
with bladder, ovarian and lung cancer. Attendance at a specialist hospital and having surgery 
contributed to better survival. People who lived further from a specialist hospital were more 
likely to have advanced or unknown stage, be treated in a general hospital and not receive 
potentially curative surgery. 
The aims of each of the studies are revisited and placed in context with findings in the 
literature and previous registry based patterns of care studies in NSW. Particular emphasis is 
given to the literature on clinician referral prior to diagnosis, factors that influence who sees 
a specialist and travel barriers to surgery for people living further from specialist care. This 
chapter also discusses limitations and implications for current practice. It also suggests 
recommendations that may assist people who are diagnosed with cancer in NSW to obtain 
better specialist surgical care and outcomes regardless of where they live. 
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1.1. Introduction 
The relationship between distances to appropriate treatment and cancer survival is complex 
and multifactorial. Distance from treatment is an access measure that takes account of the 
distance from a patient's home to appropriate affordable treatment and ultimately whether a 
person receives treatment. Improvements in cancer survival are widely accepted as the 
definitive outcome for people diagnosed with cancer and the goal of cancer treatment. 
The aim of this thesis is to examine whether people with cancer in New South Wales (NSW) 
have poorer survival when they live further from specialist surgical care. Three cancer types, 
namely bladder, lung and ovarian cancer are examined in detail. 
Previous studies have shown that the impact of distance to surgical care varies by cancer 
type.. Bladder cancer patients are often referred to urologists while lung cancer patients are 
referred to a thoracic physician or surgeon for specialist assessment. Gynaecologists or 
gynaecological oncologists treat ovarian cancer patients.  
Specialist services are influenced by the availability of clinical practice guidelines. There are 
Australian clinical practice guidelines exist for people diagnosed with lung and ovarian 
cancer, but none for bladder cancer. Therefore, designated specialist centres were 
determined for lung and ovary but not for bladder cancer 
. The number and location of specialist services are also influenced by health service 
policies.  Australian, US, and UK policies that specifically focus on access to specialist care 
for cancer are examined in chapter 1. 
Specific emphasis is given to stage at diagnosis and the receipt of surgery as factors that may 
mediate the relationship between distance and specialist care. Patient, tumour and treatment 
factors likely to mediate the effect of distance on cancer survival are also considered. 
1.2. Cancer in rural Australia 
Distance from a patient’s home to specialist care and hospital of treatment is important in 
Australia and NSW because Australia is a large continent with a dispersed population 
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mainly located in cities and coastal regions. In 2013, 30 per cent of the Australian population 
and cancer patients lived in rural and remote areas.1, 2 
This thesis focuses on people living in NSW. NSW is 800,642 square kilometres3 in size and 
is the most populated state in Australia with 7.41 million people or 32% of the Australian 
population1. Overall, NSW has a population density is 9.3 persons per 1000 square 
kilometre, but in reality, most people live in the metropolitan Sydney region or Greater 
Sydney (4.67 million or 63% of the population).1 
Cancer is unique compared to other diseases because improvements in cancer survival can 
be measured using mandatory data collections that cover the entire population. Cancer 
registries have registered new cases of cancer, cancer deaths and survival for over 40 years 
in many countries including Australia.4-6 In 2012 an estimated 120,700 Australians were 
diagnosed with cancer7 with approximately a third or 37,525 new cases diagnosed in NSW.8 
Compared to people living in major cities, higher death rates for specific cancers, 
particularly lung cancer, is reported in people living in remote and very remote areas of 
Australia and NSW. Furthermore, while death rates from cancer have been declining since 
the 1990s in Australia, they are declining at a much slower rate in rural areas than they are 
for urban areas. 2, 7, 9 , 10 
Poorer cancer survival in rural and remote areas of Australia and NSW is reported for many 
cancer sites. 2, 7, 11, 12Poorer cancer survival in people who live further away from treatment 
may be explained by a number of factors including lack of timely detection due to lower 
numbers of general practitioners (GPs) per head of population,13, 14 the limited availability of 
diagnostic equipment,  diagnosis at an advanced stage, 12, 15, 16 limited treatment 17 or 
suboptimal treatment.18, 19 Even after taking account of age, stage, socioeconomic status and 
type of cancer, people living in rural areas of NSW have been found to be less likely to be 
diagnosed with localised cancer.20 
Treatment for cancer can only commence once diagnosis has occurred, with the type of 
treatment strongly influenced by the stage at diagnosis. In Australia, patients present either 
to their GP or to the emergency department of their local hospital with symptoms or their 
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cancers are diagnosed incidentally as part of another investigation. Referral patterns from 
GPs to specialist doctors influence treatment options. Treatments for people with bladder, 
lung and ovarian cancer include surgery, chemotherapy, radiotherapy or a combination of 
therapies and may include palliative care if curative treatment is not an option. 
People concerned about symptoms need to access a GP and other cancer health professionals 
to obtain a diagnosis, referral and follow up treatment. Rural Health Services in Australia 
and NSW are smaller and dependent on services provided by GPs.13, 14 The ratio of primary 
and secondary health care professionals in rural populations (GPs, registered nurses and 
allied health staff) is significantly lower than in urban populations. 21 A similar pattern is 
observed for oncology services in rural and regional Australia where a survey of 160 rural 
hospitals (98% response rate) reported significant deficiencies in services including that only 
21% had a medical oncology service, 7% had radiation oncology service, 6% had surgical 
oncology and 24% a palliative care specialist.21 
Rural lung cancer patients have more symptoms and take longer to consult their GPs leading 
to a later diagnosis and fewer treatment options.22 Surveyed residents in rural areas believed 
that they waited longer for a GP appointment (23% in Rural and Remote;16% in Urban 
Areas).23 In addition, people in rural and remote areas in Queensland were over four times 
more likely to report difficulty accessing health services than those living in major cities 
(odds ratio (OR) 4.3  95% CI 2.72-6.80).24 
Surgery (to remove cancerous tissue from the body) is the oldest cancer therapy available. 
The goal of surgery varies. It can be used to diagnose cancer, determine where it is located 
and whether it has spread to other organs in the body.25 For patients whose cancer is 
localised to the organ of origin, surgery, is often the definitive treatment. 23, 26 Lower post-
operative mortality27-29 and better long term survival has been found when patients are 
treated by specialists30, 31 in specialist hospitals32, 33 or hospitals with high volume surgical 
procedures for cancer.34 35, 36 
The challenge for Australian and NSW residents and cancer patients from remote and rural 
locations is that specialist hospitals are located mainly in the cities. To access specialist 
doctors, people need a referral to one or more specialists and therefore care coordination.37 
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They will also need to travel to the city. Many may need to obtain accommodation and take 
time off from work and family commitments. Any one of these factors could be a barrier to 
timely diagnosis, surgery and other treatment options and ultimately explain why survival is 
poorer in rural and remote regions. 
Treatment in specialist hospitals has many other advantages. Apart from best practice 
surgery, patients treated in specialist centres have access to multidisciplinary team review 
which has recently been shown in an Australian study to be an independent predictor of 
survival:38, 39 Furthermore, surgery in a private hospital40 or having private health insurance 
has also been shown to improve survival outcomes. 41-48 Even patients with lung cancer who 
are older or those with comorbidities, have a survival advantage if they have surgery in a 
high volume specialist centre.36, 49 For patients for whom surgery is not an option, attendance 
at a specialist centre will also increase the likelihood of clinical trial participation.50-52 
Few population-based studies have examined the impact on cancer survival of access to and 
receipt of best practice cancer surgery. There have been a number of patterns of care studies 
in Australia and in NSW for cancers of the lung, 53-56 ovary, 57 breast41 and colorectum.58 
Many of these studies have documented surgical management but have not examined cancer 
survival. More recently, linkage of cancer registry data to hospital data has enabled the 
examination of surgical treatment in cancer patients. Many early data linkage studies were 
conducted in Western Australia (WA) 42, 46, 59-61 and more recently in Queensland.17, 62 These 
studies have examined rural and urban differences in access to surgery and survival but they 
have either not taken into account stage at diagnosis (WA) or hospital of treatment 
(Queensland). 
The studies reported in this thesis are possible due to reasons unique to NSW. Firstly, the 
NSW CCR routinely records summary stage (extent of disease) at diagnosis along with other 
patient and tumour information. Hospital and surgical treatment information, available from 
the NSW Admitted Patient Data Collection (APDC) is linked to the CCR. Geocoding of the 
CCR has also enabled distance to be measured to surgical services. Furthermore, recently, a 
number of comparative studies have compared linked NSW data for lung, colorectal cancer63 
and prostate cancer64 with patterns of care data and have concluded that linked routinely 
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collected data in NSW provides accurate information on potentially curative surgical 
treatment. 
This chapter, initially, examines the literature on the impact of distance from a person’s 
home to a health service for people with any condition. Next, appraised are studies of 
distance to cancer services and specialist surgical services. Priority is given to studies that 
focus on cancer registry linked data for bladder, ovarian and lung cancer. Discussed also are 
relevant papers for other cancer sites particularly those that consider straight-line distance 
from surgical treatment and cancer survival. 
1.3. Access to health services in rural Australia 
There are a number of ways of measuring distance to and access to services. Currently, the 
majority of Australian studies that have examined the impact of distance to treatment and 
access to services in Australia have used the Accessibility/Remoteness index for Australia 
(ARIA).65, 17, 66-69 2, 11, 70This index is based on five categories: highly accessible, accessible, 
moderately accessible, remote and very remote based on groupings of the ASGC.71, 65, 72 
National and state cancer registry reports2, 11 of five year relative survival by ARIA grouping 
report poorer survival for cancers of the bowel, breast (female), liver, lung, ovary, pancreas, 
stomach and tongue in rural areas.11 Poorer survival in rural areas could be due to many 
factors including presentation at a late stage or limited treatment options. Population-based 
ecological studies of cancer survival provide some understanding of the effects of cancer 
stage and treatment. 
One of the earliest studies of cancer survival in NSW that also took account of cancer stage 
12 reported that rural residents in NSW had 35% poorer survival compared to those living in 
urban areas. This study examined cancer survival by ARIA grouping for 20 cancer sites in 
NSW and found higher risks of death for people with cancers of cervix, prostate and for all 
cancers combined, with significant variations in other cancer sites. After adjusting for stage 
at diagnosis, the risk of death for cancer sites combined reduced to 25%. Not all people had 
lower survival in remote areas. People with lung cancer were more likely to die when they 
lived in moderately accessible areas even after adjusting for stage. This suggests that 
variation in treatment or other factors may influence survival. 
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A number of Queensland studies17, 69 have examined whether survival was lower in rural and 
remote regions due to treatment differences by comparing incidence, mortality and surgical 
procedures by ARIA grouping. Baade et al. 17 examined whether access to surgery varied for 
men with prostate cancer depending on urban or rural residence at the time of diagnosis. The 
authors reported that while incidence rates were similar for men in urban and rural areas 
(indicating similar risk profiles), rates of surgery (radical prostatectomy 182.2/100000 Rural 
v 239.2/100000 Urban; P<0.01) were lower in rural areas. Furthermore, death rates were 
higher in rural areas (56.9/100000 Rural v 45.8/100000 Urban P<0.01) and survival poorer 
(5-year relative survival, 87.7% Rural v 91.4% Urban; P<0.01) in rural areas.17 
Access to and use of health services in Australia using ARIA groupings have been more 
thoroughly investigated in women than men, mainly because of the contribution of the 
Australian Longitudinal study of Women’s Health.73-76 This study included three cohorts of 
women interviewed regularly over a 17-year period. Overall, women were found to have less 
access to bulk billing GPs and fewer visits to specialists in rural areas than in major cities. 
Women, living in rural and remote areas, also, had higher death rates from their lung cancer, 
had more chronic obstructive pulmonary disease, higher smoking prevalence rates 
(particularly in older women) and higher obesity rates than women in urban areas. 2 
One limitation of ARIA as a measure of distance to services is its potential correlation with 
the socioeconomic index for areas (SIEFA) measure. This is a measure of socioeconomic 
disadvantage that has geographic groupings in common with ARIA.2 To distinguish the 
effects of ARIA and Socioeconomic index for areas (SEIFA) for people with lung cancer, a 
Queensland study77 used a method called Classification and Regression Tree (CART) 
analysis. High incidence rates occurred in males when they lived in disadvantaged or remote 
and very remote areas of the middle SEIFA grouping. While for females, rates were higher 
in middle or low SEIFA regions in major cities. 
A further limitation of ARIA is that it is a measure of distance to and access to general 
goods and services rather than health or cancer-specific services in particular. A number of 
Queensland studies have also noted this limitation.78, 79 Therefore; straight-line distance has 
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an advantage in that it measures distance to and access to specific hospitals and cancer 
services. 
1.4. Distance to treatment and how to measure it 
There are a number of ways of measuring distance and access to a variety of health services. 
Straight-line distance (in kilometres or miles), measures distance from the patient’s home or 
the centroid of a patient's postcode of residence at diagnosis to a specific treatment 
facility.79,78 The treatment facility may be an outpatient facility80-83 or a GP surgery; the 
closest hospital to the patient’s home; the closest specialist hospital that provides surgery;84-
86 the closest medical oncology facility that provides chemotherapy;85 or the closest 
radiotherapy facility.87, 88Apart from straight-line distance, distance travelled by car, or time 
taken to travel, have also been used as measures of distance.16, 87-89 
There are numerous software applications available to calculate straight-line distance 
provided two geocoded coordinates are available. Calculation of straight-line distance can 
occur using any geographic information software (GIS).90, 91 92A number of cancer registry 
based studies of distance have used an algorithm referred to as the “Great Circle Distance 
Calculator”93 which measures the shortest distance between any two points. The method, 
based on spherical geometry, takes account that the earth is a sphere. The distances 
calculated are as the crow flies. The North American Association of Central Cancer 
Registries (NAACCR) first developed this algorithm in Statistical Analysis System (SAS) 
software 94 and a number of US cancer registry studies have applied this algorithm95-98 to 
their studies or used GIS software to calculate travel distances.99, 100 
In this thesis, calculation of straight-line distance occurs using the geocoded longitude (X) 
and latitude (Y) coordinate from a patient’s cancer registry geocoded address at diagnosis to 
the geocoded longitude (X) and latitude (Y) coordinate in an appropriate specialist public 
hospital by applying the SAS program developed by NAACCR. Specialist hospitals are 
identified using Canrefer, 101 a NSW web based directory of cancer services managed by the 
Cancer Institute NSW, Australia’s first statewide cancer control agency. Because all 
Australians are entitled to treatment free-of-charge in public hospitals, 102 straight-line 
distance is a measure of access to best care that includes both distance to and affordability of 
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care. Compared, are the current and new geocoded methods of allocating boundaries in the 
CCR. In addition, the advantages and limitations of the straight-line distance is provided in 
Chapter 3. 
1.5. Measurement of cancer survival 
Trends in survival over time and differences between geographical regions are used by 
cancer control agencies, researchers and the health system to determine priorities and 
evaluate cancer control efforts. Relative survival is the common method used by cancer 
registries to report survival. Cancer survival is the proportion of patients diagnosed with 
cancer who are alive at the end of a defined period, usually five years. Population-based 
cancer registries routinely report five year relative survival rates.103 104, 105 Relative survival 
“rate” is a misleading term because it is a ratio namely the ratio of deaths experienced in a 
cancer cohort over a defined period after adjusting for the background mortality (all deaths 
experienced in the population, by age and sex).103, 106-108 Background mortality, in the form 
of life tables for specific years is obtained from the ABS. 
Following up a cohort of cancer patients to determine whether they are alive or dead is 
essential for complete and accurate reporting of cancer survival. Cancer registries undertake 
population-based survival analysis by following a cohort of patients diagnosed within a 
defined time up to a particular date, for example 30th December 2008. Survival time is the 
difference between the date of diagnosis of a patient and the date of death recorded on the 
death certificate.5, 109 Follow-up of patients to determine the date of death is either active or 
passive. Active follow-up, involves contacting doctors, hospitals and coroner’s offices to 
determine, whether a patient is dead or alive at a point in time.105, 110  Whereas, passive 
follow-up requires matching the cancer registry database, to state and national death 
registers.105 US SEER registries, use active follow up while Australian registries use passive 
follow up supplemented by writing to doctors for discrepant cases. In NSW when a match 
occurs (based on patient demographic factors (e.g., name, address and date of birth) the date 
of death, and sometimes the cause of death is added to a person’s record on the cancer 
registry database. If a match is uncertain, cancer registry staff resolve this discrepancy by 
writing to doctors and hospitals seeking further information. 
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Studies that compare five year relative survival rates, for example between hospitals with 
varying caseloads, or between geographical areas such as, Europe,111-121 Australia11 and the 
United States -122, 123 can be used to evaluate progress in cancer control efforts. This is 
particularly informative when survival information can be analysed with other information 
for the same country, for example risk factor profiles, screening participation rates, the 
proportion of patients presenting with localised stage and the distribution of cancer services. 
Recently, the International Cancer Benchmarking Partnership (ICBP) compared cancer 
survival in 2.4 million patients in 12 jurisdictions. Cancer survival was higher in Sweden, 
Australia and Canada for lung, ovarian, bowel and breast cancer and lower in the UK and 
Denmark.124-128 These survival comparisons while providing valuable insight are limited to 
comparisons of age, sex, tumour histology and stage. For each additional variable of interest 
(for example socioeconomic status or ethnicity) specific life tables need to be developed 
which can be both impractical and resource intensive to produce. For example, to undertake 
the International Benchmarking Partnership study of cancer survival, 250 different life tables 
were developed.124 
Cause specific survival may be an acceptable alternative to relative survival for population-
based registries provided follow up of patients is comprehensive and recording of cause of 
death complete.129-131Similar results using both methods within the same population should 
provide a level of reassurance that one method can be a substitute for the other. Recently, an 
Australian study found similar cause specific and relative survival estimates for all cancer 
and many cancer sites for indigenous and non indigenous Australians at one and five years 
post diagnosis. 132 Furthermore, the Geneva Cancer Registry found less than one per cent 
difference in survival estimates for breast cancer using cause specific and relative survival 
methods after 20 years of follow up. 133 In addition, cause specific survival is more familiar 
to clinicians because Kaplan Meier survival curves and Cox proportional hazards modelling 
are methods commonly used to evaluate outcomes in clinical trials. Furthermore, cause 
specific survival analysis allows for easy adjustment of patient, tumour and treatment factors 
because life tables for every variable of interest are not required. 
Fortunately, all cancer registries in Australia11 and Scandinavia134, and most in the US, 130 
record the cause of cancer death on their databases. For example, people diagnosed with 
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lung cancer who die from it, have their death recorded as a lung cancer death or if they die 
from an unrelated cause, for example, AMI, have a non cancer death recorded. In this thesis, 
the cause specific survival method is compared to other more routinely used methods of 
survival (net and relative) to determine whether cause specific survival is an acceptable 
method for use in chapters 4-8. These methods of survival are compared in two registries 
(NSW and Northern and Yorkshire (NY) for four cancer sites (breast, prostate, colorectal 
and lung). Allocation of cause of death to NY cancer cases occurs by applying similar rules 
as those used in NSW. Finally, differences in survival between the two registries, are 
investigated and discussed in Chapter 3. 
1.5.1. Cancer registration standards 
Cancer registration processes vary by country, particularly completeness of data and the 
source that initiates the registration of a case of cancer. International differences in survival 
rates may be due to different cancer registration practices that may influence completeness 
of cancer registration and result in differences in the reporting of cancer survival. 
Internationally, cancer registries code and report cancer incidence and survival to a common 
standard. Registries contribute to the international publication Cancer Incidence in Five 
Continents,135 which requires them to follow the International Association of Cancer 
Registries (IACR) standards.4 Registries routinely measure and report indicators which can 
be used to benchmark the quality of their data against other registries. The highest quality 
registries have high proportions of registered cases that are histologically verified, low 
proportions of registered cases that are notified by a death certificate and mortality incidence 
ratios that approximate measured cancer survival estimates. . Beral and Peto136 suggested 
that the higher survival in Sweden compared to the UK might be due to differences in 
registration practices. Their concern was the lack of mandatory notification in the UK may 
affect the completeness of the registry incidence data and commencing a registration from a 
death certificate may lead to biased estimates of survival because good prognosis cancers 
may be missing. Others have refuted these suggestions based on simulation studies. 137, 138 
Regardless of who is correct, it is clear that comparison of survival needs to take account of 
different cancer registration practices. In NSW, and in other Australian registries, cancer 
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notification, is legislated under the Public Health Act.139 Pathology notifications have been 
mandatory since 1986 and inpatient hospital notifications have been received since 1992.140 
Initiation of a registration of cancer occurs after receiving a notification from any one of the 
following sources: hospitals, pathology laboratories, cancer care centres, radiotherapy 
centres and death registers. The greater the number of notification sources the more likely 
that a registry has accurate and complete data.  In the UK, notification of cancer is not 
mandatory; registries receive death certificates and obtain further information by checking 
with family doctors and hospital files using this information to register a case.. 
1.5.2. Allocation of the cause of death in Australian cancer registries 
The cause of cancer death recorded by cancer registry coders in Australian cancer registries 
is not always concordant with the cause of death determined by the ABS.11The ABS records 
the cause of death based on information recorded on the death certificate only.141 Australian 
registries including the NSW CCR use all notification sources and not just death certificates 
to determine the cause of death.142, 143 Furthermore, Australian registries follow up with 
doctors and hospitals to resolve and determine the cause of death when a discrepancy arises. 
Linking cancer registry data with hospital data, as has been done in the studies in this thesis, 
provides a previously unavailable opportunity to examine survival due to distance to a 
specialist surgical hospital while taking account of patient, tumour and surgical treatment 
factors in cancer registry patients.  
Relative survival is currently the established method used by cancer registries, 
epidemiologists and health service providers. Cause specific survival needs to might be an 
acceptable alternative. provided similar results are obtained. Further discussion of this topic 
occurs in Chapter 3. 
1.6. Studies of distance to treatment in non cancer patients 
This section explores the issue of distance to health services and treatment outcomes in 
several non cancer contexts. This section explores the issue of distance to health services and 
treatment outcomes in several non cancer contexts, to determine whether access to service 
due to distance is influenced by the type of disease or the type of service. 
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1.6.1. Distance and the likelihood of receiving treatment for mental health 
patients 
Patients with mental illness often present with an acute mental health crisis. The ability to 
deal with a crisis depends on what services are available. One of the earliest studies to 
consider distance and the impact on health services was conducted in 1964. This study 144 
looked at veterans who attended a mental health outpatient clinic. Distance was measured in 
miles from the patient’s address to the Denver Mental Hygiene clinic. This study found that 
the closer a veteran’s residence was to the clinic, the greater the probability that the veteran 
would receive treatment. A subsequent study looked at the travel distance for outpatient 
treatment of depression in Pittsburgh and also found that patients received less treatment 
with increasing distance from services.80 
A number of single institution studies have examined the impact of increasing distance from 
treatment on access to that treatment, with different results depending on the health 
condition and type of service. Evaluation of people with eating disorders occurred to see 
whether distance affected treatment adherence or attendance. No significant impact on 
outpatient attendance or treatment adherence occurred.83 However, patients who travelled 
greater distances attended fewer appointments than those who lived closer, had longer 
appointments and had their treatment planned ahead of time. The authors suggest that the 
improved compliance with treatment was most likely a result of these factors. In contrast, 
patients admitted for inpatient substance abuse treatment were 2.6 times more likely to 
attend when they lived within 10 kilometres of an outpatient’s health service. 82Longer time 
in drug treatment was a predictor of better client outcomes.81 Of the 1,735 clients attending 
the clinic, those who travelled more than one mile from their treatment centre were 50% less 
likely to complete their treatment. 
1.6.2. Distance and increased hospitalisation in diabetic children and young 
adolescents 
The effect of distance from the patient’s home to hospital of care was investigated in 
diabetic children and young adolescents living in Germany. 145 Increased length of stay 
occurred for patients with increasing distance from hospital after adjustment for age, 
duration of diabetes, metabolic control and hypoglycaemia. This study involved a third of all 
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German children who needed diabetic care with the authors concluding that “patient near” 
care was required to reduce hospitalisation for these children. 
1.6.3. Distance and compliance to treatment for human immunodeficiency virus 
(HIV) 
There has only been one study, to my knowledge, to investigate distance and patient 
compliance with treatment for people with the HIV. Distance measured as driving distance 
from the patient’s home to the US Department of Defence hospitals did not influence 
treatment utilisation in these patients.146 However, staff could only use defence force health 
services and treatment centres, available only in major cities. As patients did not have a 
choice of provider, people had no choice but to travel for treatment of their disease. 
1.6.4. Distance to specialist care for a common acute disease – AMI 
Two US studies have observed the impact of driving time and straight-line distance to 
treatment for people having an AMI. 147, 148 This study, using data from the US Census and 
the American Hospital Association annual survey, focused on access to specialist care. 
Driving distance measured from the population centres of each census area to the closest 
treatment centre for each survey participant had no impact on specialist care. However, most 
of the adult population (80%) lived within one hour of the facility where appropriate 
treatment was available. Therefore, access was not considered a barrier to health care.147 
The second study, a US study of 218,247 Medicare beneficiaries older than 65 years, 
examined straight-line distance from the patient’s home to the nearest specialist hospital 
(defined as providing cardiac catheterisation to 75 or more AMI patients annually) and 
survival to four years after an AMI. People living further away had a 6% higher mortality 
than those that lived close to a specialist centre as well as less access to treatment. 
Admission to a high volume hospital within the first 24 hours resulted in the best survival 
outcomes.148 
Varying results in outcome in the non cancer setting depends on the type of presenting 
problem and the availability or otherwise of a service.146 Distance from outpatient care, the 
type of service and compliance with treatment were important for patients with mental 
health, drug abuse, depression and eating disorders. While for patients with myocardial 
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infarction, the first study showed that most people lived within proximity of service, whereas 
the second showed poorer survival, due to less intensive treatment and reduced access to 
expert care. 
1.7. Specialisation and centralisation of cancer services 
Cancer patients do not generally have the same requirement for emergency medical attention 
as patients who have an AMI, or an acute mental health episode. The typical journey of a 
cancer patient varies depending on the type of presentation and the health system. In 
Australia, the typical process for a person who is concerned about symptoms is to consult 
their family GP for diagnostic work-up and referral. Other people are asymptomatic at 
diagnosis, with their cancer identified through screening or as an incidental finding during 
medical investigations for an unrelated health problem.  
The usual pathway for both symptomatic and asymptomatic patients is for the GP to 
undertake some diagnostic tests and then refer to a specialist for further investigation and 
management. Some patients present and have their cancer diagnosed via an emergency 
department attendance and subsequent hospital admission. Clinical management for people 
with cancer usually involves one or more treatment modalities including surgery, 
chemotherapy and radiotherapy. Given the specialist nature of these therapies, and varying 
availability across the state, consideration of the centralisation and specialisation of cancer 
services has been the focus of health policy, both in Australia and internationally, and has 
stimulated research into the impact of distance to cancer treatment. This next section 
addresses these issues. 
1.7.1. Specialisation and centralisation of services in the UK and US 
To date, most studies of distance from a person’s home to a cancer treatment centre focused 
on whether increased specialisation or centralisation of services led less treatment in people 
who live more remotely. In the UK, the policy framework for the commissioning of cancer 
services more commonly referred to as the Calman-Hine framework149, 150recommended the 
centralisation of cancer services. A number of studies of straight-line distance were 
undertaken to determine whether cancer patients had less treatment (surgery, radiotherapy or 
chemotherapy) when they lived further away from specialist cancer care.84-86, 89, 151-158 
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However, only a small number of studies have examined the impact of distance to cancer 
treatment on cancer survival. 85, 159 
Other studies have evaluated the effectiveness of the Calman-Hine framework to improve 
clinical service delivery, finding for breast151, 152 and colorectal patients151, 153that there was 
an increase in adherence to standards and surgical specialisation after implementation with a 
trend towards an improvement in five year survival. 152 A comparison of surgeon workloads 
in breast and colorectal cancer (CRC) surgery in the NY Area for the period 1990-93, 1994-
97 and 1998-2000 also found that there had been a major shift towards surgical 
specialisation.151 The Calman-Hine framework replaced by the UK Cancer Plan in 2000160 
emphased improving patients experience of care, reducing inequalities improving quality of 
care and ultimately survival. Since then, a number of studies have measured differences 
between National Health Service (NHS) trusts including the proportion undergoing 
surgery,161 differences in cancer survival,162-165 differences due to specialisation151 and most 
recently, variation in 30 mortality rates.166 In all cases considerable variation exists between 
NHS trusts. 
Most US studies have focused on the centralisation of cancer surgery and consolidation of 
services into high volume hospitals. These studies show that with increasing surgical 
volume, the proportion undergoing surgery had better short and long term survival. 29, 34, 167-
173, 174 One study specifically examined the impact of centralisation over a 10 year period and 
found that as travel distance increased so did hospital volume. Patients who had surgical 
procedures for pancreatic, oesophageal, colon and rectal cancers moved from surgery in low 
volume hospitals to high volume hospitals with an increase in travel burden occurring for 
patients who lived more remotely. Importantly though, in-hospital mortality declined in 
those receiving cancer procedures in high volume centres (with the exception of rectal 
cancer), a desirable outcome regardless of the travel burden.172 
1.7.2. Specialisation and centralisation of services in Australia 
In Australia, the National Strategic Framework for Rural and Remote Health a collaboration 
between the Commonwealth and State Government endorsed by the Standing Council on 
Health in 2011,175 has as its first goal “to improve access to appropriate and comprehensive 
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health care.” Issues identified as priorities for people living in rural areas include improving 
access, developing appropriate models of care, having a sustainable workforce and the 
development of collaborative partnerships.175, 176 
The goal of cancer care is to provide equitable access to improve cancer care.- Rural patients 
need to have increased access to diagnostic testing, coordinated care, multidisciplinary team 
review, patient accommodation and appropriate cancer oncology and radiotherapy services 
locally. 177 In the 2009/2010 Australian Federal budget, $1.3 billion was dedicated to 
building two integrated cancer centres (Lifehouse at Royal Prince Alfred (RPA) and 
Parkville in Melbourne) with $560 million 178 177 dedicated to enhance or build 10 regional 
cancer centres. The new or enhanced services ranged from radiotherapy bunkers, linear 
accelerators, Computer Axial Tomography (CAT), MRI and Positron Emission Tomography 
(PET) scanners. Additional patient accommodation was also funded for three NSW regional 
cancer centres.179 These centres will mostly provide diagnostic services as well as 
chemotherapy and radiotherapy. 
However, most specialist surgical care in NSW and in other Australian states will be located 
in major cities. Furthermore, plans recommend consolidation of specialist surgical 
services.180, 181 Therefore, travelling to cancer-specific specialist surgical care for people who 
live more remotely will continue to be required even when all regional centres are built and 
operational. 
To assist patients and GPs in rural and remote locations, a number of programs and projects 
have been introduced. For example, Cancer Network (CanNET)’ was a large demonstration 
program funded by Cancer Australia to develop strategies to link regional and metropolitan 
cancer services. Seven cancer service networks were set up in 2009. The purpose of these 
networks was to build pilot projects that managed the diagnosis and treatment of rural 
patients through clinical networks. Each state set up a web based directory of cancer services 
and overall 1,196 health care providers underwent education about issues facing rural 
patients. 182 In addition, a comprehensive literature review was undertaken on the 
effectiveness of “managed clinical networks”.176 
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In NSW, the web based service directory ‘Canrefer ‘was developed by the Cancer Institute 
NSW as part of the CanNet initiative.101 This directory of NSW public specialist hospitals 
referred to in chapters 5 -8 of this thesis identified specialist surgical services where 
cardiothoracic surgeons and gynaecological oncologists operate. 
1.8. The impact of distance to treatment in cancer patients 
Outlined below are all known UK, US and Australian registry studies that have measured 
straight-line distance to cancer services. These studies highlight issues associated with 
accessing cancer treatment services for people who live more remotely. 
1.8.1. Increasing distance from radiotherapy services and the likelhood of best 
practice surgery for breast cancer 
Historically, the majority of cancer registry studies that have examined distance to treatment 
have measured distance to radiotherapy centres. A large number of US Surveillance 
Epidemiology and End Results (SEER) cancer registry studies demonstrate that with 
increasing straight-line distance from radiotherapy centres, women diagnosed with breast 
cancer were more likely to have a mastectomy instead of the recommended breast 
conserving surgery and post-operative radiotherapy.96, 98, 183-187 
Additional barriers that reduce the likelihood of breast conserving surgery and follow up 
radiotherapy are the weather and reliance on public transport. Travelling in winter was found 
to be an additional barrier for US patients who lived >20 miles from a radiation treatment 
facility (P = 0.002).100 In contrast, in northern England the likelihood of breast conserving 
surgery in women with breast cancer (n=6,014)158 was not significantly different with 
increasing distance or length of a car journey, after adjusting for age, deprivation and 
hospital type. However, women with breast cancer who lived in areas without a regular bus 
service were less likely to undergo radiotherapy after breast conserving surgery. 158 
1.8.2. Distance to cancer treatment and the likelihood of treatment 
The majority of studies on distance to cancer treatment services occurred in the UK. 
Distance measured from the patient’s home to a hospital of treatment, or cancer centre or GP 
surgery and the likelihood of receiving treatment (surgery, chemotherapy, radiotherapy) was 
examined.84-86, 156-158, 188 Jones86 also estimated travel time and travel distance from the 
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patient’s postcode to the nearest hospital offering cancer treatment for people diagnosed 
with breast, colon, rectum, lung, ovary and prostate cancer. This study reported that 
regardless of cancer site, all patients were significantly less likely to receive radiotherapy 
with increasing distance to a radiotherapy centre. Lung cancer patients were also less likely 
to have surgery with increasing distance. Rectal and lung cancer patients were also less 
likely to receive chemotherapy. Ovarian cancer patients who lived in the most remote 
quartile were more likely to undergo surgery if they were younger than 70 years whereas, 
men living in the same quartile, were less likely to undergo surgery when they were aged 70 
years or older. It is possible that some degree of patient selection, due to clinical judgement 
or patient preference was occurring because of distance to cancer treatment. 
A later study found that among people living in northern England with non small cell lung 
cancer (NSCLC), those who lived further from a specialist centre were less likely to undergo 
surgery after adjustment for age, sex socioeconomic status and another treatment 
(chemotherapy and radiotherapy). Access to surgery further reduced with increasing 
deprivation.157 In addition, patients whose closest NHS facility was a district hospital (their 
general public hospital) were significantly less likely to undergo thoracic surgery than those 
whose closest hospital was a cancer centre, regardless of whether a medical oncology facility 
was available, after adjustment for age and sex. Patients in the most distant quartile and 
those most socially deprived were least likely to receive treatment. Those living in the most 
deprived areas were least likely to have a histological diagnosis, active treatment and 
thoracic surgery for NSCLC. 
In contrast, a US study of people diagnosed with NSCLC who lived further from specialist 
cancer centres were more likely to have surgery, but much less likely to receive radiotherapy 
or chemotherapy.189 Surgery, the authors suggest was provided as an alternative to 
radiotherapy for patients who lived further from a cancer centre because radiotherapy was 
less accessible and would have required frequent visits. 189 A more recent US study of 
NSCLC patients reported similar results to those reported in the UK, with 61% of patients 
attending a National Cancer Institute (NCI) centre for surgery when they lived less than 30 
minutes away. The likelihood of attendance decreased with increasing distance.190 Other 
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factors predictive of attendance at an NCI hospital included treatment by a specialist six 
months prior to diagnosis and urban residence. 
1.8.3. Distance to cancer treatment and survival 
The relationship between distance from treatment and cancer survival is complex with the 
impact of distance on survival, mediated by factors like stage and varying by type of cancer. 
Early Scottish 191-193 and UK studies84-86, 194found that for the majority of cancer sites 
examined, the hazard of death increased with increasing straight-line distance to a cancer 
centre. Campbell, 192 in Scotland, used straight-line distance to treatment and found the 
hazard of death for women with ovarian cancer was greater with increasing distance to a 
cancer centre. In contrast, Jones, 85 in a study in northern UK, examined a number of 
accessibility measures, including distance and travel time to a cancer centre, but observed no 
association of distance with late stage or poorer survival for women diagnosed with ovarian 
cancer86. He did find, though, that being treated first at a cancer centre rather than a general 
hospital resulted in better survival. 
In a further Scottish study of people diagnosed with lung cancer, a higher hazard of death 
was reported for those who lived 6–23 kilometres from a cancer centre compared with those 
who lived within 5 km of their home after adjusting for age, sex and settlement size.191 
In contrast, rural USA non small lung cancer patients living further away from a specialist 
cancer centre were significantly more likely to undergo surgery but much less likely to 
receive radiotherapy or chemotherapy. Patients were more likely to be treated with surgery if 
they  had private medical insurance (1.52; 1.03 to 2.26). Among patients who did not have 
surgery, those with private insurance were more likely to receive another form of anticancer 
therapy-either radiation or chemotherapy (1.57; 1.18 to 2.09). Residing farther from a cancer 
treatment centre was associated with a greater chance of having surgery. 195 
Most of the early studies, did not measure cancer stage, and could only adjust for a handful 
of factors usually those routinely captured in the cancer registry. In addition, most studies 
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used all cause survival rather than cause specific survival because they did not record the 
cause of death and therefore assumed that patients died of their cancer. 
1.8.4. Distance to cancer treatment in an Australian setting 
Four WA studies used linked cancer registry and hospital data and evaluated the impact of 
distance from and access to cancer surgery for breast, lung, colorectal and prostate cancers. 
After adjustment for ARIA and type of hospital, the proportion undergoing surgery was 
found to vary by cancer type.42, 46, 59, 196Men diagnosed with prostate cancer were more likely 
to undergo a radical prostatectomy when admitted to a rural hospital or a public hospital.42 
Colorectal patients,46 breast cancer patients47 and lung cancer patients22, 59 had less surgery 
when admitted to rural or public hospitals and had more surgery when admitted to private 
hospitals. 
The Queensland Cancer Registry (also geocoded) has examined straight-line distance to 
radiotherapy for people with lung, breast and CRC. Waiting times for lung cancer patients 
were found not to vary due to distance to radiotherapy after adjustment for sex, age, therapy 
intent, cancer histology and stage, and performance status based on Eastern Cooperative 
Oncology Group (ECOG) score.197 More recently, straight-line distance to the closest 
radiotherapy facility and travel time were examined for people diagnosed with breast and 
CRC. Poorer survival occurred with rectal cancer but not colon cancer as a result of 
increasing distance. A six per cent increase in mortality occurred for every 100 km increase 
in distance to the closest radiotherapy centre. 16, 88 78 
One of the earliest studies to consider distance from treatment, the hospital that the treatment 
was received in and whether surgery was undertaken was a Queensland Registry study of 
breast cancer by Thompson et al.19 This study found the likelihood of women having a 
mastectomy was higher in rural areas, in those treated in public hospitals, and for women 
who had the comorbidities of anaemia or heart failure. In contrast, appropriate treatment 
(breast conserving therapy) was more likely for women when they were treated in private 
hospitals or hospitals with high surgical caseloads. 
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A subsequent Queensland study examined actual road travel distances and travel time to the 
closest radiotherapy facility and cancer survival (five year cause specific) for 6,848 rectal 
cancer patients. 87 Travel distances and times were calculated using geocoded coordinates 
from the patients address to the nearest radiotherapy facility. Relative to patients living 
within 50 kilometres and adjusting for age, sex and stage at diagnosis, patients living 100-
200, 200 -399 and 400 + kilometres from a radiotherapy facility were more 16%, 30% and 
25% more likely to die from any cause.87 There were a number of limitations to this last 
study. Whether patients actually received radiotherapy was unknown, 25% of the sample 
had unknown stage and while cause specific survival was used, the accuracy of the cause of 
death had not been evaluated. 
1.8.5. Patient assisted travel schemes in Australia 
Distance can be considered an impediment to accessing health care for many Australians. 
Health transport may be required at different points within the health system. 198 In 2011, 
Australia had the highest passenger car usages per 1000 population (558 per 1000), 
compared to any other developed country (UK 453, Canada 420 and US 403 per 1000 
population) 199 reflecting strong reliance on the car for transport. 
Each state in Australia has Patient Assisted Travel Schemes (PATS).200 These schemes 
provide travel assistance to people living in rural and remote locations to assist them to 
access health care. The current patient transport schemes require that patients need to fund 
the upfront costs of travel and accommodation, with reimbursement at a later date. There are 
inconsistencies across jurisdictions in how much is provided. Out of pocket expenses and 
lack of support for care givers have been documented as barriers to accessing health care in 
rural and remote residents.201 One suggestion to improve access is for regional health 
authorities to issue vouchers for patients.201 
Historically, in Australia, the Royal Flying Doctor Service (RFDS) 202 has provided 24 hour 
emergency service to patients to attend GPs and other specialist services. However, the 
RFDS is a not for profit organisation that receives some funding from the Australian 
Government, but mostly relies on fund raising and donations. Australia wide, 63 planes 
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operate from 21 bases that on average provide a total of 290,000 patient transportations in a 
year.202 
In NSW, patients who have a car and travel over 100 kilometres are partly subsidised and 
can apply for Isolated Patient Transport and Accommodation Scheme (IPTAAS) funding to 
cover transport and accommodation costs. This policy, developed by the NSW Ministry of 
Health, does not include the cost of meals and incidental expenses (road tolls, parking, 
booking fees) which are not reimbursable. Patients who are pensioners and health care 
cardholders are not required to contribute. The specific purpose of IPTAAS is to assist 
patients to travel to specialist medical appointments.203In this thesis, the potential impact of 
IPTAAS funding is evaluated for people diagnosed with NSCLC who live 100km or more 
from the nearest accessible specialist hospital (NASH). The likelihood of advanced or 
unknown stage, no surgery and predictors of cancer survival are discussed in chapters 7, 8 
and 9. 
As the work in this thesis focuses on three types of cancer, namely bladder, lung and ovarian 
cancer, a rationale for selecting these cancer sites is provided in the next section. 
1.9. Why bladder, ovarian and lung cancer? 
Bladder, ovarian and lung cancer were selected for analysis in this thesis as each has surgical 
resection as - a component of treatment but each represents a different surgical context in 
terms of service delivery. Bladder cancer surgery is performed by urologists throughout 
NSW and is not a sub-specialty procedure. Furthermore, there are no national clinical 
practice guidelines, such as those endorsed by the National Health and Medical Research 
Council (NHMRC), to promote evidence-based best practice or to guide referral pathways. 
In contrast, ovarian cancer surgery can be performed by general gynaecologists or specialist 
gynaecological oncologists and there are NHMRC clinical practice guidelines 204 which 
describe recommended surgical care, including management by a specialist gynaecological 
oncologist. 205, 206 Lung cancer resection is peformed in only a few centres, but like ovarian 
cancer, national guidelines recommend treatment by sub-specialist thoracic surgeons. 202, 203 
Currently, little is known about the surgical management of bladder cancer patients in 
Australia. An earlier NSW study shows that survival is poorer in women, and older age at 
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diagnosis is a characteristic of these patients with 40 per cent of women who are diagnosed 
with bladder cancer aged 80 years or older. 207 Distance to specialist care may account for 
this survival difference. 
An Australian patterns of care study has investigated pathways to diagnosis in women who 
are diagnosed with ovarian cancer. 57, 208 However, to our knowledge, surgery, hospital of 
treatment and the impact of distance to a specialist hospital have not been investigated. 
For lung cancer, if detected at a localised stage, surgical intervention is potentially curative. 
While there have been a number of NSW patterns of care studies, 53-56, 209 type of surgery, 
hospital of treatment and distance to the nearest accessible hospital have not been examined. 
There are a small number of UK and US studies that have considered distance to specialist 
care and cancer survival for bladder,210 ovary and lung. 85, 86 However, these studies have 
lacked important covariates, like stage at diagnosis, comorbidity and have used all cause 
survival because they did not have cause of death information. 
1.10. Best practice clinical guidelines 
1.10.1. Best practice surgery for bladder cancer 
Bladder cancer represents 2 per cent of all new cancer cases diagnosed in Australia and 
NSW.7, 211 Unlike most other cancers survival from bladder cancer is consistently higher in 
men.115, 212, 213 Women diagnosed with bladder cancer in NSW have a 13% higher likelihood 
of death than men, after adjusting for age, stage, histology, socioeconomic status and period 
of diagnosis.207 
Clinical practice guidelines developed by the National Comprehensive Cancer Network 
(NCCN) 214 in the US and the National Institute of Clinical Excellence (NICE) in the UK 
215recommend that people diagnosed with bladder cancer be referred to a urologist at centres 
that undertake more than 50 cases per annum.215 In addition, there is consistent evidence that 
survival is poorer in bladder cancer patients when cystectomy occurs more than 90 days 
after diagnosis. 216-218 
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The only Australian guidelines are consensus guidelines developed by the Australian & New 
Zealand Faculty of Radiation Oncology Genito-Urinary Group who recommend 
radiotherapy and adjuvant chemotherapy as the standard treatment option for muscle 
invasive bladder cancer.219 Little is known about clinical management particularly surgical 
management of bladder cancer in Australia. One paper provided an overview of the current 
recommended treatment220 but there are no studies that have examined surgical management 
of bladder cancer. The Royal Australian College of GPs recommend that patients presenting 
with haematuria, the most common symptom at presentation, be referred to a urologist and 
that patients with bladder cancer that is invading muscle are best treated with cystectomy. 220 
According to the Urological Society of Australia and New Zealand, the majority of 
urologists are located in large rural and Sydney hospitals. 220 
1.10.2. Best practice surgery for ovarian cancer 
Ovarian cancer is a poor prognosis cancer that is characterised by vague symptoms and late 
stage at presentation. In 2008, ovarian cancer was the tenth most common cancer in females 
in NSW and the sixth most common cause of female cancer deaths.211 Internationally, NSW 
has good ovarian cancer survival compared to other countries.126, 221 
Survival from ovarian cancer in NSW women has previously been found to be most 
influenced by extent of cancer at diagnosis and the cell type of the cancer.222 Clinical 
practice guidelines recommend referral of women suspected of or who have symptoms of 
epithelial ovarian cancer to a gynaecological oncologist and treatment in a gynaecological 
oncology service (GOS) hospital. 204, 223-227 NCCN guidelines227 do not specifically nominate 
such a service but recommend surgical cytoreduction to 1cm or less. Cytoreductive surgery 
(resection of macroscopic metastatic disease) is the accepted standard of care for women 
with advanced ovarian cancer. 228, 229 
1.10.3. Best practice surgery for lung cancer 
In 2008, lung cancer was the fourth most common cancer and the most common cancer 
causing death responsible for 20% of all Australian and NSW cancer deaths.7, 211 Lung 
cancer is comprised of two main cell types, small cell lung cancer (SCLC) and NSCLC.230 
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Patients with small cell lung cancer and those with distant metastases have the poorest 
survival.124, 125 
Internationally, NSW has good lung cancer survival with patients in the UK and Denmark 
having lower survival than elsewhere, partly because of a more adverse stage distribution in 
these countries.125, 221 For NSCLC, the proportion with metastatic disease at diagnosis ranged 
from 46.8% in Sweden, 47.5% in Australia to 61.2% in Denmark.125 However, patients 
presenting with localised NSCLC are considered potentially curable if treated surgically.206, 
231 Therefore, rapid diagnosis and appropriate staging are essential if patients are to obtain 
the best outcomes. 
Surgical resection of lung cancer with curative intent was introduced in 1933.232 A review in 
1994 reported that no randomised control trials had assessed the effectiveness of surgery in 
the treatment of localised non small cell lung cancer because of ethical concerns.233 In 2010, 
a Cochrane review of surgery for local NSCLC, examined the results of 13 clinical trials of 
surgery and 2,290 patients and concluded that there was no compelling evidence that lung 
cancer surgery improved survival compared with other types of therapy such as radiotherapy 
and chemotherapy  although, one trial found that overall survival was superior in patients 
with stage I to III NSCLC who underwent resection and complete mediastinal lymph node 
removal. Another trial found that the recurrence rate was higher when patients had a 
segmental resection as opposed to a lobectomy. None of the other trials demonstrated a 
significant improvement in survival compared with non surgical therapy.234 
Nevertheless, US231, UK235, 236 and Australian guidelines206 all recommend surgery for 
localised NSCLC. In 2005, the Australian NHMRC guidelines recommended surgical 
resection for patients with early stage NSCLC, with lobectomy the preferred procedure.206 In 
2007, the American College of Chest Physicians produced evidence-based clinical practice 
guidelines 237 recommending that surgical resection should be the treatment of choice for 
stage I and stage II NSCLC, with adjuvant chemotherapy required for stage II patients. 
Radiotherapy is recommended for patients with inoperable NSCLC or for patients who 
refuse surgery. 237 According to NICE guidelines in the UK, 169, 175 patients not considered 
suitable for a lobectomy because of comorbid disease or inadequate lung function are 
recommended to have limited resection or radical radiotherapy. Before patients undergo 
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surgery, lymph node sampling, Endobronchial Ultrasound (EBUS) and biopsy to determine 
stage is recommended.226, 235 
US guidelines recommend evaluation by a thoracic surgical oncologist for patients with 
stage I and II lung cancer regardless of whether non surgical options are used. 237 More 
recently, two studies167, 238 compared outcomes of lobectomy between cardiothoracic and 
general surgeons, finding better adherence to guidelines, lower post-operative morbidity and 
better long term survival among patients treated by cardiothoracic surgeons. 
While none of the lung cancer guidelines specify the type of hospital patients should be 
treated in, appropriate staging of lung cancer depends on the availability of equipment 
including imaging CT and PET scans, needle biopsies, and surgical staging 
(mediastinoscopy and video assisted thoracoscopic surgery (VATS)) 239 and skilled staff to 
perform these procedures. 
1.11. Mediating factor–stage at diagnosis 
1.11.1. Advanced stage at diagnosis 
Determining cancer stage at diagnosis is important to ensure that patients get stage 
appropriate treatment. Surgery would be required for early stage solid tumours whereas at 
late stage, chemotherapy or radiotherapy may be the most appropriate treatment option. In 
addition, if diagnosed at late stage, referral to palliative care and appropriate pain 
management is recommended.206, 231, 235 
Stage at presentation and receipt of treatment are two factors known to influence survival. 
Scottish patients were found to have a high chance of disseminated disease at diagnosis with 
increasing distance from a cancer centre.193 Patients were less likely to have histologically 
verified tumours, receive chemotherapy or undergo surgery with increasing time to a 
thoracic surgical hospital.33, 85, 86, 157 UK patients living in the most deprived quintile were 
more likely to be diagnosed with stage four CRCs, less likely to receive chemotherapy and 
colon patients were less likely to receive surgery. 156 Distance to treatment was not 
significant for either rectal or colon cancer. The most likely reason for this is that the 
variance attributed to distance was captured through other factors like late stage, lower 
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likelihood of chemotherapy and no surgery.156 One of the limitations of this study is that 
only 65% of the sample had stage information. 
In a recent US study, travel burden using driving time or driving distance was found not to 
be significantly associated with later stage at diagnosis for lung cancer and CRC but was for 
breast cancer. However, a major limitation of this study was that 11% of information was 
missing, which on investigation was found to be mainly lung cancer patients.99 Scoggins et 
al. 99 also compared driving time and driving distance and found that both predicted late 
stage at diagnosis for breast cancer patients and longer time to treatment for CRC patients. 
For lung cancer patients, male gender, older age and severe comorbidity were associated 
with an increased likelihood of advanced stage. Higher education, considered a proxy for 
high socioeconomic status was associated with a greater likelihood of diagnosis at a 
localised stage and less than 28 days between referral and admission.240, 241 
1.11.2. Unstaged or unknown stage at diagnosis 
Lack of staging information can indicate suboptimal investigation or poor cancer registration 
practices. Most studies that have investigated factors predictive of unknown stage have done 
so to investigate cancer registration practices. 235 236 Gurney et al.242 suggested a number of 
reasons why a registry did not stage a cancer. These were; a cancer type may be difficult to 
stage or investigations may have been limited or that some services or providers did not 
provide data on staging to the registry. Males compared with females experienced 
significantly lower levels of unstaged cancers of the liver, pancreas, oesophagus, and 
stomach, but significantly higher levels of unstaged lung, bronchial and thyroid cancer. 243 
Other factors predictive of unknown stage include older age 244 those with any 
comorbidity242, 243 and non married patients. 242, 243 
There is only one study to have investigated distance to treatment and the likelihood of 
unknown stage at diagnosis. 245 Silverstein et al., found that lung cancer patients were more 
likely to be unstaged if they were older, not living with a spouse and lived in rural areas with 
fewer primary care physicians. Consequently, including unknown stage, rather than 
excluding it from our analysis, as many studies do, 99,240,241 and examining factors associated 
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with its likelihood will provide valuable information. These issues are discussed further in 
Chapters 5 and 7. 
1.12. Mediating factor - likelihood of appropriate surgery 
The likelihood of appropriate surgery for cancers where presenting symptoms are often 
vague and at a late stage (as is the case for lung and ovarian cancer) increased if treatment 
occurs in specialist centres. A number of studies have demonstrated a relationship between 
specialist centres and the likelihood of cancer surgery.27, 174, 246 
1.12.1. Bladder cancer and surgery 
Studies that have examined the relationship between bladder cancer surgery and hospital 
type have provided mixed results and there is currently debate about whether radical 
cystectomy procedures should be centralised.247 A metanalysis of post-operative mortality 
after cystectomy found that it was inversely associated with high volume providers. 247 A 
SEER study examined 4,465 bladder cancer patients who underwent cystectomy28and found 
that patients treated in low volume hospitals were 48% more likely to die in the post-
operative period. High volume hospitals had higher rates of preoperative testing and higher 
use of continent diversion than low volume hospitals. 
1.12.2. Lung cancer and surgery 
The effect of volume on mortality depends on the procedure with mortality varying by as 
much as 10 per cent in patients undergoing a lobectomy. The mortality risk was much higher 
for patients who were older. Canada, like NSW, has a single payment system where equal 
access for all is the underlying principle. Evaluation of the proportion of patients undergoing 
lung cancer surgery occurred after services at 43 hospitals moved to 13 specialist centres. 
This study found that the number of lung cancer resections increased and patients had lower 
30-day mortality after a pneumonectomy and lobectomy.29  Receiving treatment in an 
institution with an approved residency program was found to be positively associated with 
receiving recommended guideline based treatment248 after adjusting for age, stage, 
comorbidity and ethnicity. People with lung cancer were found to have better post-operative 
mortality167 and 6% higher five year survival when treated in a high volume hospital.249 
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1.12.3. Ovarian cancer and surgery 
Improved survival has been demonstrated in women with ovarian cancer who have 
cytoreductive surgery with a positive 6.3% increase in survival for every 10% increase in the 
proportion of patients undergoing cytoreductive surgery.250 Furthermore, a US study of 
31,897 women with stage III and IV ovarian cancer 251 found that women had a lower 
likelihood of death if they were treated in high volume centres HR 0.76 (p<0.001) compared 
to low volume centres. Patient characteristics associated with the likelihood of receiving 
surgery in high volume hospitals was evaluated using a Californian patient discharge 
database of 719,608 patients. Referral to the high volume hospital was less likely to occur 
for non whites, Medicaid and underinsured ovarian cancer patients. A similar pattern 
occurred for the other nine conditions examined by Liu.35, 252 
In a large US registry (SEER) study, women treated at a facility “with an approved 
residency training program” had better survival after adjustment for age, stage, comorbidity 
and ethnicity. The authors suggested that appropriate surgical staging was the most likely 
explanation.248 Similarly, ovarian cancer patients operated on at a teaching hospital in 
Norway were found to have significantly lower risks of death compared to those treated at 
other hospitals after adjustment for surgery and other independent predictors of survival.253 
Furthermore, patients referred to thoracic surgical centres were 51% (OR 1.51 95%CI 1.16-
1.97) more likely to have surgery than those referred to non surgical centres after adjusting 
for age, sex, performance status, comorbidity and stage.33 
A study of 45,929 ovarian cancer patients with stage III and IV advanced epithelial cancer 
concluded that a surgical volume of greater than 21 cases per year was associated with a 
higher likelihood of patients receiving standard treatment and significantly predictive of 
improved overall survival.254 A more recent review of ovarian cancer surgery concluded that 
increasing age, performance status, surgical complexity and nutritional status all affected 
surgical risk.255 
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1.13.  Patient, tumour and treatment factors that impact on cancer 
survival 
Important patient, tumour and treatment factors need to be considered as potential 
confounders in the analyses of associations between distance from specialist services and 
cancer survival. Presented below are individual patient, tumour and treatment factors known 
independently to influence cancer survival that need to be analysed in statistical modelling. 
The most common method used to model the hazard of death is Cox proportional hazards. 
Studies that use this method associated with bladder, ovarian and lung cancer are discussed. 
1.14. Patient factors and cancer survival 
1.14.1. Sex 
Cancer survival is generally poorer in men than it is for women for most cancer sites largely 
because men tend to present at a later stage than women.11, 143, 207, 211, 221, 256 Bladder cancer 
survival is consistently poorer in women and the reason for this survival difference is largely 
unexplained. 207, 257 213 258 A small number of studies have suggested potential reasons 
including, anatomical differences (women have a thinner detractor muscle potentially 
increasing invasion of the urethra);259 longer delay in women; more advanced disease at 
diagnosis260-263 and a higher proportion of muscle invasive transitional cell carcinoma than 
men.264 
In a recent analysis of a UK lung cancer audit of 34,513 NSCLC patients, males were found 
to have a greater hazard of death after adjusting for age, socioeconomic status, stage, 
comorbidity, performance status, chemotherapy, surgery, radiotherapy, clinical trial 
participation and hospital of treatment.33, 265 
In contrast, while Australian based lung cancer patterns of care have not examined survival 
by sex53-56 females were however, found to be less likely to have treatment than males after 
adjustment for other factors. Therefore, sex is an important factor to consider as a potential 
confounder in analyses of the impact of distance on patient outcomes. 
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1.14.2. Age 
NSW, 143 Australian11 and international studies124, 256, 266 of five year cancer survival overall 
and for individual cancer sites show that a patient’s cancer survival reduces with increasing 
age at diagnosis. Five year survival from all cancer in NSW for the latest available period 
was 86% for patients aged less than 40 and decreased to 43% for patients aged 80 years and 
older.143 However, population registry studies of survival take into account a limited number 
of factors. For example, sex, age, period of diagnosis and sometimes stage, but they cannot 
take into account other factors.11 
Age alone can be a direct factor that influences survival or it can interact or mediate another 
factor, indirectly influencing cancer survival. Older patients may have one or more comorbid 
illnesses267 or be less extensively investigated. Both factors influence treatment options. 
In a recent SEER study of 28,977 stage III and IV NSCLC patients, younger age at diagnosis 
predicted a greater likelihood of referral to specialists, which predicted a higher likelihood of 
adherence to guideline based therapies.268 Janda et al269 predicted treatment outcomes and 
other risk factors for early death of elderly women with advanced ovarian cancer. They 
found that a woman's age, stage at presentation, presence of comorbidities, and oncology 
treatment facility was independently associated with overall survival at 12 months from 
diagnosis. Patients who received both surgery and chemotherapy showed significantly 
improved survival as compared to patients who received only surgery or chemotherapy. For 
patients 80 years and over who had surgery first, perioperative mortality was significantly 
greater in the high-risk group compared to patients within the moderate and low-risk group. 
1.14.3. Ethnicity 
Most studies of ethnicity or race have been undertaken in the US using SEER data.123, 212, 
270In a SEER study 271 of 17,739 patients (stage one and stage two lung cancers) who were 
recommended for surgical therapy (mean age, 75 years; 89% white, 6% black), black 
patients less frequently underwent resection compared with white patients (69% vs 83%, 
respectively; P <.001). After adjustment, black race was associated with lower odds of 
receiving surgical therapy (odds ratio = 0.43; 99% CI, 0.36-0.52). 
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The US Department of Veterans affairs extended data from clinical trials and collected 
additional socioeconomic and genetic data for patients with lung and colon cancer.272 They 
found that black patients had significantly lower tumour resection rates, increased 
mediastinal involvement and advanced stage at diagnosis compared to whites. However, 
once stage was taken into account there was no significant difference in survival.273, 274 
Unadjusted 5-year survival rates were lower for black patients compared with white patients 
(36% vs 42%, respectively; P <.0001).Mulligan et al275 found that there were no differences 
in survival between black and white patients when access to medical care is universal. Male 
sex, incomplete resection, and advanced stage were significant predictors of poor lung 
cancer survival. Predictors of good survival were bronchoalveolar carcinoma histology and 
smoking cessation of seven years or more. The international CONCORD study of cancer 
survival 256 found survival was substantially lower in black patients with breast, colorectal 
and prostate cancer in 16 US states and six metropolitan areas. Depending on the cancer site, 
when all ethnicities were combined, relative survival ranged from 2% lower for breast 
cancer and 5% lower for prostate cancer. 
1.14.4. Socioeconomic status 
Differences in cancer survival by socioeconomic status (SES) have been reported in many 
countries, with poorer survival found in people living in deprived areas.11, 276-289 The Index of 
Relative Disadvantage is used in most population-based Australian studies as the measure of 
SES. It is a composite variable derived from census indices of education and occupation.290 
Five year survival in NSW declines with each SES grouping for cancer overall (all types 
except non-melanoma skin cancer), prostate, breast, cervical, lung mesothelioma, myeloma, 
non-Hodgkin’s lymphoma and cancer of unknown primary.11 
In NSW, the most comprehensive study of survival and SES status was undertaken by Yu.68 
Five year relative survival of 13 cancer types diagnosed between 1992 and 2000 were 
compared by SES, before and after adjusting for stage at diagnosis. Patients in the lowest 
SES areas had a 10 to 20% higher risk of death than those in the highest SES areas. 
Significantly, worse survival occurred in lower SES areas for cancers of the stomach, liver, 
lung and breast. 68 
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Greenwald et al291 found that SES grouping and whether or not surgery was received most 
explained differences in the hazard of death. Patients in the top 10 per cent income group 
were 45% more likely to receive surgical treatment and 102% more likely to attain 5-year 
survival than those in the lowest 10 per cent group. 
In a recent review and metanalyses of SES inequalities and lung cancer treatment, 46 papers 
were reviewed and 23 met the criteria for inclusion. 292 Patients in lower SES groups had less 
surgery and chemotherapy but not radiotherapy. The reduced likelihood of surgery due to 
SES remained are adjusting for stage. Furthermore, the reduced likelihood of surgery due to 
low SES occurred in both universal and non universal health systems. SES is a proxy for 
many relationships. For example, patients living in lower SES tend to have higher rates of 
smoking, more advanced stage at diagnosis and less treatment. 
1.14.5. Comorbidity 
Coexisting conditions or comorbidities are important mediators in the distance survival 
relationship. 210Cancer and comorbidities are more prevalent in the elderly patients.293 
Comorbidity may also preclude a patient from undergoing surgery, or if they do undergo 
surgery, impact on outcome210, 294, 295 A systematic review of indices of comorbidity 
identified 13 different methods.296 Compared to other indices, the Charlson index was found 
to be the most extensively studied index for predicting mortality. 
Most studies of linked cancer registry and hospital data in NSW use the Charlson index as 
the measure of comorbidity. Examination of the quality of NSW comorbidity data for lung 
and CRC patients occurred by comparing linked administrative data and survey data for 
same patients. The comorbidity diabetes had the highest level of agreement between the two 
data sets of the 17 comorbid conditions while chronic obstructive pulmonary disease 
(COPD) was found to have the lowest level of agreement.63, 64 
A later study also compared the quality of comorbidity information in two separate sources 
for NSW prostate cancer patients and found that diabetes also had the highest level of 
agreement while COPD and heart disease the lowest. Agreement between the two data sets 
increased, however, by 14-16% for each of the 17 conditions recorded in the Charlson index 
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when all hospitalisations for the study period were included.64 In this thesis comorbidity is 
measured using the Charlson index and is discussed further in Chapters 4 to 8. 
1.15. Tumour related factors and cancer survival 
1.15.1. Histological subtype of cancer 
Cancer is a heterogeneous disease made of many cell types. Cancer can be classified in two 
ways; by the tissue in which the cancer originates (histological type) and by the primary 
site.297 Cancer survival varies by histological type140. This section focuses on the histological 
types of cancer for people diagnosed with primary bladder, ovary and lung cancer. Cancer 
registries determine the cell type of cancer or morphology code from pathology reports 
notified to the registry. 297 Morphology codes are grouped into histological types using the 
International Classification of Diseases for Oncology.135, 298 Regular updates are specified in 
Cancer Incidence in Five Continents.135 Therefore, comparison of histological types of 
cancer captured in registries should be consistent and able to be compared. 
Bladder cancer has two main histological groups. 212 The most common type of bladder 
cancer arising in the lining is transitional or urothelial carcinoma and constitutes more than 
90% of bladder cancer cases. Papillary transitional cell urothelial carcinoma (70%) has the 
appearance of finger like fronds and does not invade the muscle wall of the bladder. 
Papillary transitional has a five year survival rate of 91.5% and non papillary has once of 
61.2%.212 The most common symptom for papillary and non papillary transitional cell 
carcinoma is microscopic haematuria. 299 
Estimates of relative survival vary widely for bladder cancer. US estimates are always 
higher than Australian estimates because US registries include in situ cases when reporting 
invasive bladder cancer. Five year relative survival estimates for papillary transitional 
carcinoma were 65 per cent in Victorian males and females and 66 per cent in NSW females. 
Whereas, survival from transitional cell carcinoma was 43 per cent in Victorian males and 
females and 43 per cent for NSW females. NSW males had higher five year survival 
estimates of 49.3 per cent.140 
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Lung cancer is comprised of two main histological groups small cell and NSCLC. 230 Within 
the NSCLC group, the most common histological type is squamous cell lung carcinoma. 230 
The second most common type of NSCLC is adenocarcinoma (found on the periphery of the 
lung) which has been increasing in recent years surpassing squamous carcinoma as the most 
common histologic subtype in a number of countries. Adenocarcinoma is more often 
asymptomatic relative to other forms of NSCLC. The third most common cell type is large 
cell carcinoma which accounts for approximately 9% of all lung cancers. Large cell is a 
poorly differentiated cancer that has the lowest survival. In order, five year survival for 
SEER NSCLC ranged from 20% for adenocarcinoma, 17% for squamous and 12% for large 
cell. 230 Similar survival differences as those reported by SEER registries were observed by 
histological subtype in Australian lung cancer patients.300 
Ovarian cancer is comprised of a number of different histological types with serous 
adenocarcinoma (arises directly from the ovarian surface epithelium) regarded as the most 
common and relatively homogeneous group 301 with five year survival estimates of 40% in 
NSW140 and Australia.302 Survival for other ovarian tumours reflect the cell type. Mucinous, 
endometriod and clear cell carcinomas have higher five year survival estimates than serous 
tumours. Survival estimates in NSW and Australia was 58%, 77% and 65% respectively. 140 
302 Unspecified carcinoma of the ovary has the poorest survival at 14%. 140 302 
1.16. Treatment factors and cancer survival 
1.16.1. Emergency department presentation 
Lower SES, older age at diagnosis, and female sex have been identified as predictors of 
emergency department admissions for lung cancer.188, 303, 304 Type of hospital admission 
(emergency versus elective) was examined in UK breast, lung and CRC patients admitted to 
hospital between 1999 and 2006. Fifty-two per cent of all lung cancer patients were admitted 
as emergency patients. Patients admitted to hospital through the emergency department are 
less likely to have surgery for their lung cancer, regardless of their age at diagnosis (adjusted 
odd's ratio for lung cancer surgery of 0.52 (0.46 to 0.59) in patients aged 80-89 compared to 
those aged 50-59. Breast and colorectal patients admitted via the emergency department 
were also less likely to undergo resection.304 
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About half of all Northern and Yorkshre lung cancer patients admitted through the 
emergency department had only a chest x-ray and no definitive diagnosis of lung cancer. 
These patients were also less likely to be histologically confirmed, receive specialist care or 
have private health insurance.188 In a more recent study of breast, lung and prostate cancers 
in the east of England for the period 2006-2008, advanced stage and older age were found to 
most predict an emergency presentation, followed by comorbidity and female sex. After 
adjusting for age, stage and comorbidity, an emergency department presentation remained 
predictive of short-term mortality (defined as death within a month of diagnosis).305 
Two WA linkage studies have investigated emergency department presentations. In the first 
study, 20% of all lung cancer patients had their cancer detected at an emergency department 
admission.60 The second study found that the proportion of women diagnosed with ovarian 
cancer at an emergency department presentation decreased from 26.5% in 1982–1987 to 
15.4% in 1994–1998. At the same time the proportion of women with ovarian cancer 
undergoing surgery increased and a 15% increase in relative survival occurred.61 
1.16.2. Delay in diagnosis of cancer 
Understanding reasons for a delay in diagnosis may alter the progression of the disease and 
improve patient survival. Reasons for delays in diagnosis depend on patient and provider 
factors and is stongly influenced by presenting symptoms. Macleod 306 in a systematic 
review noted that misdiagnosis was a common reason for delay regardless of cancer site 
because symptoms were attributed incorrectly to non cancer causes. For other cancer sites, 
the most common reasons for a delay in diagnosis included: inadequate patient examination; 
use of inappropriate tests or failure to follow up inconclusive test results. Most studies of 
cancer patients that have measured delay from symptom awareness to diagnosis are limited. 
Many were retrospective and, therefore, subject to recall bias, qualitative and therefore based 
on views of a small number of patients307, 308 or were systematic reviews of existing 
literature.306, 309 Consequently, few studies have examined survival due to a delay from first 
symptoms to diagnosis. 
In Swedish study of 343 bladder cancer patients, the median delay from symptom awareness 
to the first consultation was 15 days. The delay was longer when the presenting symptom 
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was urgency rather than haematuria. The average time from the GP to the urologist was 62 
days but longer in patients who were older, and those who had more referrals particularly 
women. 310 
There is no evidence that reducing the time from symptom onset to presentation at a GP 
improves survival outcomes for women diagnosed with ovarian cancer.311 In a representative 
sample of Australian women diagnosed with ovarian cancer between 2002 and 2005, 90% of 
whom presented to a general practitioner with symptoms, 55% had presented at one month 
70% at two months and 92% within 6 months of diagnosis. Cancer survival was similar 
regardless of time from symptom onset to diagnosis. Consequently, it is unlikely that 
reducing the time from symptom onset to diagnosis will alter the progression of ovarian 
cancer. 
Delays in lung cancer were examined in a retrospective audit of electronic medical records 
in 587 patients in two tertiary centres. Two clinicians independantly reviewed the records 
and found that the most common preventable delay was the failure to recognise abnormal 
imaging results and failure to complete key diagnostic procedures (first needle biopsy) in a 
timely manner.312 
1.16.3. Delay from diagnosis to surgery 
Cancer site and histological subtype determine whether a delay from diagnosis to surgery 
influences cancer survival. Colorectal and breast cancer patients who had surgery 12 or more 
weeks after their diagnosis had hazard ratios of 2.65 and 1.91 respectively. No increase in 
the hazard of death was found in lung and thyroid patients.313 After adjusting for cancer site, 
people who had higher incomes had shorter delays to surgery and lower mortality, while 
those who travelled further had longer delays and higher mortality. Most people who 
travelled outside of their hospital referral area did so to access specialist care. Therefore, 
while travelling to a high volume specialist centre may improve outcome it may also lead to 
a delay in surgery. 313 
Timely referral to surgery is particularly important for bladder cancer patients. With the 
exception of one study314 that showed no impact on survival, the majority of people with 
bladder cancer who had a cystectomy later than 12 weeks from diagnosis had worse survival 
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and poorer clinical outcomes (increase in muscle invasion – more advanced stage and 
grade).28, 216, 217, 310, 313, 315-317 
However, for women with ovarian cancer a full diagnosis is often not made until the patient 
undergoes surgery. Therefore, reducing the time from diagnosis to surgery was found to 
have no impact on survival.308, 311 
Similarly, for people with NSCLC, reducing the time from diagnosis to surgery was not 
associated with better cancer survival regardless of stage at diagnosis, 318, 319 and did not 
result in an increase in tumour progression for patients who waited longer for 
radiotherapy.197 
1.16.4.  Patient insurance status 
Numerous US 44, 48, 320-323 35 and Australian46, 57, 285, 324 studies document the impact of having 
private health insurance status on overall survival for prostate, breast, lung and colorectal 
cancers.322 Lung132, 138 and breast cancer patients 325 were more likely to undergo surgery if 
they had private medical insurance. Conversely, lung cancer patients had a reduced 
likelihood of undergoing a lobectomy44 or any resection326 for NSCLC without health 
insurance. Uninsured lung, oesophagus and breast cancer patients and those with Medicaid 
only were less likely to receive care in high volume hospitals. They also had lower rates of 
surgery.35 In addition, patients with private insurance, who did not have surgery, were more 
likely to receive another form of anticancer therapy, either radiation or chemotherapy (1.57; 
1.18 to 2.09). 325 
Australian CRC patients treated in private hospitals327 46, 328, 329 were found to have 
significantly better survival outcomes, after adjustment for age, sex and stage. European 
prostate cancer patients with localised stage who had private health insurance were found to 
have more staging procedures, more surgery less recurrence and a lower hazard of dying 
than patients without insurance.48 
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1.17. Thesis aims 
The overall aim of this thesis is to understand whether distance from, and access to, surgical 
care (bladder), and specialist surgical care (ovary and lung cancer) influences the likelihood 
of presenting with advanced or unknown stage, receiving no surgical treatment and whether 
these lead to poorer survival, after adjusting for patient, tumour and treatment factors. 
More specifically, the aims for each chapter in this thesis are: 
1. To examine two methodological issues related to the measurement of distance and 
cancer survival. Specifically to 
a. compare current and new methods of allocating small geographical areas and 
verify that geocoded coordinates applied to the NSW CCR can be used to 
measure straight-line distance by (Chapter 2) and 
b. determine whether relative, net and cause specific survival methods have similar 
results in NSW and Northern and Yorkshire. Compare the difference in survival 
between NSW and another registry (the Northern and Yorkshire cancer 
registry). Different survival methods will be compared for selected cancer sites 
(Chapter 3).  
2. To investigate why bladder cancer survival is consistently poorer in women who 
undergo a cystectomy or have a segmental resection after adjustment for patient, tumour 
and treatment factors. and 
a. To investigate whether distance to surgical hospitals is an independent predictor of 
bladder cancer survival. This study evaluates the impact of distance to actual care rather 
than specialist care because of the absence of guidelines providing advice on the surgical 
management of bladder cancer (Chapter 4). 
3. To investigate whether distance to specialist care is associated with ovarian cancer 
survival after taking account of patient, tumour and treatment factors. In addition, to 
investigate factors associated with treatment in public general hospitals (as opposed to 
specialist hospitals or private general hospitals) and factors predictive of surgery for 
ovarian cancer (Chapter 5).  
4. To investigate whether increasing distance to a specialist centre was associated with 
advanced stage or unknown stage NSCLC and whether this influences hospital of 
attendance after adjustment for patient, tumour and treatment factors (Chapter 6). 
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5. To investigate whether increasing distance to the nearest accessible specialist hospital 
(NASH) a public hospital with a thoracic surgical service is associated with failure to 
receive surgical treatment for localised primary NSCLC after adjusting for for patient, 
tumour and treatment factors (Chapter 7). 
6. To investigate whether increasing distance to the NASH is associated with poorer 
survival for patients with localised, regional and distant stage primary NSCLC after 
adjusting for potentially confounding variables (Chapter 8). 
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2. Evaluating geocoding of the CCR and measuring 
distance in people diagnosed with cancer in NSW 
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2.1. Abstract 
Background The New South Wales (NSW) Central Cancer Registry (CCR) records the 
residential address of all people with cancer at the time of diagnosis. On the basis of this 
address, a National Locality Index (NLI) encoder is applied that determines Local 
Government Areas and subsequently, the Area Health Services (AHS) at the time of 
diagnosis. The aims of this study are to evaluate the impact of geocoding the CCR data, by 
comparing historical and geocoded methods of allocating Local Government Areas (LGAs) 
and to evaluate whether straight-line distance can be calculated from geocodes. Methods. 
Numbers of cases of cancer diagnosed between 1999 and 2004 and grouped to 2001 LGAs 
based on geocode coordinates were compared with the number of cases allocated using the 
current NLI method. Straight-line distance was calculated from each persons case address at 
diagnosis to Royal Prince Alfred (RPA) hospital using the Great Circle Distance Calculator. 
The mean distance in kilometres for all cases diagnosed between 1972 and 2004 within an 
LGA was obtained and the minimum and maximum distance values calculated. Results. For 
86% of LGAs there was a plus or minus 0.02% difference in the proportion of total cases 
within each NLI and geocode allocated LGA. Mean distance in kilometres for cases within 
an LGA to RPA were consistent with known distances. The proportion of cases that lived 
further than 100 km was consistent and increased by year of diagnosis. As expected all rural 
AHSs were located 100km or more from RPA. Conclusion. The number of incidence cases 
within an LGA is similar regardless of the method of allocation. Therefore incidence, 
mortality and survival estimates for each LGA will be consistent. The mean distance in 
kilometres from the LGA to RPA using the Great Circle Distance Calculator was consistent 
with the known location of LGAs providing confidence that distance in kilometres to other 
specialist hospitals in Sydney Australia can be obtained using this method and applied to 
subsequent studies in this thesis. 
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2.2. Introduction 
Cancer Registries report geographic differences in patterns of cancer incidence, mortality 
and survival to evaluate progress in cancer control programs. The NSW Central Cancer 
Registry (CCR) publishes incidence and mortality rates by Local Health Districts (LHD) and 
small geographical regions or Local Government Areas (LGAs) annually and reports 
survival every three to five years. 
The CCR is a historical database of all cases of cancer diagnosed in NSW from 1972 to 
2009. The residential address of all persons with cancer at the time of diagnosis is recorded. 
Applied to this address is a National Locality Index encoder (NLI) 1 developed by the 
Australian Bureau of Statistics (ABS). The NLI coder consists of a localities index and street 
index. A locality is where people live, most localities are associated with one LGA but 
sometimes these are split into two LGAs on the basis of street information.2 Since 1984, 
LGAs are updated annually to reflect changes proclaimed by State and Territory government 
authorities.2 With every change in boundaries, the ABS would publish annual updates to the 
NLI coder and produce concordance maps. An LGA at the time of diagnosis is allocated to a 
person’s case address (the full address of a person at diagnosis for each case of cancer). 
Subsequently groups of LGAs are associated with an LHD at the time of diagnosis. 
Geocoding is the process of linking address data to a location on the Earth's surface.3 4 
Geographical coordinates expressed as longitude and latitude are assigned to a person’s 
address at diagnosis. Changes in geographical regions occur in NSW due to census and 
population changes. Therefore, the entire cancer registry database needs updating to reflect 
boundary changes. 
In 2007, the ABS announced that it would no longer provide new versions of the NLI coder 
because from 2011 onwards population boundaries would be geocoded based on the census. 
Therefore, geocoding the NSW CCR was both a necessity and an opportunity to develop 
new measures like distance. 
A major advantage of geocoding each person’s address is that the geocoded coordinates can 
be linked to a defined shape or polygon of geocoded coordinates (that outline the boundaries 
of a population area) using a spatial join using geocoding software like ESRI ArcGIS 9.3 
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software. 5 As new population boundary files are developed, cancer cases (numerator) can 
easily be linked to populations (denominator) and rates calculated. Furthermore, geocode 
coordinates allow the measurement of distance from a patient’s home to where they are 
treated. 
Addresses on the cancer registry were geocoded by the Northern Rivers University 
Department of Rural Health as part of a consultancy. Two geocoding methods were applied 
to the case addresses of people diagnosed with cancer and living in NSW between 1972 and 
2004 using two different geocoding methods. These were FEBRL (Freely Extensible 
Biomedical Record Linkage)6 and Map Marker7. Both methods can clean and georeference 
individual records. The FEBRL6 software was developed by the Ministry of Health and used 
the extensive Geocoded National Address File (GNAF) to allocate geocodes. The GNAF 
data file8 has 13 million geocoded physical addresses derived from a variety of national and 
state based datasets. Map Marker is a geocoding product from MapInfo that allocates a 
geocode using a set of weights that scores each portion of the address against an Address 
Dictionary. Both methods provide a longitude and latitude coordinate for every case 
associated with a 2001 census boundary code and a final geocode was assigned based on the 
most precise estimate.9 
Of the 809,551 cases geocoded 82.7%, were geocoded using the complete address 7.8% 
were geocoded to a street only 8.5% to a locality and for 0.87% there was not enough 
information to geocode. There were also 6,419 records that did not geocode. Therefore, the 
reasons why these records did not geocode needed to be investigated and rectified. It was 
also necessary to check the quality of geocoding in the CCR to ensure that there had not 
been any incorrect assignment of longitude and latitude coordinates.10 In addition, the 
distance measure required validation. 
This study investigates three aims. The first aim compares the number of cases within each 
LGA using the current and new-geocoded methods. The second aim evaluates whether the 
Great Circle Distance Calculator can calculate plausible distance in kilometres from each 
person’s geocode coordinates at diagnosis to one treatment facility (RPA hospital). The last 
aim evaluates the proportion of the population who lived greater than 100 kilometres from 
RPA by year of diagnosis and within rural AHS of residence. 
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2.3. Methods 
2.3.1. Methods aim one - comparison of 2001 boundaries 
All NSW cases of cancer with a date of diagnosis between 1999 and 2004 were included in 
this comparison. The number of cases within an LGA was determined by the National 
Locality coder.1 To determine the numbers of cases within each 2001 LGA, some 1999 
LGAs were grouped. For example, the Blacktown LGA in 1999 was one area but by 2001, it 
had split into three LGAs (north, south-east and south-west Blacktown). Geocode 
coordinates within 2001 LGA boundaries were linked back to the NSW CCR database by 
unencrypting the ID provided to Northern Rivers. The numbers of cases of cancer within 
each LGA using the NLI and geocoded methods were compared and the difference in 
numbers of incidence cases obtained by subtracting one number from the other. The 
contribution of each LGA as a proportion of the total cases was calculated for each method. 
For example, if an LGA contributed 1.75% of cases for both methods then the difference in 
the proportion of total cases would be 0. 
2.3.2. Methods aim two - distance to RPA 
All NSW cases of cancer with a date of diagnosis between 1972 and 2004 were included in 
this comparison. Distance between each case on the cancer registry database and RPA was 
calculated using the Great Distance Circle Calculator a Statistical Analysis Systems (SAS)11 
algorithm obtained from the North American Association of Cancer Registries (NAACR) 11 
using SAS 9.2. 12 The longitude and latitude coordinates for RPA were obtained from the 
NSW Ministry of Health. The Great Circle Distance is the shortest distance between two 
points on the surface of the earth. The shape of the earth is a flattened spheroid the distance 
calculated in the SAS program ignores the differences in the effect of elevation. Distance is 
calculated in miles as the crow flies if the crow flies at sea level and then converted into 
kilometres.11, 13 The law of cosines for spherical geometry is used. 
The SAS program includes the following formula 
SAS Code: 
Distance in miles= 1.150779 * 60 * (180/CONSTANT ('PI')) * 
 71 
Arcos (sin (latr1) * sin (latr2) + cos (latr1) *cos (latr2) * cos (longr2-longr1)); 
latr1= Latitude of a person’s address 
latr2= latitude of RPA 
longr1=longitude of a person’s address 
longr2=longitude of RPA 
Arcos (arc of a cosine) is in radians which are converted to degrees (60) and then nautical 
miles, then statute miles (1.150779). 
For example 
• the latitude of RPA hospital = -33.889637 
• the longitude of RPA hospital =151.182475 
• distance in miles between a patient home and RPA is obtained by applying the 
algorithm and is converted to kilometres by multiplying by a conversion factor of 
1.60943. 
Distance in kilometres from each person’s residential address at the time of diagnosis (for 
each case of cancer) to RPA hospital. The mean distance within an LGA was calculated for 
all cases of cancer as well as the shortest (minimum) and longest distance (maximum) 
distance from the LGA to RPA. Mean distance for each LGA was mapped using ArcGIS 9.3 
with different colours representing five categories. The lowest and highest categories were 
open ended and categories in between grouped into 150 km groupings (2-100, 101-255,256-
396, 397-558 and 559-931). 
2.3.3. Methods aim three-distance to RPA by AHS 
The number and the proportion of cases that live 100 km or more from RPA tabulated by 
year of diagnosis and by 2005 AHS Regions of residence. 
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2.4. Results 
There were 1,144 indeterminate address records in people diagnosed between 1999 and 2004 
(approx. 1%) that failed to geocode. Case addresses were not assigned geocodes for the 
following reasons: the address included the name of a caravan park only, or a nursing home, 
hostel or post office (PO) box. To correct these records, cancer registry staff added the 
closest street address by checking other notifications for the same case and by looking up 
address details of historical and current nursing homes. The address of the post office was 
used for case addresses where only a PO Box was available. All address records on the CCR 
database were eventually geocoded for the period 1972 to 2004. 
2.4.1. Results aim one - comparison of 2001 boundaries 
The difference between the two methods is the difference in the number of cases between 
the historical LGA method and the new geocoded method. There was zero or no difference 
between 63% of all LGAs, 23% had a difference of 0.02% and 9% had a difference of 
0.04%. For 86% of LGAs there was plus or minus 0.02% difference in the numbers of cases 
within each NLI and geocode allocated LGA.The largest difference was Hurstville LGA 
with a difference of 178 cases or 0.1%. Case addresses that did not map were those 
designated as indeterminate by Febryl and MapMarker and rectified as described above 
(Chapter 2Appendix 1 Table 1, Figure 1). 
Chapter 2 Figure 1 Frequency histogram of the percentage difference in the number of cases within 2001 LGAs 
allocated using the geocoded method and the NLI coder in NSW between 1999 and 2004. 
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2.4.2. Results aim two - distance to RPA 
The mean distance for cases within a LGA was calculated and mapped. The most distant 
LGA was Broken Hill where residents lived a mean distance of 931 km (929 km minimum 
or 934 km maximum) from RPA. The closest LGA was Leichardt with a mean distance of 
two kilometres (minimum 0 km maximum 5km). All LGAs were internally consistent with 
the known distances (Appendix 1 Table 1 Figure 2). 
The proportion of people diagnosed with cancer that lived greater than 100 km from RPA by 
year of diagnosis was similar and consistent, with a gradual increase in the proportion of 
people who lived 100kms or more from RPA for each year of diagnosis (Chapter 2 Table 1). 
2.4.3. Results aim three - distance to RPA by AHS 
Finally, most people diagnosed with cancer who lived in a rural AHS lived 100km from 
RPA, which is consistent and expected (Chapter 2 Table 2). 
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Chapter 2 Table 1 NSW CCR incidence cases by year of diagnosis and the proportion of cases less than 100km or more 
than 100km from each person’s home to RPA hospital. 
year of 
diagnosis 
100k or 
less 
101 k or 
more 
Total 
cases 
% 100 k 
or less 
% 100K 
or more 
 1972  8,265   3,134   11,399  73% 27% 
 1973  8,292   3,204   11,496  72% 28% 
 1974  8,829   3,465   12,294  72% 28% 
 1975  9,101   3,547   12,648  72% 28% 
 1976  9,573   3,897   13,470  71% 29% 
 1977  9,670   4,007   13,677  71% 29% 
 1978  9,820   4,030   13,850  71% 29% 
 1979  10,265   4,278   14,543  71% 29% 
 1980  10,774   4,436   15,210  71% 29% 
 1981  11,138   4,658   15,796  71% 29% 
 1982  11,335   5,047   16,382  69% 31% 
 1983  11,921   5,175   17,096  70% 30% 
 1984  12,180   5,608   17,788  68% 32% 
 1985  12,550   5,764   18,314  69% 31% 
 1986  12,908   6,254   19,162  67% 33% 
 1987  13,482   6,422   19,904  68% 32% 
 1988  13,582   6,781   20,363  67% 33% 
 1989  13,836   7,104   20,940  66% 34% 
 1990  14,237   7,386   21,623  66% 34% 
 1991  15,198   7,663   22,861  66% 34% 
 1992  15,622   8,306   23,928  65% 35% 
 1993  16,523   8,909   25,432  65% 35% 
 1994  17,325   9,374   26,699  65% 35% 
 1995  17,422   9,654   27,076  64% 36% 
 1996  17,136   9,380   26,516  65% 35% 
 1997  17,784   9,749   27,533  65% 35% 
 1998  18,114   9,722   27,836  65% 35% 
 1999  18,188   10,132   28,320  64% 36% 
 2000  18,653   10,644   29,297  64% 36% 
 2001  19,221   11,168   30,389  63% 37% 
 2002  19,963   11,863   31,826  63% 37% 
 2003  20,570   12,019   32,589  63% 37% 
 2004  20,561   12,194   32,755  63% 37% 
 Total  464,038   234,974   699,012      
 ** distance is as the crow flies and is not road distance 
 * excludes indeterminate codes - 2005 extraction 
 
   
Chapter 2 Table 2 NSW CCR incidence cases 1972-2004 by AHS with the proportion of cases less than or more than 
100 km from each person’s home to RPA hospital. 
AHS of Residence 100 k or less 101 k or more total cases %100k or less %100k or more 
South-Western Sydney 117,792 1,602 119,394 99% 1% 
South-Eastern Sydney-Illawarra AHS 127,481 10,737 138,218 92% 8% 
Western Sydney 80,479 2,286 82,765 97% 3% 
Northern Sydney Central Coast AHS 133,201 168 133,369 100% 0% 
Hunter-New England 4,796 88,821 93,617 5% 95% 
North Coast 68 51,014 51,082 0% 100% 
Greater Southern 115 47,206 47,321 0% 100% 
Greater Western 43 33,113 33,156 0% 100% 
Total 463,985 234,965 698,950 66% 34% 
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Chapter 2 Figure 2 The mean distance in kilometres for NSW CCR cases within each LGA to RPA Hospital for cases diagnosed between 1972 and 2004 
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2.5. Discussion 
The first aim compared whether the number of cases within each LGA was similar using the 
current and new-geocoded methods. In 86% of LGAs, there was a difference of plus or 
minus 0.02% in the numbers of cases within each NLI and geocode allocated LGA, 
providing confidence that both methods resulted in similar numbers of incidence cases for an 
LGA. The second aim evaluated whether the Great Circle Distance Calculator could be used 
to calculate plausible distance in kilometres from each LGA to RPA. Mean distances in 
kilometres from each LGA to RPA hospital were consistent with the known distance for 
each LGA providing further certainty that geocode coordinates applied to the Great Circle 
Distance Calculator was the correctly measured distance in kilometres in NSW. The last aim 
evaluated whether the proportion of the population who live greater than 100 kilometres 
from RPA was consistent by year of diagnosis and AHS of residence. The proportional 
breakdown by year of diagnosis was consistent, and all rural AHS located 100km or more 
from RPA provided further reassurance. 
It was important that LGAs allocated using new methods are consistent with and similar to 
LGAs allocated using historical methods. Otherwise, increases in the numbers of cases 
within an LGA may be a methodological artefact due to the new method rather than a real 
occurrence. Furthermore, census variables like SES14 and the Accessibility and Remoteness 
Index of Australia (ARIA)15 and other census characteristics16 need to be routinely linked to 
LGA boundaries. For example, NSW has the third highest incidence rate of melanoma in the 
world of all registries that contribute to Cancer Incidence in Five Continents. 17 Exposure to 
ultraviolet (UV) radiation is a known risk factor for melanoma. Incidence rates of melanoma 
increase the closer a person lives near the equator which is consistent with increasing UV 
radiation.18 There is an increasing trend in the rates of melanoma in NSW in coastal LGAs as 
they move closer to the Queensland.18 Therefore, sun protection initiatives need 
implementation and monitoring in these LGAs. A decline in incidence rates and mortality 
rates and an improvement in survival are indicative of success. Another example is the 50% 
reduction in the incidence of cervical cancer that has occurred since the 1990s. This 
reduction in incidence occurred after the introduction of the Cervical Screening program, 
indicating that it had been successful. The little or no difference in the allocation of cases 
within each 2001 LGA regardless of method provides confidence that rates should be 
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consistent over time and that differences observed for incidence, mortality and survival are 
real and not the result of a methodological artefact. 
The mean distance in kilometres from each LGA to RPA hospital calculated in this study 
used the Great Circle Distance Calculator which provided consistent plausible distance 
measures providing confidence that the method could be used to calculate distance to other 
hospitals satisfactorily. Furthermore, the algorithm and SAS code had already been 
developed and validated by the North American Association of Cancer Registries.11 
Moreover, the method has been applied to a large number of cancer registry studies. 19, 20 21, 22 
23, 24 25-27 However, other methods of calculating distance could have been used if these had 
been available. Therefore, it is important to consider whether different methods of allocating 
straight-line distance produce different results. Recently, Geoscience Australia28 compared 
the Great Circle method, with the approximate ellipse and Vincentys’ formula method. All 
three methods produced similar estimates of straight-line distance with less than one 
kilometre difference between methods at 1000 kilometres, 28 the maximum distance from a 
person’s residence to RPA that is recorded on the CCR database. This provided reassurance 
that the method used would give similar distance results. 
One limitation is that we were not able to measure travel distances and compared this to 
straight-line distance because this information was not available. However, a comparison of 
straight-line and travel distances in the UK indicated that there was a high degree of 
correlation between the two measures (r = 0.856).29 Furthermore, a study of travel time and six 
different methods of accessibility to the closest medical provider found that road distance 
and straight-line distance (from the geocoded street of a person to the geocoded street of the 
provider) predicted 96% and 94% of the variability in travel time respectively. Other 
measures, for example, rural or urban residence or providers per head of population 
explained only 30% and 83% of the variability in travel time respectively.30 
Apart from the ability to measure distance to treatment there are many advantages of 
geocoding the NSW CCR database. Population and other demographic data link to registry 
data by spatial joining in ArcGIS software. The ABS has produced small areas of population 
referred to as mesh blocks based on geocoded boundaries. Mesh Blocks are the smallest 
geographic region of population for which census data is available. In 2011, there were 
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approximately 347,000 Mesh Blocks covering the whole of Australia.31 For the first time 
cancer and population, data will be geocoded. 
Ideally, all agencies that use geocodes should investigate the impact of boundary changes on 
historical data by comparing the results of existing methods with boundaries created using 
the geocodes. These comparisons provide confidence that distance to hospital is a reliable 
measure that can be calculated for subsequent studies in this thesis. While this study 
compared cases to the end of 2004, geocoding now routinely undertaken in the NSW CCR, 
with the 2004 to 2008 data geocoded using the same methodologies as described. 
Discussed in Chapter 4 is the impact of distance to hospital of surgery on bladder cancer 
survival for people who undergo a cystectomy or resection. Discussed also is the impact of 
distance and treatment in a specialist hospital on cancer survival for women with ovarian 
cancer in Chapter 5. Similarly, the impact of distance to the nearest accessible specialist 
hospital (NASH) on the likelihood of advanced or unknown stage, no surgery and cancer 
survival is examined for people with lung cancer in Chapters 6, 7 and 8. 
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Chapter 2 Appendix 1 Table 1 NSW CCR incidence cases grouped to 2001 LGA groups using Geocoded coordinates and 
the conventional NLI encoder. 
2001 LGA 
 Geocoded 
boundaries 
number Per cent 2001 
 NLI coded 
boundaries 
Freque
ncy 
Per cent %diffe
rence 
cases 
different 
Albury (C) 1081 0.71 Albury 1095 0.71 0 14 
Armidale Dumaresq (A) 
 Ci  
443 0.29 Armidale 519 0.34 -0.05 76 
Armidale Dumaresq (A) 
B l 
64 0.04 Dumaresq 10 0.01 0.03 -54 
Ashfield (A) 922 0.6 Ashfield 912 0.59 0.01 -10 
Auburn (A) 957 0.63 Auburn 966 0.63 0 9 
Ballina (A) 1116 0.73 Ballina 1141 0.74 -0.01 25 
Balranald (A) 65 0.04 Balranald 67 0.04 0 2 
Bankstown (C) 3830 2.51 Bankstown 3885 2.53 -0.02 55 
Barraba (A) 82 0.05 Barraba 82 0.05 0 0 
Bathurst (C) 667 0.44 Bathurst 684 0.45 -0.01 17 
Baulkham Hills (A) 2834 1.86 Baulkham Hills 2748 1.79 0.07 -86 
Bega Valley (A) 910 0.6 Bega Valley 913 0.59 0.01 3 
Bellingen (A) 381 0.25 Bellingen 392 0.26 -0.01 11 
Berrigan (A) 238 0.16 Berrigan 235 0.15 0.01 -3 
Bingara (A) 68 0.04 Bingara 55 0.04 0 -13 
Blacktown (C) - North 1063 0.7 Blacktown 4184 2.72 0.01 -26 
Blacktown (C) - South-
E  
1838 1.21      
Blacktown (C) - South-
W  
1257 0.82      
Bland (A) 185 0.12 Bland 190 0.12 0 5 
Blayney (A) - Pt A 112 0.07 Blayney 172 0.11 -0.01 60 
Blayney (A) - Pt B 45 0.03      
Blue Mountains (C) 1766 1.16 Blue Mountains 1762 1.15 0.01 -4 
Bogan (A) 101 0.07 Bogan 101 0.07 0 0 
Bombala (A) 86 0.06 Bombala 99 0.06 0 13 
Boorowa (A) 79 0.05 Boorowa 78 0.05 0 -1 
Botany Bay (C) 889 0.58 Botany 895 0.58 0 6 
Bourke (A) 58 0.04 Bourke 59 0.04 0 1 
Brewarrina (A) 45 0.03 Brewarrina 48 0.03 0 3 
Broken Hill (C) 601 0.39 Broken Hill 628 0.41 -0.02 27 
Burwood (A) 645 0.42 Burwood 654 0.43 -0.01 9 
Byron (A) 646 0.42 Byron 647 0.42 0 1 
Cabonne (A) - Pt A 35 0.02 Cabonne 349 0.23 -0.01 -1 
Cabonne (A) - Pt B 19 0.01      
Cabonne (A) - Pt C 294 0.19      
Camden (A) 732 0.48 Camden 784 0.51 -0.03 52 
Campbelltown (C) 2190 1.44 Campbelltown 2188 1.42 0.02 -2 
Canterbury (C) 2822 1.85 Canterbury 2736 1.78 0.07 -86 
Carrathool (A) 85 0.06 Carrathool 76 0.05 0.01 -9 
Central Darling (A) 57 0.04 Central Darling 59 0.04 0 2 
Cessnock (C) 1162 0.76 Cessnock 1183 0.77 -0.01 21 
Cobar (A) 109 0.07 Cobar 107 0.07 0 -2 
Coffs Harbour (C) - Pt A 1279 0.84 Coffs Harbour 1673 1.09 -0.01 -32 
Coffs Harbour (C) - Pt B 362 0.24 
   
  
Conargo (A) 24 0.02 Conargo 7 0 0.02 -17 
Concord (A) 648 0.43 Concord 641 0.42 0.01 -7 
Coolah (A) 105 0.07 Coolah 110 0.07 0 5 
Coolamon (A) 99 0.06 Coolamon 108 0.07 -0.01 9 
Cooma-Monaro (A) 229 0.15 Cooma-Monaro 237 0.15 0 8 
Coonabarabran (A) 181 0.12 Coonabarabran 185 0.12 0 4 
Coonamble (A) 120 0.08 Coonamble 122 0.08 0 2 
Cootamundra (A) 262 0.17 Cootamundra 262 0.17 0 0 
Copmanhurst (A) 104 0.07 Copmanhurst 76 0.05 0.02 -28 
Corowa (A) 292 0.19 Corowa 300 0.2 -0.01 8 
Cowra (A) 346 0.23 Cowra 349 0.23 0 3 
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Chapter 2 Appendix 1 Table 1 NSW CCR incidence cases grouped to 2001 LGA groups using Geocoded coordinates 
and the conventional NLI encoder. 
 2001 LGA 
 Geocoded 
 
number Per cent 2001 
 NLI coded 
 
Freque
ncy 
Per cent %diffe
rence 
cases 
different 
Crookwell (A) 140 0.09 Crookwell 142 0.09 0 2 
Culcairn (A) 115 0.08 Culcairn 117 0.08 0 2 
Deniliquin (A) 250 0.16 Deniliquin 315 0.21 -0.05 65 
Drummoyne (A) 898 0.59 Drummoyne 916 0.6 -0.01 18 
Dubbo (C) - Pt A 788 0.52  851 0.55 0.01 -4 
Dubbo (C) - Pt B 59 0.04 Dubbo 
  
  
Dungog (A) 203 0.13 Dungog 212 0.14 -0.01 9 
Eurobodalla (A) 1176 0.77 Eurobodalla 1177 0.77 0 1 
Evans (A) - Pt A 22 0.01 Evans 96 0.06 0 4 
Evans (A) - Pt B 78 0.05      
Fairfield (C) 3136 2.06 Fairfield 3170 2.06 0 34 
Forbes (A) 299 0.2 Forbes 300 0.2 0 1 
Gilgandra (A) 123 0.08 Gilgandra 121 0.08 0 -2 
Glen Innes (A) 170 0.11 Glen Innes 214 0.14 -0.03 44 
Gloucester (A) 134 0.09 Gloucester 132 0.09 0 -2 
Gosford (C) 4637 3.04 Gosford 4720 3.07 -0.03 83 
Goulburn (C) 532 0.35 Goulburn 589 0.38 -0.03 57 
Grafton (C) 525 0.34 Grafton 577 0.38 -0.04 52 
Great Lakes (A) 1256 0.82 Great Lakes 1256 0.82 0 0 
Greater Lithgow (C) 523 0.34 Greater Lithgow 536 0.35 -0.01 13 
Greater Taree (C) 1284 0.84 Greater Taree 1289 0.84 0 5 
Griffith (C) 480 0.31 Griffith 481 0.31 0 1 
Gundagai (A) 137 0.09 Gundagai 135 0.09 0 -2 
Gunnedah (A) 340 0.22 Gunnedah 357 0.23 -0.01 17 
Gunning (A) 48 0.03 Gunning 45 0.03 0 -3 
Guyra (A) 102 0.07 Guyra 112 0.07 0 10 
Harden (A) 117 0.08 Harden 106 0.07 0.01 -11 
Hastings (A) - Pt A 1350 0.89     -29 
Hastings (A) - Pt B 943 0.62 Hastings 2322 1.51 0  
Hawkesbury (C) 1056 0.69 Hawkesbury 1058 0.69 0 2 
Hay (A) 102 0.07 Hay 106 0.07 0 4 
Holbrook (A) 72 0.05 Holbrook 71 0.05 0 -1 
Holroyd (C) 1828 1.2 Holroyd 1875 1.22 -0.02 47 
Hornsby (A) 3177 2.08 Hornsby 3244 2.11 -0.03 67 
Hume (A) 164 0.11 Hume 165 0.11 0 1 
Hunter's Hill (A) 414 0.27 Hunter's Hill 403 0.26 0.01 -11 
Hurstville (C) 1901 1.25 Hurstville 2079 1.35 -0.1 178 
Inverell (A) - Pt A 131 0.09      
Inverell (A) - Pt B 277 0.18 Inverell 422 0.27  -14 
Jerilderie (A) 40 0.03 Jerilderie 43 0.03 0 3 
Junee (A) 133 0.09 Junee 132 0.09 0 -1 
Kempsey (A) 819 0.54 Kempsey 812 0.53 0.01 -7 
Kiama (A) 551 0.36 Kiama 546 0.36 0 -5 
Kogarah (A) 1362 0.89 Kogarah 1286 0.84 0.05 -76 
Ku-ring-gai (A) 2842 1.86 Ku-ring-gai 2872 1.87 -0.01 30 
Kyogle (A) 234 0.15 Kyogle 260 0.17 -0.02 26 
Lachlan (A) 188 0.12 Lachlan 193 0.13 -0.01 5 
Lake Macquarie (C) 4836 3.17 Lake Macquarie 4844 3.15 0.02 8 
Lane Cove (A) 809 0.53 Lane Cove 821 0.53 0 12 
Leeton (A) 274 0.18 Leeton 271 0.18 0 -3 
Leichhardt (A) 1325 0.87 Leichhardt 1333 0.87 0 8 
Lismore (C) - Pt A 759 0.5      
Lismore (C) - Pt B 246 0.16 Lismore 979 0.64  26 
Liverpool (C) 2309 1.51 Liverpool 2288 1.49 0.02 -21 
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and the conventional NLI encoder. 
 2001 LGA 
 Geocoded 
 
number Per cent 2001 
 NLI coded 
 
Freque
ncy 
Per cent %diffe
rence 
cases 
different 
Lockhart (A) 69 0.05 Lockhart 88 0.06 -0.01 19 
Lord Howe Island 10 0.01 Lord Howe Island 10 0.01 0 0 
Maclean (A) 681 0.45 Maclean 690 0.45 0 9 
Maitland (C) 1214 0.8 Maitland 1218 0.79 0.01 4 
Manilla (A) 91 0.06 Manilla 89 0.06 0 -2 
Manly (A) 1056 0.69 Manly 1057 0.69 0 1 
Marrickville (A) 1437 0.94 Marrickville 1436 0.94 0 -1 
Merriwa (A) 63 0.04 Merriwa 72 0.05 -0.01 9 
Moree Plains (A) 283 0.19 Moree Plains 287 0.19 0 4 
Mosman (A) 700 0.46 Mosman 699 0.46 0 -1 
Mudgee (A) 443 0.29 Mudgee 432 0.28 0.01 -11 
Mulwaree (A) 153 0.1 Mulwaree 111 0.07 0.03 -42 
Murray (A) 232 0.15 Murray 176 0.11 0.04 -56 
Murrumbidgee (A) 50 0.03 Murrumbidgee 53 0.03 0 3 
Murrurundi (A) 58 0.04 Murrurundi 62 0.04 0 4 
Muswellbrook (A) 280 0.18 Muswellbrook 283 0.18 0 3 
Nambucca (A) 571 0.37 Nambucca 585 0.38 -0.01 14 
Narrabri (A) 302 0.2 Narrabri 332 0.22 -0.02 30 
Narrandera (A) 214 0.14 Narrandera 224 0.15 -0.01 10 
Narromine (A) 152 0.1 Narromine 153 0.1 0 1 
Newcastle (C) - Inner 108 0.07 Newcastle 3818 2.49   
Newcastle (C) - 
R i d  
3659 2.4 5902 2 0   
North Sydney (A) 1351 0.89 North Sydney 1355 0.88 0.01 4 
Nundle (A) 25 0.02 Nundle 30 0.02 0 5 
Oberon (A) 113 0.07 Oberon 100 0.07 0 -13 
Orange (C) 884 0.58 Orange 907 0.59 -0.01 23 
Parkes (A) 371 0.24 Parkes 375 0.24 0 4 
Parramatta (C) 2987 1.96 Parramatta     2935         1.91 0.05 52 
Parry (A) - Pt A 118 0.08    0.08 49 
Parry (A) - Pt B 174 0.11 Parry 243 0.16 -0.05 69 
Penrith (C) 2778 1.82 Penrith     2775         1.81 0.01 -3 
Pittwater (A) 1599 1.05      
Port Stephens (A) 1565 1.03 Port Stephens 1586 1.03 0 21 
Pristine Waters (A) - 
N b id  
109 0.07 Nymboida 80 0.05 0.02 -29 
Pristine Waters (A) - 
Ul  
169 0.11 Ulmarra 147 0.1 0.01 -22 
Queanbeyan (C) 486 0.32 Queanbeyan 534 0.35 -0.03 48 
Quirindi (A) 138 0.09 Quirindi 138 0.09 0 0 
Randwick (C) 2968 1.95 Randwick    2969         1.93 0.02 1 
Remainder of ACT 10 0.01     -10 
Richmond Valley (A) - 
 
319 0.21 Casino 338 0.22 0.18 -29 
Richmond Valley (A) 
B l 
273 0.18 Richmond River 283 0.18   
Rockdale (C) 2340 1.54 Rockdale 2319 1.51 0.03 -21 
Ryde (C) 2305 1.51 Ryde 2317 1.51 0 12 
Rylstone (A) 124 0.08 Rylstone 122 0.08 0 -2 
Scone (A) 210 0.14 Scone 219 0.14 0 9 
Severn (A) 93 0.06 Severn 65 0.04 0.02 -28 
Shellharbour (C) 1246 0.82 Shellharbour 1247 0.81 0.01 1 
Shoalhaven (C) - Pt A 790 0.52 Shoalhaven  2935  1.91  -18 
Shoalhaven (C) - Pt B 2127 1.4      
Singleton (A) 418 0.27 Singleton 404 0.26 0.01 -14 
Snowy River (A) 117 0.08 Snowy River 129 0.08 0 12 
South Sydney (C) 1905 1.25 South Sydney 1911 1.24 0.01 6 
Strathfield (A) 673 0.44 Strathfield 687 0.45  14 
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and the conventional NLI encoder. 
 2001 LGA 
 Geocoded 
 
number Per cent 2001 
 NLI coded 
 
Freque
ncy 
Per cent %diffe
rence 
cases 
different 
Sutherland Shire (A) - 
 
2801 1.84 Sutherland  4990  3.25  -3 
Sutherland Shire (A) - 
W  
2186 1.43      
Sydney (C) - Inner 191 0.13 Sydney  408  0.27  2 
Sydney (C) - Remainder 219 0.14      
Tallaganda (A) 86 0.06 Tallaganda 88 0.06 0 2 
Tamworth (C) 925 0.61 Tamworth 978 0.64 -0.03 53 
Temora (A) 171 0.11 Temora 173 0.11 0 2 
Tenterfield (A) 161 0.11 Tenterfield 163 0.11 0 2 
Tumbarumba (A) 98 0.06 Tumbarumba 150 0.1 -0.04 52 
Tumut (A) 288 0.19 Tumut 293 0.19 0 5 
Tweed (A) - Pt A 1862 1.22 Tweed 2626 1.71  -42 
Tweed (A) - Pt B 722 0.47      
Unincorp. Far West 35 0.02 Unincorp Far West 7 0 0.02 -28 
Uralla (A) 135 0.09 Uralla 121 0.08 0.01 -14 
Urana (A) 41 0.03 Urana 51 0.03 0 10 
Wagga Wagga (C) - Pt A 1091 0.72 Wagga Wagga   1203  0.78  -50 
Wagga Wagga (C) - Pt B 62 0.04      
Wakool (A) 101 0.07 Wakool 98 0.06 0.01 -3 
Walcha (A) 120 0.08 Walcha 119 0.08 0 -1 
Walgett (A) 158 0.1 Walgett 166 0.11 -0.01 8 
Warren (A) 80 0.05 Warren 88 0.06 -0.01 8 
Warringah (A) 3449 2.26 Warringah 5084 3.31 -1.05 36 
Waverley (A) 1625 1.07 Waverley 1634 1.06 0.01 9 
Weddin (A) 126 0.08 Weddin 126 0.08 0 0 
Wellington (A) 234 0.15 Wellington 246 0.16 -0.01 12 
Wentworth (A) 158 0.1 Wentworth 161 0.1 0 3 
Willoughby (C) 1400 0.92 Willoughby 1397 0.91 0.01 -3 
Windouran (A) 5 0 Windouran 4 0 0 -1 
Wingecarribee (A) 1103 0.72 Wingecarribee 1124 0.73 -0.01 21 
Wollondilly (A) 702 0.46 Wollondilly 680 0.44 0.02 -22 
Wollongong (C) 4648 3.05 Wollongong 4651 3.03 0.02 3 
Woollahra (A) 1612 1.06 Woollahra 1633 1.06 0 21 
Wyong (A) 4078 2.68 Wyong 4129 2.69 -0.01 51 
Yallaroi (A) 69 0.05 Yallaroi 72 0.05 0 3 
Yarrowlumla (A) - Pt A 185 0.12 Yarrowlumla 148 0.1 0.02 -37 
Yass (A) 217 0.14 Yass 221 0.14 0 4 
Young (A) 322  0.21 Young 339  0.22  -0.01  17 
 
152421 
  
153562 
   
 diff 1,141 
not allocated in 2001 
boundaries because 
they were 
indeterminate 
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Chapter 2 Appendix 1 Table 2 The mean distance within each LGA to RPA and the minimum and maximum distance 
values within each LGA for people diagnosed with cancer between 1972-2004 (ranked from most distant to RPA and the 
least distant) 
LGA  
1972-2004 
'Mean 
Distance 
1972-2004 
'Min. 
Distance 
1972-2004 
'Max Distance 
Broken Hill 931 929 934 
Unincorporated NSW 898 783 1004 
Wentworth 839 795 916 
Central Darling 767 610 849 
Balranald 718 639 779 
Wakool 675 637 730 
Tweed 664 628 675 
Bourke 653 575 810 
Byron 630 610 641 
Murray 621 605 649 
Kyogle 607 564 636 
Brewarrina 603 557 667 
Ballina 603 586 618 
Windouran 603 592 655 
Lismore 600 573 626 
Deniliquin 597 592 602 
Hay 588 571 646 
Richmond Valley 582 542 600 
Cobar 558 445 714 
Conargo 556 543 591 
Tenterfield 555 507 632 
Berrigan 545 518 569 
Walgett 543 449 613 
Maclean 532 512 546 
Jerilderie 522 487 547 
Moree Plains 520 463 595 
Carrathool 509 447 574 
Copmanhurst 507 496 555 
Corowa 502 472 529 
Yallaroi 498 474 566 
Grafton 495 488 498 
Murrumbidgee 492 476 505 
Pristine Waters 481 410 514 
Severn 476 436 510 
Urana 475 440 501 
Griffith 474 451 503 
Inverell 466 441 556 
Glen Innes 464 460 467 
Bogan 460 430 531 
Hume 459 422 478 
Albury 456 449 461 
Bingara 448 412 460 
Leeton 446 436 471 
Coffs Harbour 441 423 467 
Narrandera 433 400 461 
Culcairn 430 404 461 
Lockhart 420 401 440 
Guyra 417 399 440 
Bellingen 416 403 435 
Coonamble 415 356 473 
Narrabri 414 369 492 
Holbrook 405 365 419 
Lachlan 404 350 453 
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minimum and maximum distance values within each LGA for people diagnosed 
with cancer between 1972-2004 (ranked from most distant to RPA and the least 
 
 
LGA 
1972-2004 
'Mean 
Distance 
1972-2004 
'Min. 
Distance 
1972-2004 
'Max Distance 
Warren 404 364 452 
Barraba 396 383 422 
Nambucca 394 365 405 
Coolamon 387 366 404 
Bombala 384 357 412 
Armidale Dumaresq 378 354 409 
Wagga Wagga 376 344 420 
Bland 375 327 461 
Uralla 371 334 418 
Tumbarumba 360 338 399 
Kempsey 357 330 384 
Snowy River 354 315 396 
Manilla 352 334 362 
Coonabarabran 347 307 407 
Junee 345 320 367 
Temora 343 314 379 
Bega Valley 342 276 396 
Gilgandra 340 317 372 
Narromine 337 309 374 
Gunnedah 331 287 357 
Walcha 320 265 329 
Cooma-Monaro 319 256 357 
Tumut 318 291 345 
Gundagai 311 282 343 
Tamworth 311 303 330 
Parry 309 283 346 
Hastings 309 278 328 
Cootamundra 302 286 314 
Dubbo 300 279 327 
Parkes 300 267 364 
Forbes 299 267 356 
Weddin 283 252 337 
Coolah 274 244 302 
Nundle 272 258 294 
Quirindi 271 254 296 
Harden 269 247 285 
Young 268 242 315 
Wellington 254 215 281 
Greater Taree 252 216 281 
Eurobodalla 246 205 298 
Murrurundi 243 225 265 
Queanbeyan 242 239 249 
Cabonne 238 180 275 
Yass 236 220 269 
Yarrowlumla 232 211 274 
Cowra 230 184 258 
Boorowa 227 202 240 
Gloucester 221 204 249 
Merriwa 216 192 243 
Tallaganda 213 169 259 
Great Lakes 212 155 252 
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Chapter 2 Appendix 1 Table 2 The mean distance within each LGA to RPA and the 
minimum and maximum distance values within each LGA for people diagnosed 
with cancer between 1972-2004 (ranked from most distant to RPA and the least 
 
 
LGA 
1972-2004 
'Mean 
Distance 
1972-2004 
'Min. 
Distance 
1972-2004 
'Max Distance 
Mudgee 211 178 252 
Scone 206 190 235 
Orange 204 189 225 
Gunning 204 182 223 
Blayney 187 170 209 
Muswellbrook 181 152 194 
Crookwell 171 140 200 
Dungog 167 147 194 
Goulburn 165 159 170 
Rylstone 162 124 192 
Evans 158 125 190 
Bathurst 157 149 164 
Mulwaree 153 112 207 
Port Stephens 148 126 159 
Singleton 145 107 185 
Shoalhaven 140 102 210 
Maitland 133 128 145 
Oberon 128 105 149 
Cessnock 120 85 138 
Newcastle 119 114 129 
Greater Lithgow 109 91 150 
Lake Macquarie 106 80 117 
Wingecarribee 99 72 132 
Kiama 94 87 105 
Shellharbour 81 78 90 
Wyong 72 60 92 
Blue Mountains 69 46 96 
Wollongong 65 36 85 
Wollondilly 62 44 74 
Hawkesbury 51 39 96 
Gosford 50 38 79 
Camden 46 34 52 
Penrith 44 34 54 
Campbelltown 36 27 51 
Blacktown 32 24 43 
Pittwater 28 22 35 
Liverpool 27 19 50 
Baulkham Hills 24 17 59 
Fairfield 24 18 34 
Hornsby 22 14 59 
Holroyd 21 17 25 
Sutherland Shire 19 13 33 
Parramatta 18 13 25 
Warringah 17 12 30 
Ku-ring-gai 16 11 23 
Bankstown 16 10 20 
Auburn 14 11 16 
Manly 13 11 19 
Hurstville 13 9 17 
Kogarah 12 9 15 
Ryde 12 7 15 
Willoughby 10 7 12 
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Chapter 2 Appendix 1 Table 2 The mean distance within each LGA to RPA and the 
minimum and maximum distance values within each LGA for people diagnosed 
with cancer between 1972-2004 (ranked from most distant to RPA and the least 
 
 LGA 
1972-2004 
'Mean 
Distance 
1972-2004 
'Min. 
Distance 
1972-2004 
'Max Distance 
Strathfield 9 8 11 
Rockdale 9 5 14 
Canterbury 9 5 14 
Mosman 9 7 11 
Concord 9 6 11 
Waverley 8 6 10 
Lane Cove 8 5 10 
Randwick 8 4 13 
Burwood 7 6 9 
Hunter's Hill 7 5 9 
North Sydney 7 5 9 
Woollahra 7 4 11 
Botany Bay 6 4 9 
Drummoyne 5 4 7 
Ashfield 5 3 6 
Sydney 3 2 5 
South Sydney 3 0 5 
Marrickville 3 0 5 
Leichhardt 2 0 5 
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3.1. Abstract 
Background Understanding the impact of differences in the measurement of cancer survival 
is important to ensure reported differences in state, national and international studies are due 
to survival experienced between regions and not due to differences in methodology. This 
study has three aims. The first aim is to compare three survival analysis methods in two 
registries for high (breast and prostate cancer) medium (bowel) and poor (lung) prognosis 
cancers diagnosed between 2000-2008 in New South Wales (NSW), Australia, and the 
Northern and Yorkshire Cancer Registry and Information service (NYCRIS). The second 
aim is to apply the NSW cause of death allocation rules to NYCRIS data and evaluate 
measurement of cause specific survival. The third aim is to measure the difference in age 
adjusted survival by cancer type between NSW and Northern and Yorkshire (NY) at each 
time from diagnosis. Methods Survival estimates were calculated for NSW and NY using 
the cause specific survival (CS) method, the Ederer II method of relative survival (RS) and 
the recently recommended Pohar Perme (PP) method of survival. Age adjusted estimates for 
each method were obtained after applying the International Classification of Standardised 
Survival (ICSS) weights to age-specific survival estimates resulting in adjusted survival 
estimates. Results In NSW, unadjusted survival estimates varied little method for all sites 
and times from diagnosis analysed. This was also true for most cancer sites in NY except 
for bowel cancer where cause specific survival estimates were higher than relative or net 
estimates. The difference in age adjusted survival estimates in NSW and NY were between 5 
and 11% higher in NSW than in NY depending on the cancer site regardless of the method 
and at each time from diagnosis. Conclusions The cause specific method of survival 
produced similar estimates to relative and net survival estimates in NSW. Therefore, cause 
specific survival in an acceptable alternative to relative and net survival methods.  
Differences in survival reported in NSW and NY appear real and not due to differences in 
survival methodology or the cause of death allocation. 
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3.2. Introduction 
Benchmarking of cancer survival between regions or countries, as in the International Cancer 
Benchmarking Partnership (ICBP)1, 2 requires accurate estimates of survival. Artefactual 
differences in survival from particular cancers may arise because of differences in 
completeness of ascertainment of incident cancers,3, 4 methods of estimating cause specific 
survival,5, 6 methods for ascertaining the fact of death and cause of death,7 and age structures 
of the populations.8 
The New South Wales Central Cancer Registry (NSWCCR) and the Northern and Yorkshire 
Cancer Registry and Information Service (NYCRIS) as part of UK registries are participants 
in the ICBP. To date there have been a number of publications that have compared survival 
by country for the major cancers of breast, 9 colorectal 10, lung 11 and ovary. 12 These papers 
show a similar pattern of better survival in Sweden, NSW and Canada and poorer survival in 
the UK and Denmark. 
However, Beral and Peto,13 suggest poorer survival in the UK might be due to lack of 
statutory cancer registration in England and Wales, resulting in under registration and high 
proportions of cases registered from death certificates only.14 Under registration, is strongly 
refuted by Woods et al. who consider that 40% of long-term survival in patients would need 
to have been missed to explain the survival differential between the UK (poor survival) and 
Sweden (highest survival). 15,16,17 
Relative survival is the preferred method for estimating cancer survival in populations, 
because of the uncertain accuracy of cause of death ascertained from death certificates.18, 19 
Relative survival requires date of death only with period, country, age and sex specific life 
tables used to adjust for effects on survival of causes of death other than the cancer of 
interest. 20 
Recently, a new estimator (Pohar Perme or net survival) is suggested as an alternative to the 
relative survival method. This method implemented in the new Concord-2 (Global 
surveillance of cancer survival) study calculates the average predicted survival for each 
individual.21, 22 Unlike relative survival, that calculates the ratio of the observed survival 
divided by the expected survival, this new method uses the background mortality to estimate 
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death from other causes to produce an unbiased estimate of true net survival. Danieli 23 
suggests the net method be used when comparing the cancer impact between countries and 
within time periods because it takes into account the association between increasing age at 
diagnosis and the excess hazard of dying from cancer.24 
Cause specific survival may be an acceptable alternative to relative survival provided the 
cause of death is recorded accurately. SEER registries currently examine cancer survival in 
racial and ethnic population subgroups routinely using this method. 6,25 Furthermore, the 
cause specific survival method is familiar to clinicians because it allows modelling of 
treatment and other prognostic factors known to influence survival without the requirement 
of life tables. 
When making international comparisons 2, 17, 26age standardisation is required to adjust for 
differences in the age structures between populations and is routinely used when reporting 
cancer survival in the UK. 
In this paper, there are three questions of interest: 
1. Is cause specific survival a practical alternative to the more traditional relative or net 
survival methods? 
2. What is the effect on cancer-specific survival estimates for NY of using two methods 
of allocating the cause of death? 
3. What are the differences in cancer survival estimates between NSW and NY for each 
cancer type at each time after diagnosis? 
3.3. Methods 
3.3.1. Data sources: 
The New South Wales (NSW) Central Cancer Registry (CCR) is a population based registry 
of all new cases of cancer and deaths from cancer in the population of NSW.27 In 2011, just 
under one-third (32%) of Australia's population resided in NSW with 7.2 million people. 28 
Notification of invasive cancer and in situ breast cancer and melanoma is mandatory under 
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the NSW Public Health Act for all public and private hospitals, cancer centres, radiotherapy 
units and public and private pathology laboratories. 27 
The Northern and Yorkshire Cancer Registry Information Service (NYCRIS) is a population 
based cancer registry covering 13.3% of the UK population with a mean population of 
6,555,870 29 which is a similar size to NSW. NYCRIS receives weekly death certificate 
information for all patients who have a mention of cancer on the death certificate or those 
previously flagged by the registry with a diagnosis of cancer. The information updates 
existing records or initiates new registry records by searching for hospital or GP records. 30 
The data source for NYCRIS was a merged data set, obtained from the National Cancer 
Intelligence Network UK, National Cancer Data Repository (NCDR)31 of cancer registry and 
Office of National Statistics (ONS) provided death certificate data. 
Both CCR and NYCRIS registries contribute to Cancer Incidence in Five Continents 
indicating that both registries meet an agreed quality standard. 32 In addition, five year 
observed relative and age-standardised survival were compared for an earlier time (1992–
2000) for lung, breast and colorectal cancers which, will offer some insight into previously 
reported differences in survival between NSW and NY.33 
Incident cases for cancers of the breast (C50) and prostate (C61); colon rectum and anus 
(C18, C19, C20, C21) and cancers of lung and bronchus (C33, C44) were followed up to the 
end of 2008 in the CCR and NYCRIS. These cancers were chosen to cover the range from 
high survival (breast and prostate), medium survival (colon, rectum and anus) and the poor 
survival (lung and bronchus). 34 
3.3.2. Methods aim one - is cause specific survival a practical alternative to the 
more traditional relative or net survival methods? 
Analysis was undertaken using STRS (Survival Time Relative Survival), a programme 
developed by Paul Dickman 35 using STATA 12.1. 36 Unadjusted survival estimates 
calculated for NSW and NY using the cause specific survival (CS) method, the Ederer II 
method of relative survival (RS) and the recently recommended Pohar Perme (PP) method of 
survival. 37-39 
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Ederer II, replaced the original Ederer I method 39 in the US Surveillance Epidemiology End 
Results (SEER) cancer statistics review in 2011.5 Age, sex and year specific life tables used 
in the International Cancer Benchmarking Project 1 were used for relative and net survival 
estimation in both NSW and NYCRIS. 
3.3.3. Methods aim two - What is the effect on cancer specific survival estimates 
for Northern and Yorkshire of using two methods of allocating the cause of 
death? 
The NSW CCR derives the cause of death using the following process. The CCR receives 
person-identified text based death certificates fortnightly from the NSW Registry of Births, 
Deaths and Marriages and an annual file of ICD-10 coded cause of death information (up to 
20 codes per death certificate) from the Australian Bureau of Statistics. The final cause of 
death allocation uses a hierarchy of rules. If a person has the same three-digit cause of death 
code as they have for a registered cancer then they are deemed to have died of that cancer. If 
the registered cancer has a specific code (e.g. C50.4) and the cause of death is a less specific 
(C50.9), then the most specific code is taken to be the cause of death. If there are no C codes 
that correspond to the registered cancer, a non-cancer death is recorded. If the cause of death 
is different from the C code of the registered cancer, records are examined, by a medical 
coder and the cause of death is manually determined with reference to pathology reports, 
other registered cancers and responses to letters sent to doctors, and in accordance with 
written procedures. 
UK registries do not allocate the cause of cancer death. Instead four cause of death codes 
from each of Parts 1 (sections a, b and c) and 2 of the death certificate are linked to each 
person on the NYCRIS database who has died. 40 Therefore, in this study the cause of cancer 
death was allocated for NYCRIS by applying rules used in the NSWCCR. 
For each person who had died two causes of death (method 1 and method 2) were assigned. 
The first cause of death method reviewed all ICD-10 codes in Part 1 (sections a, b and c) of 
the death certificate and provided the cause of death C code was the same as their registered 
case, the person was considered to have died from their cancer. The second method repeated 
the procedure but looked for a valid C code in Part 2 of the death certificate. Part 1 of the 
death certificate lists the disease or condition directly leading to death with a, b and c due to 
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(or as a consequence of each other. Whereas Part 2 of the death certificate refers to other 
significant conditions contributing to the death, but not related to the disease or condition 
causing it. For both methods if there was no mention of the cancer that the person was 
registered with then the person was recorded as dying from another cause of death. 
For each case, the vital status in both registries was determined using the following criteria: 
died from their cancer, died from another cause, alive or censored at the 30th of December 
2008. Cases with no date of death were considered alive. People categorised as having “died 
from another cause” were checked to determine that the relevant site-specific cancer code 
had not been overlooked. 
3.3.4. Methods aim three - differences in age adjusted survival estimates for 
cancer specific, relative and net survival methods 
Age standardised survival rates for each cancer site and each analysis type were obtained by 
applying the International Classification of Survival (ICSS) weights to age-specific survival 
estimates for each method of survival. The difference, between the NSW and NYCRIS age 
standardised point estimates of survival, for each period, from diagnosis was subtracted. The 
confidence limits for the difference in point estimates were calculated by squaring and then 
summing the standard errors (SE) of the age adjusted survival estimates for NSW and 
NYCRIS and then taking the square root of the sum. 
3.4. Results 
3.4.1. Results aim one - is cause specific survival a practical alternative to the 
more traditional relative or net survival methods? 
Differences between five year unadjusted cause specific, relative and net survival 
percentages in NSW ranged from 0.0 to 1.4 percentage points depending on cancer type 
(Chapter 3 Table 1). Breast cancer survival at five years was 88.0%, 88.4% and 88.4% for 
cause specific, relative and net respectively and showed the least difference. Lung cancer 
survival in NSW males at five years was slightly higher at 15.1% for cause specific; 13.7% 
and 14.2% respectively for relative and net. 
In NY cause specific survival was mostly higher than relative and net survival (ranged 1.0 to 
4.3 for relative and 1.1 to 2.9 for the net survival method), and net survival was usually the 
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same as relative survival (0.0-1.5). However, differences varied by cancer site - ranging from 
0.0 for prostate cancer (relative and net) to 4.3% higher for cause specific bowel cancer 
(Chapter 3 Table 1). 
The smallest differences in survival estimates between analysis methods were for breast 
cancer (0.0 to 0.4 in NSW and 0.5 to 1.5 in NY) and the greatest for bowel cancer in NY 
(1.1-4.3) (Chapter 1 -Table 1). 
3.4.2. Results aim two - What is the effect on cancer specific survival estimates for 
Northern and Yorkshire of using two methods of allocating the cause of death? 
Five year cause specific survival estimates for breast cancer were similar to the relative and 
net when the cause of death was allocated using method one (breast: method one 83.1% 
relative 82.1% and net 81.6 %). Similarly, observed for prostate cancer (method one 79.5% 
relative 80.6%. and net 80.9%). 
Five year cause specific bowel and lung cancer estimates were similar to relative and net 
only after the additional cancer specific deaths from method two were included (bowel cause 
specific (method 2) 50.9% relative 51.4% and net 52.9 %) and lung (cause specific (method) 
two 6.9% relative 6.9% and net 7.3% ) (Chapter 3, Figure 2). 
3.4.3. Results aim three - differences in cancer survival estimates between New 
South Wales and Northern and Yorkshire for each cancer type at each time 
after diagnosis? 
Survival estimates in NSW were 5-11% higher than NY depending on the cancer site even 
after taking account of the cause of death allocation. 
For breast cancer patients, there was little difference in age adjusted cancer survival between 
NSW and NY for the first year post diagnosis. At five years, age adjusted breast cancer 
survival in NSW was 4.8% (95%CI 4.2-5.4) higher than NY females for cause specific and 
6.7% (95%CI 5.0-8.4) and 6.6% (95%CI 4.5-8.7) for relative and net survival (Table 2). 
The difference in five year prostate cancer estimates of survival were similar regardless of 
the method used with 8.0% (95%CI 5.6-10.5) higher survival in NSW males than NY males 
for cause specific; 8.3% (95%CI 5.0-11.5) and 7.7% (95%CI 2.4-12.0) for relative and net 
survival. At five years, age adjusted cause specific bowel cancer survival estimates were 
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8.3% (95% CI 5.7-10.9) higher in NSW males and 7.8% (95%CI 5.0-10.6) higher in NSW 
females than NY males and females. However, relative and net survival estimates and 
confidence intervals were the same with NSW survival on average 11.0% higher than NY 
males and females. 
Differences in lung cancer survival were greatest at six months post diagnosis with 11.0% 
and 14.0% higher estimates of survival in NSW males and females compared to NY males 
and females. However, by five years there was a 7% higher estimate in NSW males 
regardless of the method and between 7.9% and 8.5% higher survival in NSW females. 
 Confidence limits at each period since diagnosis were narrower for cause specific and 
widest for the net survival method. The confidence intervals are much wider for net survival 
because the standard errors are large and they also increase over time. Regardless of the 
survival method used, confidence limits became wider over time (Figure 3 Table 2). 
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Chapter 3 Figure 1a Comparisons of cause specific, relative and net survival in New South Wales and the Northern and Yorkshire Region of England 2000-2008 for breast  and prostate cancers 
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Chapter 3 Figure 1b Comparisons of cause specific, relative and net survival in New South Wales and the Northern and Yorkshire Region of England 2000-2008 for bowel and lung cancers (continued) 
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Chapter 3 Figure 2 Comparisons of age adjusted survival for breast, prostate, bowel and lung cancers for cause specific, relative and net survival in New South Wales and Northern and Yorkshire regions 
2000-2008 
 
Method 1 –The relevant cause of death code is found in Part 1(sections a, b and c) of the death certificate 
Method 2 – The relevant cause of death code is found in Parts 1 (sections a, b and c) and 2 of the death certificate 
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Chapter 3 Figure 3 Comparisons of New South Wales and Northern and Yorkshire regions of the difference in age adjusted for cause specific, relative and net survival of breast, prostate, 2000-2008 
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Chapter 3 Figure 3 Comparisons of New South Wales and Northern and Yorkshire regions of the difference in age adjusted for cause specific, relative and net survival of breast, prostate, bowel and lung 
cancers, 2000-2008 
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Chapter 3 Table 1 Unadjusted five year cause specific, relative and net survival estimates for New South Wales and Northern and Yorkshire regions by 2000-2008 
  New South Wales Northern and Yorkshire 
  
Cause 
specific  95%CI Relative  95%CI Net 95%CI 
Cause 
specific  95%CI Relative  95%CI Net 95%CI 
Breast 88.0 (87.5-88.4) 88.4 (87.8-88.9) 88.4 (87.8-88.9) 83.1 (82.7-83.5) 82.1 (81.5-82.6) 81.6 (81.0-82.3) 
Prostate 88.0 (88.0-89.0) 89.0 (89.0-90.0) 89.0 (88.0-90.0) 79.0 (79.0-80.0) 81.0 (80.0-81.0) 81.0 (80.0-82.0) 
Bowel males 65.1 (64.3-65.8) 64.0 (63.1-65.0) 64.7 (63.8-65.7) 55.7 (54.8-56.5) 51.4 (50.4-52.4) 52.9 (51.9-53.9) 
Bowel females 65.4 (64.5-66.2) 65.0 (64.0-66.0) 66.0 (64.9-67.0) 55.3 (54.3-56.1) 51.3 (50.3-52.4) 52.4 (51.2-53.5) 
Lung males 15.1 (14.4-15.8) 13.7 (13.0-14.4) 14.2 (13.5-14.8) 8.4 (8.0-8.9) 6.9 (6.5-7.3) 7.3 (7.0-7.7) 
Lung females 18.8 (17.9-19.8) 17.4 (16.4-18.3) 17.6 (16.7-18.5) 10.1 (9.6-10.6) 8.4 (7.9-8.9) 8.6 (8.2-9.1) 
*LCI lower confidence interval, UCI Upper confidence interval 
Chapter 3 Table 2 The percentage difference in five year age adjusted cause specific, relative and net survival estimates and associated 95% confidence limits between NSW and Northern and Yorkshire 
regions by cancer site 
  Cause specific survival Relative survival Net survival 
 
 
95%CI 
 
95%CI 
 
95%CI 
Breast 4.8 (4.2-5.4) 6.7 (5.0-8.4) 6.6 (4.5-8.7) 
Prostate 8.1 (5.6-10.5) 8.3 (5.0-11.5) 7.7 (3.4-12) 
Bowel males 8.3 (5.7-10.9) 11.4 (1.6-21.2) 11 (1.2-20.8) 
Bowel females 7.8 (5.0-10.6) 11 (1.0-21.1) 11.1 (1-21.1) 
Lung males 6.9 (4.7-9.1) 7 (4.8-9.1) 7.0 (-8.8-22.9) 
Lung females 7.9 (5.0-10.7) 8.5 (5.8-11.2) 8.5 (-7.3-24.4) 
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3.5. Discussion 
In NSW, five year unadjusted survival estimates were similar at each period from diagnosis 
regardless of the method used and for each cancer site. Similarly, in NY cause specific 
survival estimates were similar for most cancer sites with the exception of colorectal cancer, 
which was 4% higher than relative and net survival estimates at five years. The effect of 
cause of death on five year cancer specific survival estimates in NY depended on cancer site. 
For the higher survival cancers, breast and prostate method one provided similar estimates to 
relative and net survival. Whereas, for the poorer survival cancers of bowel and lung, 
method two provided similar cause, relative and net survival estimates. Differences in age 
adjusted five year survival estimates in NSW were 5% to 11% higher depending on the 
cancer type. The differences by cancer site were similar regardless of the method except for 
the five year cause specific estimates for breast cancer and bowel cancer which were 2% and 
3% lower than net or relative survival methods. 
Survival estimates in NSW were similar regardless of the method used or the cancer site. 
This finding is consistent to the findings of a recent Australian study that also compared 
relative and cause specific survival for the same cancer sites and reported that one and five 
year relative survival estimates produced similar results.41 
Cause specific survival is only a viable alternative if there is good cause of death coding. 
The most plausible reason for the similar survival estimates in NSW compared to the 
slightly higher cause specific estimates in NY (compared to relative and net) are the 
procedures undertaken to allocate the cause of death. NSW uses multiple sources of 
notification to determine a case of cancer. The cause of death is determined by death 
certificate and supplemented by pathology and another notification sources. Other Australian 
registries have similar practices to those described in NSW. 
Recently, the Geneva Cancer Registry compared cause specific and relative survival 
estimates for breast cancer and reported almost perfect survival estimates with a difference 
at 20-year survival of less than 1%.42 The Geneva Cancer Registry like the CCR determines 
the cause of death of each registered cancer patient by examining all available clinical 
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information relating to the patient’s disease. Furthermore, they also examine all treatment 
information. 
In NY, there are a number of differences in registry practices compared to NSW. For 
example, while hospital notifications, pathology reports and GP records are used to register a 
case there is a heavy reliance on death information to first initiate a case and then trace back 
to the GP and other hospital records. Furthermore, a person can die from cancer without 
having a corresponding case of that cancer. These two issues will influence the allocation of 
the cause of death and therefore cause specific survival estimates; which may explain why 
cause specific survival estimates for NY were slightly higher for colorectal and lung cancer 
compared to relative and net survival estimates. 
In NSW and NY relative and net methods showed similar results at each period from 
diagnosis for a cancer site. Survival estimates using relative and net methods are considered 
the same provided there is no one particular demographic variable that is strongly 
influencing the hazard of death. 38 Age at diagnosis is an important demographic variable 
known to influence the excess hazard of death. The net survival method better adjusts for 
this effect. 24 
In addition, there are some issues associated with the net method that may cause difficulties 
for cancer registries. We found that while point estimates were similar using the relative and 
net survival method, confidence limits were wider using the net survival method for each 
cancer site. Dickman 43and Roche22 both report that the survival estimates using the net 
survival method have large variances explaining the wide confidence limits. In comparison, 
the Ederer II method of relative survival has smaller confidence limits and it has also been 
implemented in the SEER STAT application. 5 Therefore, in the absence of cause of death 
information, the Ederer II method would appear to be the most appropriate and easily 
accessible method of survival for registries. 
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3.5.1. What is the effect on cancer-specific survival estimates for Northern and 
Yorkshire of using two methods of allocating the cause of death? 
The cancer specific survival estimates for NY using method 1 that is allocating the cause of 
death based on Parts 1 (sections a, b and c) of the death certificate resulted in similar 
survival estimates as relative and net survival for cancers of the breast, prostate and lung. 
Whereas, the inclusion of Parts 1 and 2 of the death certificate resulted in similar estimates 
of survival for colorectal cancer. Others 6, 44 have similarly reported good agreement between 
the relative survival and cause specific survival estimates, for most cancer sites, with 
colorectal cancer showing the most variability due to the differences in the misallocation of 
rectal or colon cancer as the cause of death. Had examination of pathology and other sources 
of notification occurred, as is the practice in NSW and Geneva, the death recorded as bowel 
cancer in part 2 of the death certificate may have been considered when determining the 
cause of death. 
Percy45 compared the underlying cause of death from the death certificate and hospital 
diagnoses in SEER registry data and found a high level of agreement of 98.7% for breast and 
98.1% for prostate but lower agreement of 95.6% for large bowel and 94.3% for lung. 
Furthermore, clinician assigned cause of death and death certificate cause of death coding 
were compared for cancer of the prostate. 46 A high concordance or K statistic of 0.91 was 
reported. 
Not surprisingly, most studies report that the level of agreement is higher in people who 
have one primary cancer. Lund et al47 in a study of 229,181 patients found that agreement 
between the coded cause of death and the initial diagnosis was 85% in patients with one 
primary and 64% in patients with one or more primary cancers. Similarly, Boer found that in 
people diagnosed with colorectal cancer who died of cancer within 5 years, 94.5% died from 
colorectal cancer, 3.0% died from metastases and 2.5% from other cancer death. For people 
diagnosed with colorectal cancer who have more than one cancer and die within 5 years, 
only 64.1% have a cause of death of colorectal cancer recorded.44 In the NSW and NY 
registries, the majority of cases were primary only (88% NSW and 91% for NY). Therefore, 
misallocation of cause of death because a person has more than one primary cancer is 
unlikely to be a major issue. 
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3.5.2. Differences in age adjusted survival estimates between NSW and Northern 
and Yorkshire 
The 5-11% difference in five year age adjusted survival estimates (depending on cancer site) 
between NSW and NY for the period 2000-2008 reported in this study, is similar to that 
reported in the earlier study undertaken by Yu et al.33 For example, five year age adjusted 
relative survival estimates for breast cancer were 6.3% higher in NSW than in NY for 
women diagnosed in 1992-2000 which is similar to the 6.7% (relative) and 6.6% (net) found 
in this study. Also, five year colorectal cancer survival estimates in 1992-2000 were 9.8% 
higher in NSW than NY compared to 11.4% (relative) and 11.0% (net) found in this study. 
Therefore, for breast and colorectal cancer the better survival in NSW and NY appear 
consistent regardless of method and diagnostic period. 
Both registries in our study code cases of cancer using the International Classification for 
diseases for Oncology Revision 3,34 follow the International Association of Cancer 
Registries (IACR) definitions for multiple primaries 48 and the IACR definitions for 
recording the date of diagnosis. Nevertheless, there are some differences; cancer registration 
in NSW is mandated under the Public Health Act whereas in NY, it is not. Furthermore, 
because death information is used to initiate a notification it has been suggested 13 that good 
prognosis cancers may be missing because they have not been notified independently from 
other sources. To investigate, a comparison is made of reported data quality indicators for 
NSW and NY for the same period. 32 
Accordingly, for most cancer, registry gold standard indicators that can be compared in 
NSW and NY they were comparatively similar. Both registries had high proportions of cases 
that were histologically verified (over 85% for breast, prostate and bowel cancers and 
slightly lower for lung cancer in males NSW 84.9%, NY 57.3% and females NSW 82.9% 
NY 52.8%). 32. Both registries had a low death certificate only proportion, indicating that the 
majority of registered cases had notifications from other sources besides a death certificate. 
Furthermore, one minus the difference in mortality incidence ratios previously found to be a 
good proxy for cancer survival were also similar. 49 32 
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In summary, survival estimates were similar regardless of method used in NSW and for most 
cancer sites in NY (with the exception of bowel cancer). Therefore, cause specific survival is 
a satisfactory alternative to relative and net survival in NSW and NY for most cancer sites 
except bowel cancer. Secondly, the difference in the cause of death allocation was greatest 
for bowel cancer in NY, which reduced when cancer deaths mentioned in section 2 were 
included. Thirdly, age adjusted survival estimates, were between 5 and 11% higher in NSW, 
than in NY (depending on cancer site), and after taking account two methods of cause of 
death allocation. Furthermore, reported data quality indicators were high in both registries. 
Therefore, the differences in survival rates between NSW and NY are unlikely to be an 
artefact due to method of survival or allocation of the cause of death. They may be due to 
other factors like earlier stage at presentation or different treatment in NSW compared to 
Northern and Yorkshire as has been suggested in recent International Benchmarking studies 
of cancer survival 9, 11, 50 or perhaps treatment differences that are yet to be investigated. 
3.5.3. Conclusion 
The cause specific method of survival produced similar estimates to relative and net survival 
estimates in NSW. Therefore, cause specific survival in an acceptable alternative to relative 
and net survival methods.  Differences in survival reported in NSW and NY appear real and 
not due to differences in survival methodology or the cause of death allocation. 
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4.1. Abstract 
Objective: To investigate the associations of a range of personal and clinical variables with 
bladder cancer survival in men and women in NSW to see if we could explain why bladder 
cancer survival is consistently poorer in women than in men. 
Patients and Methods: All 6,880 cases of bladder cancers diagnosed in NSW between 2000 
and 2008 were linked to hospital separation data and to deaths. Separate Cox proportional 
hazards regression models of hazard of bladder cancer death were constructed in those who 
did or did not undergo cystectomy. 
Results: Sixteen per cent of bladder cancer patients underwent cystectomy (16 per cent of 
men and 15 per cent of women). Women who underwent cystectomy were 26 per cent more 
likely to die than men (Hazard Ratio (HR) 1.26 95% confidence interval, CI 1.00-1.59) after 
adjustment for age, stage, time from diagnosis to cystectomy, distance from treatment 
facility and country of birth. None of these covariates had a material effect on the difference 
in hazard between women and men. However, when stratified by a history of cystitis, the 
adjusted hazard was 55 per cent higher in women (HR 1.55, 95%CI 1.15-2.10) than men 
with a history of cystitis while, in the absence of this history, there was no difference in the 
hazard between men and women (HR 0.99, 95%CI 0.57-1.70). This apparent modification of 
the effect of sex on bladder cancer outcome was not seen in patients treated only by 
resection: the adjusted HRs in women relative to men were 1.10 (95% CI 0.92-1.31) in those 
with a history of cystitis and 1.21 (95% CI 0.98-1.50) in those without. History of 
haematuria did not modify appreciably the association of sex with bladder cancer outcome. 
Conclusions:.Women’s poorer survival from bladder cancer than men’s remains 
unexplained. The possibility, however, that some factor associated with a history of cystitis 
may contribute to or explain the poorer outcome in women merits further investigation. (326 
words) 
Keywords: Bladder cancer, survival, cancer registry, cystitis, surgery, distance 
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4.2. Introduction 
Unlike most other cancers where cancer survival is better in women than men, bladder 
cancer survival is consistently higher in men.1, 2, 3, 4,5We previously examined predictors of 
case fatality for bladder cancers diagnosed in 1980–2003 to understand why unadjusted 
bladder cancer survival fell over time and why survival was poorer in women than in men. 
After adjusting for age, extent of disease, socioeconomic status (SES), period of diagnosis 
and histological type, the hazard of death from bladder cancer was 13 per cent (95% CI 5–
21%) higher in women than men. Fatality was most influenced by age at diagnosis, extent of 
disease, and histological type 6. 
The aim of the present study is to extend our earlier study 6 and further investigate reasons 
for the poorer survival in females; the study links cancer registry records to hospital 
separation records for bladder cancer cases diagnosed in 2000 to 2008. The latter contain a 
range of additional variables that could be relevant to the difference in bladder cancer 
survival between women and men, including risk factors, symptoms, procedures, comorbid 
conditions and distance from the treatment facility. This analysis uses these additional data 
in a search for an explanation for the poorer survival in women. 
4.3. Patients and methods 
4.3.1. Data Sources: 
The NSW Central Cancer Registry (the Registry) was the primary data source for the present 
study. Death information was retrieved by electronic linkage of the Registry with NSW 
death records up to 2008 and the National Death Index at the Australian Institute of Health 
and Welfare for cases diagnosed up to 2006. Registry operational details have been 
described previously 1. In addition to the registered cause of death provided by the ABS, 
pathology details regarding the cancer and follow up with doctors are used by the Registry 
and are thought to classify cause of death more accurately than is possible when relying 
solely on death certificate information. Bladder cancers (International Classification of 
Diseases and Related Health Conditions 10th revision code C677, which encompasses all 
malignant, that is stage T1 or worse, bladder cancers), notified to the Registry between 2000 
and 2008 were investigated in the present study. The NSW Central Cancer Registry does not 
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register in situ bladder cancer8. Notifications of invasive bladder cancer are followed up to 
ensure that they have been verified histologically and where possible a cancer registry coder 
physically sights and codes from the original pathology report. 
The NSW Ministry of Health administers the NSW APDC, the source of hospital separation 
records. Separation records are prepared after patients leave (separate from) hospital and 
provide a complete census of all patients receiving inpatient (including day-only) services 
from NSW public and private hospitals. Hospital separation records have been included in 
this analysis for the fiscal years 1999–2000 to 2008–09. Hospital medical record coders 
record and code, in the separation record, all procedures and diagnoses, symptoms and risk 
factors recorded in the medical discharge summary for a patient’s stay in hospital in 
accordance with the International Classification of Diseases – Australian Modification.9, 7 
There were 6,880 people (5,026 men, 1,854 women) diagnosed with bladder cancer in NSW 
between 2000 and 2008. The majority (92.1 per cent) were histologically verified (75.8 per 
cent by CCR coders sighting the pathology report and 15.4 per cent sighted only by hospital 
coders), 6.4 per cent were verified clinically and 0.9 per cent were verified by cytology only. 
There were 105 cases, or 1.5 per cent, identified only by death certificate or autopsy, which 
were excluded from the survival analysis but included in the descriptive and comparative 
analyses. 
The 150 registered bladder cancer cases that did not link to a hospital separation record may 
have been treated in hospitals in adjoining Australian States or Territories missed links or 
had only outpatient treatment. They were excluded from the analysis. The combined 
automated and manual linkage process had an estimated false positive rate of 0.4 per cent.10 
4.3.2. Variables available for analysis 
The following variables were obtained from cancer registry records: age at diagnosis; month 
and year of diagnosis; summary stage (extent of disease) at diagnosis, classified as localised, 
regional, distant or unknown 11; histological subtype of cancer, summarised as transitional 
cell, papillary transitional cell and other (International Classification of Disease of Oncology 
(ICD-O) version 3 morphology codes - M81203, M81303 all other M codes were grouped as 
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other) 12; country of birth, as notified to the cancer registry and reported by the patient at 
admission to hospital; place of residence, classified as metropolitan, outer metropolitan and 
rural; socioeconomic status, allocated in five categories using the Australian Bureau 
Statistics’ Index of Relative Socioeconomic Disadvantage 13; survival time in months from 
diagnosis to death or end of 2008; and status at the end of 2008 – alive, died of bladder 
cancer or died of another cause. 
These additional variables were obtained from hospital separation records: history of 
haematuria, absent or present (any of International Classification of Diseases Codes – tenth 
revision (ICD-10) disease codes Z54.2, Z51.1, Z51.2 in any record for each bladder cancer 
patient); history of cystitis, absent or present (any of ICD10 codes N30.0-N30.9 in any 
record); smoking history, current or past (any of ICD-10 codes Z86.43, Z72.0, Z71.6, F17 in 
any record); procedures undergone for the management of bladder cancer (see below); date 
of procedure to which the patient’s management was classified (see below); type of hospital 
of admission for this procedure, public or private; distance of residence from the treatment 
facility (see below); and Charlson comorbidity index (see below). 
4.3.3. Bladder cancer procedures 
Patients’ management was classified to the bladder cancer procedure they underwent that 
was most likely to be curative. Thus, cystectomy was classified ahead of resection or 
endoscopic destruction of bladder tissue and total cystectomy ahead of a prior partial 
cystectomy. Patients who did not undergo cystectomy were classified to resection if they 
underwent any resection of bladder tissue or endoscopic destruction of bladder tissue 
(hereafter any reference to resection is a reference to resection or endoscopic destruction). 
All other patients were considered to have had no specific treatment for bladder cancer. 
Chemotherapy and radiotherapy are not reliably recorded in separation records and so were 
not considered for the analysis. The hospital admission for the most curative procedure was 
used to determine the time from diagnosis to treatment, and the distance the patient travelled 
to obtain that treatment. 
 119 
 
4.3.4. Treatment delay 
Time from diagnosis to treatment was calculated as the time in months from the date of 
diagnosis to the date of the procedure from which the patient’s management was classified. 
There were 362 bladder cancer patients who apparently had a bladder cancer procedure 
before their date of diagnosis and did not have a subsequent surgical procedure; they were 
excluded from the analysis. 
4.3.5. Comorbidities 
Comorbidities were classified using the Charlson index14. The index for each patient was 
obtained by scanning 20 diagnosis fields and 11 procedure fields in the hospital separation 
record of their treatment or, with no treatment, the first bladder cancer admission at or after 
their diagnosis. The Charlson score was grouped into no, low (1-2), medium (3-4) or high 
comorbidities (5-18). Secondary cancer, most often a code reflecting the stage of the bladder 
cancer, was excluded from the comorbid conditions. 
4.3.6. Distance from treatment facility 
Distance from the treatment facility was determined by calculating the distance in kilometres 
from the patient’s geocoded address to the treatment facility’s geocoded address using the 
“Great Circle Distance Calculator”15. 
4.3.7. Statistical analysis 
An analysis was done first to see which variables were independently associated with sex. 
All variables except survival time and status at the end of 2008 were included in a logistic 
regression analysis in which sex was the dependent variable and variables removed by 
stepwise backward elimination was undertaken with the likelihood ratio test used to compare 
two models. At each step, the remaining variable with the highest type III test p value was 
the next eliminated 16. 
Survival analyses were limited to patients who were managed by cystectomy or, in its 
absence, resection; 78 per cent of women and 77 per cent of men were managed in one or 
other of these ways, the remainder had apparently received no surgical treatment (Table 1). 
Kaplan Meier survival curves were plotted to visualise the associations of survival with sex 
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and type of bladder cancer procedure. As there were intersecting survival curves for 
treatment with cystectomy and treatment with resection (Figure 2), separate multivariate 
Cox proportional hazards models of case fatality were constructed in patients managed by 
cystectomy and patients managed by resection. Again, variables were removed stepwise by 
backward elimination as described above. A stepwise, forward regression analysis was also 
undertaken as a check. 
Several sensitivity analyses were done. First, patients who died within one month of their 
procedure (cystectomy, resection), regardless of whether death was from bladder cancer or 
another cause, were excluded from the Cox regression models to examine the sensitivity of 
results to early deaths. Second, only cases whose histopathological diagnosis of invasive 
bladder cancer was verified by cancer registry staff were analysed to assess possible effects 
of coding bias, a well-known issue with bladder cancer17. Third, because of uncertainty of 
completeness of ascertainment (due to differences in coding practices in hospitals) possible 
effects of presence or absence of an ileal conduit and presence or absence of lymph node 
removal was examined only in sensitivity analyses. 
4.4. Results: 
Among the 6,880 bladder cancer patients diagnosed between 2000 and 2008 and followed to 
the end of 2008, a higher proportion of women (37%) than men (28%) had died from their 
bladder cancer (Table 1). There were no material differences between men and women in the 
proportions receiving a cystectomy, a resection, or no potentially curative bladder cancer 
surgery. 
4.4.1. Variables associated with patient’s sex 
The odds that a person diagnosed with bladder cancer was a woman were greater if aged 80 
years and older, born in Australia, diagnosed with other than transitional cell or papillary 
transitional cell carcinoma and with distant metastases at diagnosis. Women were more 
likely to receive treatment within one or two months of diagnosis, less likely to present with 
medium or high comorbid conditions and with haematuria, more likely to present with 
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cystitis, less likely to be current or ex-smokers, less likely to live in rural areas at diagnosis 
and less likely to receive treatment in private hospitals (Table 2). 
Chapter 4 Table 1 Characteristics of people diagnosed with bladder cancer and their cancers, management and 
outcome, NSW, 2000 to 2008 
Descriptive characteristics  
Men 
n=4656 
Women 
n=1,712 
Total 
n=6,368  
Age group 15-49 3% 3% 3%  
 50-59 10% 7% 9%  
 60-69 22% 17% 21%  
 70-79 37% 34% 36%  
 80+ 28% 39% 31% 
Country of birth Australian born 63% 72% 65% 
 Born in English speaking 
 
13% 11% 12% 
 Born in non- English speaking 
 
24% 17% 22% 
 Unknown country of birth 0% 0% 0% 
Socioeconomic status Highest SES 18% 19% 18% 
 Second highest SES 19% 17% 18% 
 Middle SES 19% 17% 18% 
 Second lowest SES 21% 23% 22% 
 Lowest SES 24% 24% 24% 
Summary stage (extent of disease) Localised 51% 51% 51% 
 Regional 19% 18% 18% 
 Distant 6% 9% 7% 
 Unknown 24% 23% 24% 
****Histological type Transitional cell 43% 45% 43% 
 Papillary transitional cell 50% 44% 48% 
 Other 7% 12% 9% 
Period of diagnosis 2000-2004 47% 48% 47% 
 2005-2008 53% 52% 53% 
*History of haematuria No haematuria 70% 76% 72% 
 Haematuria 30% 24% 28% 
**History of cystitis No cystitis 50% 39% 47% 
 Cystitis 50% 61% 53% 
***Smoking history Non smoker 31% 23% 29% 
 Current smoker 41% 23% 36% 
 Ex smoker 28% 54% 35% 
Potentially curable surgical 
 
#Cystectomy 18% 16% 17% 
 ##Resection 66% 67% 67% 
 ### No specific treatment 16% 17% 16% 
Charlson index No comorbidity 23% 32% 26%  
 Low comorbidity 34% 35% 34%  
 Medium comorbidity 24% 20% 23%  
 High comorbidity 19% 12% 17%  
Time from diagnosis to treatment One month 68% 71% 69%  
 Two months 6% 7% 7%  
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Descriptive characteristics  
Men 
n=4656 
Women 
n=1,712 
Total 
n=6,368  
 Three months 4% 5% 4%  
 Four or more months 22% 17% 20%  
Region of residence at diagnosis Metropolitan 38% 39% 39%  
 Outer metropolitan 36% 37% 36%  
 Rural 26% 24% 25%  
Distance from treatment facility Less than 25 km 77% 80% 78%  
 26- to 75km 13% 12% 13%  
 76 to 125km 5% 4% 5%  
 126 plus kilometres 5% 4% 5%  
Type of hospital Public hospital 57% 61% 58%  
 Private hospital 43% 39% 42%  
Status at the end of Alive 52% 47% 51%  
 Died of bladder cancer 28% 37% 30%  
2008 Died of another cause  20% 17% 19%  
 Total 73% 27% 100%  
* Haematuria codes (Z54.2, Z51.1,Z51.2), 
**Cystitis codes (N30.0-N30.9) 
***Smoking codes (Z86.43, Z72.0, Z71.6,F17) 
****Morphology codes (M81203, M81303 and all other grouped together) 
# Cystectomy codes (37014-00, 37000-00, 37000-01) 
##Resection of bladder tissue or endoscopic destruction codes (36839-04,36845-04, 36845-05,36840-02,36854-02,36839-
00,36839-02,36845-01,36840-00, 36845-00,36845-02,36845-03,36845-06,36845-07,36840-01 
### Includes cystoscopy, biopsy or other diagnostic procedure codes (36812-00, 36812-01, 36842-00, 36860-00, 36821-02, 
36818-00, 36818-01, 3685700, 36806-02, 36854-00, 36854-01, 36851-00) and no procedure codes 
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Chapter 4 Table 2 Comparison of women and men with bladder cancer, NSW, 2000 to 2008 (multivariate logistic 
regression analysis – odds ratios and 95% confidence limits) 
Descriptive  Characteristics OR# LCI# UCI# P value 
Age group 15-49 1.00 
  
 
 
50-59 0.89 0.61 1.31  
 
60-69 0.99 0.69 1.41  
 
70-79 1.32 0.93 1.86  
 
80+ 1.86 1.31 2.64 <.0001 
Country of birth Australian born 1.00      
 
Born in English speaking countries 0.59 0.51 0.70  
 
Born in non- English speaking countries 0.73 0.61 0.88  
 
Unknown country of birth 0.64 0.20 2.01 <.0001 
Summary stage (extent of disease) Localised 1.00 
  
 
 
Regional 0.90 0.76 1.06  
 
Distant 1.29 1.02 1.63  
 
Unknown 0.94 0.81 1.10 
0.0434 
 
****Histological subtype Transitional cell 1.00      
 
Papillary transitional cell 0.90 0.79 1.02  
 
Other 1.38 1.12 1.69 0.0003 
*History of haematuria No haematuria 1.00      
 
Haematuria* 0.67 0.58 0.77 <.0001 
**History of cystitis No cystitis 1.00      
 
Cystitis** 1.90 1.68 2.15 <.0001 
***Smoking Non smoker 1.00      
 
Current smoker 0.46 0.40 0.53  
 
Ex smoker 0.33 0.29 0.38 <.0001 
Charlton index Low comorbidity 0.69  0.59  0.80  
 
Medium comorbidity 0.53 0.45 0.63  
 
High comorbidity 0.43 0.35 0.53 <.0001 
Time to cystectomy Four months or greater 1.00      
 
One month 1.20 1.03 1.41  
 
Two months 1.38 1.06 1.81  
 
Three months 1.16 0.85 1.58 0.0557 
Region of residence Metropolitan 1.00      
 
Outer metropolitan 0.95 0.83 1.09  
 
Rural 0.80 0.68 0.94 0.019 
Type of hospital Public hospital 1.00      
 
Private hospital 0.68 0.60 0.77 <.0001 
# Odds Ratio, Lower 95% Confidence interval, Upper 95% Confidence Interval (CI) 
* Haematuria codes (Z54.2, Z51.1,Z51.2), 
**Cystitis codes (N30.0-N30.9) 
*** Smoking codes (Z86.43, Z72.0, Z71.6,F17) 
****Morphology codes (M81203, M81303 and all other grouped together) 
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Chapter 4 Figure 1 Kaplan Meier cause specific bladder cancer survival curves by sex, NSW, 2000 to 2008 
 
Chapter 4 Figure 2 Kaplan Meier cause specific bladder cancer survival curves by treatment, NSW, 2000 to 2008 
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4.4.2. Overall survival 
Bladder cancer cause specific five year survival was 68 per cent for men and 56 per cent for 
women (p<0.0001) (Figure 1) and for those having any procedure 68 per cent for men and 
59 per cent for women compared to 44 per cent in men and 35 per cent in women without a 
procedure (data not shown). Survival in women was poorer than in men in each treatment 
category. Survival after cystectomy was initially better than survival after resection but fell 
to less than that for resection after about 20 months (Figure 2). Because of this departure 
from proportionality of hazards, further analyses were stratified into those who had a 
cystectomy and those who had resection. Those who had no surgical procedure were 
excluded from further analysis. 
4.4.3. Survival in patients who had a cystectomy 
There were 1,081 patients (275 women and 806 men), who underwent cystectomy. The 
median time from diagnosis to cystectomy was two months for both men and women, with 
75 per cent of patients receiving their cystectomy within three months for men and four 
months for women. Women had a 31 per cent higher hazard of death in the univariate 
model, falling to a 26 per cent higher hazard of death from bladder cancer (HR =1.26 95% 
CI 1.00-1.59) after multivariate adjustment(Table 3). In addition, bladder cancer patients 
who underwent cystectomy were more likely to die if aged 80 years or older, had distant 
spread of disease or were within one or two months from diagnosis at the time of 
cystectomy. Patients with bladder cancer who lived between 26 and 125 kilometres from a 
their treatment facility were the least to die from it. Period of diagnosis, socioeconomic 
status, type of hospital, smoking status, histological type and comorbidity were not 
significantly associated with fatality following cystectomy in the multivariate model. 
Summary stage and age at diagnosis were the strongest predictors of fatality in the 
multivariate model 
The model was rerun excluding 37 people with bladder cancer who died from any cause 
within one month of their cystectomy. With this exclusion, the HR increased to 1.33 (95% 
CI 1.03-1.71) in women. When only bladder cancer cases coded by NSW registry staff were 
included in the analysis, the HR fell slightly to 1.25 (95% CI 99-1.60). Neither addition of 
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receiving an ileal conduit nor addition of having a lymph node dissection had an effect on 
the multivariate model. 
Interactions between sex and all other covariates included in Table 3 were fitted individually 
in the multivariate model. Only the interaction between sex and history of cystitis was 
statistically significant (P=0.0096). Women who had a history of cystitis had a 55 per cent 
higher hazard of death following cystectomy than men with this history (HR1.55 95% CI 
1.15-2.10) while controlling for all other covariates in the multivariate model. There was no 
difference in the hazard of death between men and women who did not have a previous 
history of cystitis (HR 0.99 95%CI 0.57-1.70) (Table 5). 
4.4.4. Patients who received resection or endoscopic resection of bladder tissue 
In the 4,235, or 62 per cent of, bladder cancer patients who underwent bladder cancer 
resection, women had a 47 per cent higher hazard of death from bladder cancer (HR=1.47 
95% CI 1.30-1.66) than men in the univariate model. This fell to 18 per cent (HR=1.18 95% 
CI 1.03-1.34) in the multivariate model (Table 4). Other variables that were independently 
associated with death following bladder cancer resection included in order of association: 
summary stage, age, histology, history of haematuria, smoking, comorbidity, time from 
diagnosis to resection, socioeconomic status, country of birth, region of residence and 
hospital (Table 4). There was no significant interaction between sex and any other variable 
in the multivariate model. The p value for the interaction of sex with cystitis was 0.7366. On 
stratification of the multivariate model by history of cystitis, the HR for death after resection 
was 1.07 (95%CI 0.90-1.29) in those with a history of cystitis and 1.21 (95%CI 0.96-1.52) in 
those with no history of cystitis. 
The model was rerun excluding bladder cancer patients who died within one month of their 
resection; the HR for death following resection in women fell a little to 1.16 (95% CI 1.01-
1.34). When only bladder cancer cases verified by Cancer Registry staff were included in the 
analysis, the HR for resection in women was unchanged at 1.18 (95% CI 1.02-1.37) (Table 
5). 
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Chapter 4 Table 3 Associations of outcome in people with bladder cancer treated by cystectomy with personal 
characteristics and aspects of their cancer and their management, NSW, 2000 to 2008 (Multivariate proportional 
hazards regression - hazard ratios and 95% confidence intervals) 
Descriptive Characteristics      
  Cases 
n= 
1,087 
Deaths 
n 
=368 
HR LCI UCI P value 
Sex Males 816 262 1.00    
Age group Females 271 106 1.26 1.00 1.59 =0.0523 
 15-49 65 27 1.00    
 50-59 147 33 0.62 0.37 1.05  
 60-69 323 105 1.05 0.68 1.62  
 70-79 443 155 1.08 0.71 1.64  
Summary stage 80+ 109 48 1.85 1.14 2.99 <.0001 
 Localised 470 112 1.00    
 Regional 454 182 2.44 1.90 3.12  
 Distant 49 39 7.62 5.16 11.25  
 Unknown 114 35 1.38 0.94 2.04 <.0001 
Time from diagnosis to 
cystectomy 
Four of more month 333 103 1.00    
 One month 406 158 1.38 1.06 1.82  
 Two months 234 74 1.04 0.69 1.55  
 Three months 114 33 1.01 0.73 1.40 =0.0444 
Distance from treatment 
facility 
Less than 25 km 799 276 1.00    
 26-75 km 139 43 0.70 0.50 0.97  
 76-125 km 58 16 0.58 0.35 0.96  
 126- plus 91 33 1.16 0.80 1.69 =0.0198 
Country of birth Australian born 681 231 1.00    
 Born in English speaking countries 136 57 1.29 0.96 1.74  
 Born in non- English speaking 
countries 
267 79 0.60 0.08 4.33  
 Unknown country of birth  3 1 0.79 0.61 1.02 =0.0423 
*Haematuria No haematuria 865 282 1.00    
 Haematuria 222 86 1.32 1.03 1.70 =0.0297 
HR – Hazard Ratios and 95% Confidence Limits (CI) 
* Haematuria diagnosis codes (Z54.2, Z51.1,Z51.2), 
# Cystectomy procedure codes (37014-00, 37000-00, 37000-01) 
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Chapter 4 Table 4 Associations of outcome in people with bladder cancer treated by resection with personal 
characteristics and aspects of their cancer and their management, NSW, 2000 to 2008 (Multivariate proportional 
hazards regression - hazard ratios and 95% confidence intervals) 
Descriptive Characteristics 
 Cases 
 n= 
 
 Deaths 
n= 
 
HR LCI  UCI P value 
Sex Males   3,090   745  1.00    
 Females  1,145   379  1.18 1.03 1.34 =0.0175 
Agegroup 15-49  103   14  1.00    
 50-59  341   52  1.07 0.59 1.94  
 60-69  815   147  1.47 0.85 2.57  
 70-79  1,511   393  2.15 1.25 3.70  
 80+  1,465   518  3.57 2.07 6.15 <.0001 
Country of birth Australian born  2,787   784  1.00    
 Born in English speaking countries  519   135  0.74 0.63 0.86  
 
Born in non- English speaking 
countries  916   204  0.83 0.69 1.00  
 Unknown country of birth  13   1  0.24 0.03 1.69 =0.0005 
Socioeconomic status Highest SES  779   194  1.00    
 Second highest SES  786   195  1.08 0.86 1.34  
 Middle SES  736   197  1.29 1.03 1.62  
 Second lowest SES  918   267  1.45 1.14 1.83  
 Lowest SES  1,016   271  1.26 1.00 1.59 =0.0126 
Summary stage Localised  2,346   463  1.00    
 Regional  590   269  2.91 2.50 3.40  
 Distant  217   177  8.01 6.65 9.65  
 Unknown  1,082   215  1.11 0.94 1.30 <.0001 
Histology Transitional cell  1,669   587  1.00    
 Papillary transitional cell  2,326   433  0.54 0.48 0.62  
 Other  240   104  1.23 0.99 1.53 <.0001 
*Haematuria No haematuria  2,977   686  1.00    
 Haematuria  1,258   438  1.34 1.18 1.52 <.0001 
***Smoking Non smoker  1,204   297  1.00    
 Current smoker  1,557   368  0.96 0.82 1.12  
 Ex smoker  1,474   459  0.84 0.73 0.97 =0.0511 
 No comorbidity  1,201   249  1.00    
Comorbidity Low comorbidity  1,364   394  1.14 0.97 1.35  
 Medium comorbidity  961   302  1.15 0.96 1.37  
 High comorbidity  709   179  0.92 0.76 1.13 =0.0451 
Time from diagnosis to 
resection Four of more months  663   142  1.00    
 One month  3,294   909  1.50 1.25 1.79   
 Two months  149   43  1.38 0.97 1.94  
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Descriptive Characteristics 
 Cases 
 n= 
 
 Deaths 
n= 
 
HR LCI  UCI P value 
 Three months  129   30  0.93 0.63 1.39 <.0001 
Region of residence at 
diagnosis Urban  1,622   434  1.00    
 Outer metro  1,576   439  0.87 0.73 1.03  
 Rural  1,037   251  0.67 0.55 0.81 =0.0002 
Hospital Public  2,220   688  1.00    
 Private  2,015   436  0.73 0.64 0.83 <.0001 
HR – Hazard Ratios and 95% Confidence Limits (CI) 
Resection of bladder tissue or endoscopic destruction procedure codes (36839-04,36845-04, 36845-05,36840-02,36854-
02,36839-00,36839-02,36845-01,36840-00, 36845-00,36845-02,36845-03,36845-06,36845-07,36840-01) 
* Haematuria codes (Z54.2, Z51.1,Z51.2), 
*** Smoking codes (Z86.43, Z72.0, Z71.6,F17) 
 
 
 
Chapter 4 Table 5 Results of sensitivity analyses in multivariate proportional hazards regression analyses of outcome in 
bladder cancer patients who underwent cystectomy and resection, NSW, 2000-2008 
Resection of bladder tissue or endoscopic destruction procedure codes (36839-04,36845-04, 36845-05,36840-02,36854-
02,36839-00,36839-02,36845-01,36840-00, 36845-00,36845-02,36845-03,36845-06,36845-07,36840-01) 
  
Regression models HR  LCI  UC1  P value 
Patients treated by cystectomy     
Univariate model (n =1,087)  1.31 1.05 1.64 0.0189 
Multivariate model in Table 3 (n =1,087) 1.26 1.00 1.59 0.0523 
Multivariate model in Table 3 excluding deaths at one month (n=1,051)  1.33 1.05 1.69 0.0178 
 
Multivariate model in Table 3 including records coded by cancer registry staff (n=1,015)  1.27 1.00 1.61 0.0483 
Patients treated by resection     
Univariate model (n = 4,241)  1.47 1.30 1.66 <0.0001 
Multivariate model in Table 4 (n = 4,241) 1.18 1.03 1.34 0.0175 
Multivariate model in Table 4 excluding deaths at one month (n=4,107)  1.16 1.01 1.34 0.0332 
Multivariate model in Table 3 including records coded by cancer registry staff (n= 3,333)  1.18 1.03 1.36 0.0198 
Cystectomy procedure codes (37014-00, 37000-00, 37000-01) 
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4.5. Discussion 
Estimated five year, cause specific survival from bladder cancer was 56 per cent for women 
diagnosed in NSW in 2000-08 and 68 per cent in men (P<0.0001), and this poorer survival 
in women was observed regardless of whether they were treated by cystectomy or resection 
(including endoscopic destruction) of bladder tissue, or had no specific therapy. Adjustment 
for a wide range of other variables associated with survival had little impact on women’s 
higher risk of death from bladder cancer following cystectomy (unadjusted HR for female 
sex 1.31, 95% CI 1.05-1.64; fully adjusted HR 1.26, 95% CI 1.00-1.59). Adjustment 
weakened the association of female sex with risk of death following resection but did not 
eliminate it (unadjusted HR for female sex 1.47, 95% CI 1.30-1.66; fully adjusted HR 1.18, 
95% CI 1.03-1.34). The variable(s) principally contributing to the weakening of the 
association of female sex with risk of death in cystectomy patients were in order of strength: 
summary stage, age at diagnosis, distance from treatment facility, the presence of 
haematuria, country of birth and time to cystectomy. For bladder cancer patients who 
underwent resection the variables principally contributing to the weakening of the 
association of female sex were in order of strength: summary stage, age at diagnosis, 
histology, time to resection, hospital type, the presence of haematuria, country of birth, 
region of residence at diagnosis, socioeconomic status, comorbidity and smoking. 
Examination of interactions between sex and other covariates found a possibly meaningful 
interaction of sex with a history of cystitis in influencing death after cystectomy: HR was 
1.55, 95%CI 1.15-2.10, in women with a history of cystitis and 0.99, 95% CI 0.57-1.70 in 
those without; p for interaction 0.0096. No such interaction was evident in women who 
underwent resection. 
Advantages of this study include that it is population-based and that linkage of cancer 
registry to hospitalisation records was near complete; only 150 cases did not link. There are 
several limitations: we did not have information on the grade of bladder cancer and we had 
only summary stage. However, the proportional breakdown and survival by histological 
subtype and summary stage in NSW was very similar to those in SEER 2 and our findings 
with respect to sex difference in survival are similar to those of population-based studies of 
AJCC or tumour, nodes and metastases (TNM) staged bladder cancer 18. We also had no 
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information about whether radiotherapy or adjuvant chemotherapy was received and could 
not address methods of bladder replacement at all adequately. As our study used only 
inpatient data, the length of time or frequency of cystitis is unknown in patients that only 
receive chemotherapy or radiotherapy and it will be important to examine this issue in future 
work. 
Haematuria, cystitis and smoking, as risk factors for or symptoms associated with a poorer 
outcome, have not been previously examined in bladder cancer using coded inpatient data. 
We could not find estimates of the proportion of bladder cancer patients who would 
normally present with haematuria or cystitis, nor were we able to characterise them well 
with respect to the time of onset. However, we could compare our estimates of smoking in 
bladder cancer patients with results of surveys of primary care patients and the NSW 
population 19and the Australian Health Survey 20and found that our results were similar. 
Although, some under-reporting of current smokers may occur due to social pressure where 
other household members were present at the interview, the extent of this issue is 
unknown21. 
Furthermore, in review of data quality in systematic databases smoking derived from 
hospital data was found to have positive predictive value of 93-96 and a specificity of 9922. 
Therefore, coding of smoking would appear to be relatively complete. In addition, we have 
no reason to believe that there would be systematic coding or reporting differences in 
haematuria and cystitis between men and women. 
The survival difference between men and women remained after adjustment, which suggests 
that other factors not considered in this study account for this difference. For example, we 
could not evaluate possible effects of anatomical differences between men and women. It 
has variously been suggested that the thicker detrusor muscle in men 18, the less robust 
bladder neck in women23 and effects of growth of glandular prostatic tissue on 
angiolymphatic drainage in men 24 may contribute to sex differences in the spread of bladder 
cancer. Differences in the suspicion of bladder cancer between men and women with 
haematuria might also lead to stage differences that are not fully controlled by stage 
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adjustment 18. Our adjustment for haematuria in the Cox proportional models addresses this 
possibility, at least to some extent. 
Differences in histological type have also been considered responsible for survival 
differences between men and women; with men reported to have a 32 per cent greater 
chance of diagnosis with superficial disease than females 25. ‘Other’ histological types were 
more prevalent in women than men in our data and there was a greater hazard of death from 
bladder cancer in patients with ‘other’ types who underwent resection, but adjustment for 
histological type did not fully explain the higher hazard of death in women. Moreover, 
histological type was not an independent predictor of survival in patients who had a 
cystectomy. 
Our findings that a history of cystitis was significantly associated with poorer survival from 
bladder cancer and that this association was present only in women were unexpected. A 
history of cystitis was substantially more prevalent in women, and this is true in the general 
population .26, 27Mungan 25 suggests that more prevalent cystitis in women may explain a 
delay in care seeking behaviour and higher stage bladder cancer at diagnosis. In addition, 
there is recent evidence of greater delay at the primary care level for women than for men; 
symptomatic treatment for voiding disorders or pain was much more likely to be given 
without further evaluation and, therefore with probable delay in referral, in women than in 
men in the year before the diagnosis of bladder cancer 28 While we could find no other 
evidence directly relevant to an association between cystitis and bladder cancer survival, 
cystitis may increase bladder cancer risk. Kantor 29 found a significantly elevated level of 
bladder cancer in those who reported three or more infections (RR =2.0). The higher hazard 
of death we observed in women with a history of cystitis who underwent cystectomy may 
suggest that progression of bladder cancer is faster in women than in men with a history of, 
or current, bladder infection. 
Mechanisms have been sought to explain the observed association of bladder cancer risk with 
urinary infection, such as urinary concentration due to urinary retention 30 and lower levels of 
glycosaminoglycan, which protect the urothelium, in women with interstitial cystitis31. Several 
studies 32, 33 show loss of impermeability of bladder urothelium in patients with interstitial 
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cystitis and abnormal expression of molecular markers, one of which is E-cadherin. It has been 
suggested that change in E-cadherin expression is an adaptation to the increased permeability of 
the urothelium32. In addition, a number of authors have reported an association between loss of 
E-cadherin and high grade and advanced stage breast, prostate 34, pancreas35 and head and neck36 
cancers. One study has suggested that cystitis mimics Barrett’s metaplasia both etiologically and 
histologically32, but it was based on only 13 samples. Apart from these studies we could find 
none that suggest possible mechanisms for poorer survival in women with a history of cystitis”. 
It has been suggested that delaying radical cystectomy in organ-confined disease is 
associated with poorer survival and that patients with low grade or low stage tumours have 
the largest increases in mortality when diagnosis is delayed37. We did not have data on the 
interval between onset of symptoms and bladder cancer treatment and could not address this 
issue directly, although it should, in principle, be dealt with by adjustment for stage. US 
studies have found that bladder cancer patients who wait longer than three months between 
diagnosis and radical cystectomy have a greater risk of disease progression 38, 39 and death37. 
Most of our patients who had a cystectomy, 75 per cent, underwent it within three months of 
their diagnosis, which compares well with 73 per cent in a US population-based study40.  
However, we did not find worse survival in patients who underwent cystectomy, or 
resection, three months or more after diagnosis. In contrast, we found that patients who 
underwent cystectomy within one month of diagnosis had a 34 per cent higher hazard of 
death than those who underwent it four or more months after. It is possible that patients in 
NSW who underwent cystectomy within a month of diagnosis had more advanced disease 
and were sicker at presentation than those who were treated later. NSW patients that 
underwent cystectomy and died within the first month had a higher proportion of either 
regional or distant metastases (66.0%) compared to patients that died later (47.3%) or were 
alive at the end of the period (34.1%). Men and women did not have different distributions 
of distance from the treatment facility. Patients who underwent cystectomy had a higher 
adjusted hazard of death if they lived within 25 kilometres of a treatment facility than if they 
lived 26 to 75 (HR 0.61 95%CI 0.43-0.88), 76 to 125 kilometres (HR 0.50 95%CI 0.29-0.88) 
or 125 kilometres away. Distance from treatment facility was not an independent predictor 
of the hazard of death for patients who underwent resection. However, greater distance from 
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the treatment facility was found to reduce the likelihood of receiving potentially curative 
surgery and radiotherapy. 41-44 45 
When we investigated comorbidity using the Charlson index, we found no significant 
difference in the number of comorbid conditions between men and women and that 
comorbidity was not independently associated with survival after cystectomy. It was with 
survival after resection. The Charlson index has been found to be a reliable indicator of 
comorbidity. 46 Other studies have also found no association between sex and comorbidity. 
47-49 
Socioeconomic status was not independently associated sex or with survival after 
cystectomy but was with survival after resection, with poorer survival in the lower 
socioeconomic groups. Other studies have found worse survival from bladder cancer in 
poorer, less educated people and in minority ethnic groups. 50 51 52 
4.6. Conclusion 
There is poorer survival from bladder cancer in women regardless of treatment and after 
adjustment for a range of other prognostic variables, and this was true in this study whatever 
the treatment received. Among the variables studied, only a history of cystitis recorded at the 
time of hospital admission appeared affect survival in women treated by cystectomy. There 
was an apparent 55% greater hazard of death from bladder cancer in women who had a 
history of cystitis and had a cystectomy than in men with this history. There was no such 
difference in those who did not have a history of cystitis. The poorer survival from bladder 
cancer in women remains largely unexplained. That a history of cystitis in women diagnosed 
with bladder cancer and treated by cystectomy may contribute to this poorer outcome merits 
further investigation. 
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5.1. Abstract 
Objective: To determine whether distance of residence from a gynaecological oncology 
service (GOS) was associated with a better survival from ovarian cancer. Methods We 
linked cancer registry records to hospital records for 3,749 women with ovarian cancer 
diagnosed between 2000 and 2008 in New South Wales, Australia. Access to a GOS was 
measured in kilometres from a woman’s geocoded address to the geocoded address of the 
closest public GOS hospital. Flexible parametric survival, Cox proportional hazards and 
logistic regression models were fitted to examine whether better access to a GOS was 
associated with a better survival, and whether extensive surgery was received for ovarian 
cancer after adjustment for patient, tumour and treatment factors. Results: The hazard of 
death from ovarian cancer was lower in women who were treated in a in GOS hospitals (HR 
0.77 95%CI 0.64-0.95), and lower in those who had extensive surgery (HR 0.47 95%CI 
0.38-0.58). The further women with ovarian cancer lived from a public GOS hospital, the 
more likely they were to be treated in a public general hospital. Women were 19 times more 
likely (OR 19.40 (95% CI 13.92-27.04) to be treated only in a general hospital when they 
lived 187km or more from a public GOS hospital than women who lived within 5km of one. 
Conclusion Distance of residence from GOS hospitals in Australia is an important 
determinant of access to GOS hospitals. Treatment in a public or private GOS hospital and 
having surgery were the strongest predictors of survival from epithelial ovarian cancer. 
Research is required into the barriers to referral of patients with ovarian cancer for care in 
GOS hospitals; low population density limits options for supply of GOS in rural areas. 
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5.2. Key words 
Key words –Ovarian cancer, access, distance, gynaecological oncology, resection, Cox 
proportional hazards, cause specific mortality or survival, logistic regression, hospital 
referral 
5.3. Introduction 
Ovarian cancer is characterised by vague symptoms and late stage at diagnosis. It has a poor 
prognosis. While stage at diagnosis is the strongest determinant of survival from ovarian 
cancer there is regional variation in survival among women presenting with advanced cancer 
that suggests factors other than stage might be important in determining survival.(1 
Australian clinical practice guidelines for ovarian cancer recommend that women who are 
diagnosed with epithelial ovarian cancer should be treated in a hospital with a 
gynaecological oncology service (GOS).2 US guidelines3 do not specifically nominate such a 
service but recommend surgical cytoreduction to 1cm or less. Cytoreductive surgery 
(resection of macroscopic metastatic disease) is the accepted standard of care for women 
with advanced ovarian cancer. 4Women treated by gynaecological oncologists in high 
volume specialist centres, 4 where cytoreductive surgery is usual for advanced cancers, have 
lower post-operative mortality5 and better survival.4, 6 Thus access to gynaecological 
oncology care could be an important factor, if not the major factor, underlying regional 
variations in ovarian cancer outcome. 
Most registry based studies of ovarian cancer survival are limited in their ability to examine 
the effects of patient, tumour and treatment related factors on cancer outcome. The NSW 
Central Cancer Registry routinely records stage at diagnosis and tumour morphology; and 
we know from an earlier NSW registry based study that a woman’s age, stage at diagnosis 
and histology are the factors that most influence survival from ovarian cancer.7 In this paper, 
we extend this analysis by linking cancer registry data to hospital data and by geocoding 
patients’ residences and treating hospitals to measure distance from a patient’s home to their 
closest public hospital with a GOS as an indicator of access to best care for ovarian cancer 
Australians are entitled to free care in public hospitals and financial assistance with travel 
and accommodation if they live 100km or more from necessary treatment). We investigate 
whether access to a GOS hospital is associated with ovarian cancer survival after taking 
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account of patient, tumour and treatment characteristics. We also examine factors associated 
with treatment in public general hospitals (as opposed to GOS hospitals or private general 
hospitals) and factors associated with having surgery for their ovarian cancer. 
5.4. Methods 
5.4.1. Study population: 
Women diagnosed with invasive ovarian cancer (including cancer of fallopian tubes and 
associated adnexae; ICD-10 C56; C57.0-C57.9) notified to the NSW Central Cancer 
Registry between 2000 and 2008 were investigated. NSW is the third largest and most 
populated state in Australia with population of 7,290,000 and an area of 800,642 square 
kilometres. Women’s Registry records were linked to NSW APDC records (records of all 
hospital separations in NSW) and they were followed up for death or survival to the end of 
31st of December 2008. Patient characteristics available included age, place of birth, 
socioeconomic status, smoking history, comorbidity, region of residence at diagnosis, 
payment status at admission to hospital, order of ovarian cancer and patients’ cancers 
characterised by stage at diagnosis and histopathological type. (See also Appendix 1, Table 
1). Histopathological types were combined into three groups based on similarity of 
survival.7) 
5.4.2. Treating hospital: 
There were 207 treating hospitals: nine were public GOS hospitals (all were teaching 
hospitals affiliated with university medical schools), seven private GOS hospitals, 103 
public general hospitals and 88 private general hospitals. GOS hospitals were those 
identified as such in the NSW Directory of Gynaecological Services.8 For each patient, the 
treating hospital was the hospital at which they had their most extensive surgery or the first 
hospital to which they were admitted after diagnosis if they had limited or no surgery. 
5.4.3. Access to gynaecological oncology: 
For each patient, we calculated the straight-line distance from the patient’s home to the 
closest public GOS hospital using the “Great Circle Distance Calculator”.9 The straight-line 
distance has been found to be highly correlated with travel time or travel distance in the UK 
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(R=0.86).10 We grouped distance in kilometres from a patient’s home to the nearest public 
GOS hospital into five categories, each containing 20% of patients. For survival, we also 
modelled distance in kilometres as a continuous variable. 
5.4.4. Treatment: 
Patients were grouped into two treatment categories based on all surgical procedures coded 
at each hospitalisation (up to 50 allowed) for all public and private inpatient admissions in 
the linked dataset. Patients were classified as having had extensive surgery if they had 
surgery that involved the removal of one or both ovaries with or without associated 
hysterectomy and salpingectomy, debulking or surgical staging. Patients were classified as 
having had limited or no surgery if they had any other procedure related to ovarian cancer 
(e.g. biopsy) or no surgery at all. A preliminary analysis showed no difference in hazard of 
death over five years between subgroups of limited surgery and no surgery (data available 
on request). Information on whether residual disease remained after surgery was not 
available. The complete list of the ICD-10-AM Version 6 MBS-Extended procedure codes 
included in these two surgical treatment groups is given in Appendix 1. Other treatment 
characteristics analysed included method of diagnosis, period of diagnosis, time from 
diagnosis to treatment and financial status (Appendix 1, Table 1). 
5.4.5. Statistical analysis 
We estimated cause specific survival from ovarian cancer and its predictors using Kaplan 
Meier curves, log rank tests, and unadjusted five year hazard [1-(5 year survival)]. We used 
the multivariable fractional polynomial (MFP) command in Stata 12.1 and found minimum 
distance from a public GOS hospital to be linear and age to be a first order polynomial with 
a cubic distribution. We fitted Royston-Parmar regression models using the log odds 
command in stpm2 implemented in Stata 12.1.11) We chose the Royston-Parmar model in 
preference to the more commonly used Cox model so that we could deal more easily with 
non proportional hazards and plot covariate adjusted survival curves. 11 Proportionality of 
hazards was examined and, if not proportional, we took account of the time varying effect 
using the tvc command. 
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Minimum distance from a public GOS (the variable of primary interest) and age, stage and 
comorbidity (known to be associated with survival) were retained in the model regardless of 
their statistical significance. All other univariable predictors in Appendix Table 1 were 
included in the backward elimination model if they were associated with survival; that is if 
they had a p value less than 0.2. We removed the least significant variable from the 
backward elimination model after conducting nested likelihood ratio tests, a p value for 
retention in the model was <0.05. All hazard ratios and their confidence limits were 
calculated using the predict command at one year and five years after diagnosis. We tested 
model fit by comparing Kaplan Meier unadjusted survival curves with the mean covariate 
adjusted survival curves for each covariate (Appendix 1).11 
We repeated our data analysis using the Cox proportional hazards modelling procedure in 
Stata 12.1 to check the stpm2 model and because multiple imputation using chained 
equations is easily implemented using Cox modelling. We used the LINCOM command to 
calculate confidence intervals for variables with time varying effects. We repeated our 
model with unknown stage included. We also imputed unknown stage using mi estimate to 
run the final Cox model with imputed stage. 
We used logistic regression to examine determinants of a woman’s odds of being treated in a 
public general hospital rather than any other type of hospital, and of having extensive 
surgery or not. Minimum distance from a public GOS, age, stage and comorbidity were 
included a priori, other patient, disease and treatment factors were included in the backward 
elimination model if they had a p value of less than 0.2 in the chi squared analysis 
(Appendix 1 table 1). A p value of less than 0.05 in the nested likelihood ratio test was used 
to decide whether a variable was retained in the final model. 
5.5. Results: 
Of 3,749 women diagnosed with ovarian cancer who were eligible for the study, 3,411 were 
included in the logistic regression analysis. Women were excluded from analysis if they had 
no hospital admission (114), appeared to have been first treated before diagnosis (32) or had 
non-epithelial tumours (150) or if their cancer had been registered only from a death 
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certificate mentioning ovarian cancer (42). Women were excluded from survival models if 
their stage at diagnosis was unknown (342) leaving 3,069 for analysis. 
Altogether, 37% of analysed women were treated in public GOS hospitals, 32% in public 
general hospitals, 17% in private GOS hospitals and 14% in private general hospitals. There 
was an average of 14 patients (range 3 to 27) per hospital per year treated in the GOS 
hospitals. There was a strong association between distance and type of hospital (Table 1). Of 
women who lived within five kilometres of a public GOS hospital, 58% attended one for 
their treatment; a further 22% attended a private GOS hospital. By contrast, only 16% of 
women who lived 187 or more kilometres from a public GOS hospital attended one; and 4% 
attended a private GOS hospital. There was also a strong association between hospital type 
and type of surgical treatment. The proportions of patients who had extensive surgery were 
86% in private GOS hospitals, 73% in public GOS hospitals, 62% in private general 
hospitals and 42% in public general hospitals. 
5.5.1. Determinants of survival 
Results of the Royston Parmer regression model are shown in Table 2. We compared the 
hazards and the cumulative odds models and found that the cumulative odds scale better 
fitted our data than the hazards model (a lower Akaike Information Criterion and Bayesian 
Information Criterion). Hazard ratios for minimum distance and age at diagnosis were 
calculated. Because of the age and stage interaction, p=0.0001 the hazard ratios for age are 
presented at localised stage and at a mean age of 63. Age at diagnosis, histological type, and 
surgery for ovarian cancer had time varying effects. 
There was an increasing trend in the unadjusted hazard of death with increase in distance 
from a public GOS hospital (HR 1.002 at 5 km distant, 1.004 at 9km, 1.013 at 27 and 1.102 
at 187+km, p=0.007 for heterogeneity – results not shown) but after adjustment for 
covariates this trend was no longer significant (p=0.16; Table 2) because of a strong 
association of distance with type of treating hospital. The unadjusted hazard of death from 
ovarian cancer was least in those treated in private GOS hospitals (Figure 1a): relative to 
treatment in a public general hospital (HR of 1), the adjusted HR was 0.57 for treatment in a 
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private GOS hospital, 0.67 for treatment in a private general hospital and 0.77 for treatment 
in a public GOS hospital (Table 2, p<0.0001 Figure 1b). 
As expected, age, stage and histopathological type were very strong predictors of a poor 
ovarian cancer outcome (Table 2). The relative hazard of death in women with more 
advanced (regional and distant stage) cancers was less at five years after diagnosis than one 
year. Relative to serous cancers (HR 1), the hazard at one year was greater in both mucinous, 
endometrioid and clear cell cancers, HR 1.54, and in adenocarcinomas and other and 
unspecified histopathological types of cancer, HR 2.65. At five years, however, the opposite 
was the case: the HR for mucinous, endometrioid and clear cell cancers was 0.20 and for 
adenocarcinoma and other types 0.64 (although consistent with a value of 1.0). These 
different patterns at one and five years reflect that survival from serous carcinomas 
continued to decline over time while for patients with mucinous, endometroid and clear cell 
carcinomas after three years remains higher and consistently poorer for patients with 
adenocarcinoma from two years onwards. 
Method of diagnosis, as recorded by the CCR, was also associated with outcome (Table 2); 
with the highest hazard of death in those with a clinical diagnosis only and the lowest in 
women with histopathologically verified cancer. These associations probably reflect stage 
and treatment effects on outcome. 
The unadjusted survival curve for extensive surgery showed at large survival difference 
between patients who has limited or no surgery and those who had extensive surgery (Figure 
2a).A one year after diagnosis, the adjusted hazard of death in women who had extensive 
surgery for their primary cancer (79.4% done within a month of diagnosis) was less than half 
that for those who did not (HR 0.47 95%CI 0.38-0.58) (Table 2). However, the adjusted 
survival curves converged over time and at 5-years the HR was 0.72 (95%CI 0.52-0.99) 
(Table 2 Figure 2 b). Results using Cox proportional hazards were not materially different to 
those using the Royston Parmer method. In addition, results for all variables in the model 
that included imputed values for unknown stage were not materially different from those in 
Table 2 (data not shown). Graphs of model fit can be found in Appendix 1 and sensitivity 
analyses are available on request. 
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5.5.2. Determinants of treating hospital 
Women living 187+km from a public GOS hospital had 19 times the odds of being treated in 
a public general hospital than women living less than 5km from a public GOS hospital 
(Table 3). Other variables significantly associated with attending a public general hospital 
were older age, diagnosis in 2005-08, having public financial status at admission, unknown 
stage, having an adenocarcinoma, or other specified or unspecified histopathological type 
and increasing time from diagnosis to treatment. 
5.5.3. Determinants of extent of surgery 
Women were less likely to have extensive surgery for ovarian cancer if they were older, had 
adenocarcinoma, other specified or unspecified histopathological type, had advanced or 
unknown stage of cancer, attended a public or private general hospital for treatment, had 
their surgery two or more months after diagnosis or had public financial status at admission 
(Table 4). There was no consistent association between distance to a public GOS hospital 
and having extensive surgery. However, when we removed hospital type from the model, the 
odds of having extensive surgery fell with increasing distance from a public GOS hospital, 
and was particularly low in women living 187 km or more from a GOS hospital (OR 0.45 
95%CI 0.34-0.59; p<0.001) relative to women living within 5 km of one (data not shown). 
5.6. Discussion 
The aspects of care that most strongly reduced a woman’s hazard of dying from epithelial 
ovarian cancer were treatment in a GOS hospital or a private general hospital and having 
extensive surgery for the ovarian cancer. Women were more likely to attend a GOS hospital 
the nearer they lived to one and were more likely to have extensive surgery if they were 
treated in GOS hospitals. Thus, distance was an important factor in determining whether 
women would receive best care for their ovarian cancer because it influenced the hospital 
that she attended and, in consequence, the likelihood of surgery. 
The association of ovarian cancer survival with distance from a woman’s home to her 
closest hospital or family doctor has been examined in UK registry studies.12, 13 Distance 
appeared not to be important; only being first treated in a cancer centre showed a significant 
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reduction in the hazard of death after adjustment for age and deprivation. This study, is 
consistent with our findings, regarding, the importance of type of hospital, but did not 
identify the importance of distance in determining the type of hospital attended. A recent 
population-based study in British Columbia, 14 that like Australia has a publically funded 
health system, also provides indirect evidence for an influence of distance on outcome of 
ovarian cancer. Examining ovarian cancer survival differences by Health Region, the study 
found that once disease characteristics (stage and grade) and treatment (optimal debulking 
and chemotherapy) were taken into account, survival differences previously attributed to 
Health regions were no longer significant. Only two of the five regions had GOS hospitals 
and therefore patients resident in the three other regions would have had to travel to access 
gynaecological oncology services. 
While the type of hospital in which a woman was treated was a strong determinant of 
whether she had extensive surgery, our results suggest that women treated in public or 
private GOS hospitals had a lower risk of death from ovarian cancer independently of 
whether they had extensive surgery. Similarly other large registry based studies of ovarian 
cancer survival have shown that women treated in teaching hospitals or, specifically, GOS 
hospitals, had a lower risk of death than women treated in non teaching (general) hospitals,6, 
12 even after adjusting for extensive surgery and chemotherapy.15 
Patient volumes may be one reason for these survival difference; hospitals managing fewer 
than ten patients with ovarian cancer per year have been found not to provide optimal 
cytoreduction.16 The average numbers of cases for all GOS hospitals was 14 per annum. 
Mercado et al. 6 also found that patients had lower hazard of death when treated in higher 
volume hospitals over and above the lower hazard that resulted from surgery. Similarly, a 
Finnish study 17 found that higher hospital volumes and surgery with less residual tumour 
were independently associated with better survival for woman with ovarian cancer. A 
systematic review has found, in addition, that treatment in a specialist hospital and surgery 
by a gynaecological oncologist both reduced the hazard of death.4 
Lack of adequate staging may also be an important contributor to poorer survival of women 
treated in general hospitals. We found a higher proportion of unknown stage at diagnosis in 
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patients treated in general hospitals. Others have found that lack of adequate staging was 
more prevalent in the absence of specialist gynaecological services and women with 
unstaged disease were more likely not to receive care from a gynaecological oncologist and 
not to receive recommended treatment than women who were adequately staged. 17 
We found an even lower hazard of death for women treated in private GOS hospitals than 
we did for those treated in public GOS hospitals. It is possible that gynaecological 
oncologists in NSW, who often operate in co-located public and private hospitals, will select 
patients who have better performance or nutritional status for treatment in private 
hospitals.18 It is also likely that gynaecological oncologists themselves, rather than their 
residents, operate on patients treated in private hospitals. 
We found most women (86%) were treated within six months of diagnosis; about 10% were 
treated seven months or more after diagnosis. The Australian ovarian cancer patterns of care 
study 18 reported a similarly high proportion of women (90%) treated within six months of 
diagnosis. Lower income and more remote residence were characteristics of the 10% of 
women who were treated six months or later after diagnosis. 19 
It is a limitation of our study that we could not determine for individual women whether 
gynaecological oncologists treated them when they were referred to GOS hospitals. 
However, it is likely that most were; an Australian patterns of care study found that 60% of 
women with ovarian cancer were treated by a gynaecological oncologist, 18 which compares 
well with the 57% of women we found who were treated at either a public or private GOS 
hospital. Lack of information on residual disease in patients who had extensive surgery and 
whether or not chemotherapy was given are also limitations. 
Major strengths of this study are that it is population-based and has high quality linkage of 
cancer registry records to all public and private hospital records. Our measure of distance 
was a measure of access to recommended care and therefore applied to all patients and not 
just to those who received a particular kind of care. We were also able to estimate cause 
specific survival and to include comorbidity as a covariate in analysis, which are noted gaps 
in earlier studies. (12, 13) 
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A recent Australian study found that 93% of ovarian cancer patients presented first to their 
family doctors; only 4% presented to a hospital emergency department. 19 This observation 
suggests that access to a GOS hospital in Australia would be strongly influenced by family 
doctors’ referral patterns. Referral also depended on symptoms, for example, women who 
presented with bleeding were more likely to be referred to a gynaecologist. Overall, 85% of 
women were found to visit three or fewer doctors before their cancer was diagnosed. (19) An 
Australian survey of family doctors’ referral practices 20 reported that most patients 
suspected of having ovarian cancer were referred initially to a general gynaecologist (70% of 
the 83% referred) rather than a gynaecological oncologist. Metropolitan GPs reported greater 
access to public gynaecological oncology services and multidisciplinary teams (80% and 
63%) than rural GPs (58% and 40% respectively). Therefore, it would appear that GP 
referral preferences are important determinants of whether or not women are referred to a 
gynaecological oncologist or to a GOS hospital when ovarian cancer is suspected or 
diagnosed. The frequency with which Australian general gynaecologists on refer women 
with ovarian cancer to a gynaecological oncologist has not been documented. 
A woman’s own choice is another important factor in determining whether or not when 
suspected of, or diagnosed with, ovarian cancer, she will see a gynaecological oncologist or 
attend a GOS hospital; for the 631 of women in our study who lived 187+km from the 
nearest public GOS hospital, travelling, time away from home and the cost of both would 
have been important considerations. 
Distance of residence from gynaecological oncology services appears to be an important 
determinant of hospital of treatment, which influences the likelihood of surgery and whether 
women diagnosed with ovarian cancer in Australia achieve the best outcomes. Research is 
needed into factors that impede referral of women with ovarian cancer to gynaecological 
oncology services, particularly when women live remotely from such services. Low 
population densities limit provision of additional GOS services in rural areas.  
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Chapter 5 Figures 1a and 1b Unadjusted and adjusted survival for women diagnosed with ovarian cancer by type of hospital of treatment,NSW, 2000 to 2008 (n=3,069) 
 
 
Based on model in Chapter 5 Table 2 
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Chapter 5 Figures 2a and 2b Unadjusted and adjusted survival for women diagnosed with ovarian cancer and whether or not extensive surgery was received,NSW, 2000 to 2008 (n=3,069) 
 
†Based on model in Chapter 5 Table 2 
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Chapter 5 Table 1 Type of hospital attended for treatment for ovarian cancer by minimum distance to a public GOS 
hospital 
 
 
 
 
 
 
 
 
 
 
 
  
Type of hospital attended 
Minimum distance from public GOS hospital (km) 
Number 0-5.0 5.1-9.0 9.1-27.0 27.1-187.0 187.1+  
Public general  9.7% 25.6% 22.4% 42.1% 61.0% 1,075 
Private general  10.3% 10.3% 12.8% 19.0% 19.0% 484 
Public GOS 57.6% 43.2% 36.8% 30.0% 16.2% 1,273 
Private GOS 22.4% 21.0% 28.0% 9.0% 3.8% 579 
Number 740 672 657 711 631 3,411 
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Chapter 5 Table 2 Hazard of dying at one year and five year from ovarian cancer and minimum distance to a public 
specialist hospital and other covariates (n=3069) 
  One year Five years   
 Characteristics HR(95%CI)1 HR(95%CI)1 p value2 
Minimum distance to a public GOS hospital (km) 
     1.0 km 1 
 
1 
  5.0 km 1.00 (0.99-1.00) 1.00 (0.99-1.00) 
 9.0 km 0.99 (0.99-1.00) 0.99 (0.99-1.00) 
 27.0.km 0.99 (0.97-1.00) 0.99 (0.97-1.00) 
 187 km 0.93 (0.83-1.03) 0.93 (0.83-1.03) p=0.1633 
Age (years)3 
     Age 49 1  1   
Age 59 1.56 (1.54-1.59) 1.36 (1.28-1.45)  
Age 69 2.89 (2.76-3.03) 1.95 (1.65-2.31)  
Age 79 6.11 (5.42-6.89) 2.73 (2.01-3.71) p=0.0001 
      
Comorbidity      
None  1  1   
Any 1.25 (1.06-1.48) 1.25 (1.06-1.48) P=0.009 
      
Summary stage4 
     Localised 1 
 
1 
  Regional 7.50 (4.09-13.74) 2.84 (1.79-4.49) 
Distant 18.56 (10.40-33.12) 4.09 (2.44-6.87) p<0.0001 
      
Histological type5 
     Serous 1  1   
Mucinous, endometriod and clear cell 1.54 (1.56-2.05) 0.20 (0.09-0.41) 
 Adenocarcinoma and other specified  2.65 (2.08-3.37) 0.64 (0.37-1.12) p<0.0001 
and unspecified histopathological types      
      
Method of diagnosis      
Cytology 1  1   
Clinical 1.59 (1.04-2.46) 1.59 (1.04-2.46)  
Histologically verified 0.57 (0.41-0.81) 0.57 (0.41-0.81) p<0.0001 
      
Type of treating hospital      
Public general  1  1   
Private general  0.67 (0.53-0.85) 0.67 (0.53-0.85)  
Public GOS  0.77 (0.64-0.95) 0.77 (0.64-0.95)  
Private GOS  0.57 (0.44-0.73) 0.57 (0.44-0.73) p<0.0001 
      
Surgery for ovarian cancer6 
     Limited, Biopsy only or no surgery 1 
 
1 
  Extensive surgery 0.47 (0.38-0.58) 0.72 (0.52-99) p<0.0001 
1Hazard Ratios (HR) and 95% Confidence Intervals (95%CI) 
2The p values for the time varying covariates reflect both nested main and time varying effects. Age at diagnosis, histology and 
surgery were time varying covariates. 
3 Effects of age are estimated at localised stage. 
4 Effects of stage are estimated at age 63 (the mean age). 
5Morphology codes were grouped empirically based on similar IARC groupings and similar survival curves. The full list of 
codes is provided in Appendix 1 
6 Appropriate surgery: ICD-10-AM Version 6 MBS-Extended procedure codes are provided in Appendix 1 
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Chapter 5 Table 3 Predictors of attending a public general hospital for treatment of ovarian cancer rather than a public 
or private GOS hospital or a private general hospital (n=3,411) 
Characteristics OR* (95%CI)* p value 
Patient    
Minimum distance to a public GOS hospital (Km) 
   0-4.9  1 
  5.0-8.9 3.96 (2.84-5.52) 
 9.0-26.9 3.40 (2.42-4.76) 
 27.0-187.1  8.30 (6.09-11.44) 
 187.5+  19.40 (13.92-27.04) p<0.0001 
    
Age at diagnosis 
   15-49 1 
  50-59 1.17 (0.85-1.60) 
 60-69 1.43 (1.04-1.95) 
 70-79 1.83 (1.34-2.50) 
 80+ 2.96 (2.11-4.15) p<0.0001 
    Comorbidity    
None 1   
Any 0.89 (0.73-1.10) p=0.5034 
    
Stage 
   Localised 1 
  Regional 1.01 (0.73-1.41) 
 Distant 1.22 (0.93-1.60) 
 Unknown 1.69 (1.18-2.43) p=0.0094 
    
Histology5    
Serous 1   
Mucinous, endometriod and clear cell 1.19 (0.92-1.55)  
Adenocarcinoma and other specified  2.26 (1.83-2.81) p<0.0001 
and unspecified histological types    
    
Year of diagnosis 
   2000-2004 1 
  2005-2008 1.41 (1.17-1.69) p=0.0002 
    
Time to treatment 1 
  At diagnosis plus or minus one month 0.52 (0.31-0.87) 
 Two to six month 1.06 (0.61-1.81)  
Seven months or greater 2.42 (1.82-3.22) 
 No procedure undertaken 4.77 (2.94-7.73) p<0.0001 
    
Financial status    
Public patient 1   
Private patient 0.16 (0.14-0.20) p<0.0001 
Odds Ratios (OR) and 95% Confidence Intervals (95%CI) 
5Morphology codes were grouped empirically based on similar IARC groupings and similar survival curves. The full list of 
codes is provided in Appendix 1 
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Chapter 5 Table 4 Predictors of having extensive surgery for ovarian cancer (N=3,259) 
Characteristics OR  95%CI  p value 
Minimum distance to a public GOS hospital (km)     
0-4.9  1 
  
5.0-8.9 1.12 (0.83-1.50) 
 
9.0-26.9 0.83 (0.62-1.11) 
 
27.0-187.1  1.30 (0.97-1.74) 
 
187.5+  0.81 (0.60-1.10) p=0.0010 
    
Age at diagnosis (years) 
   
15-49 1 
  
50-59 0.83 (0.60-1.14) 
 
60-69 0.54 (0.39-0.74) 
 
70-79 0.38 (0.28-0.52) 
 
80+ 0.21 (0.15-0.29) p<0.0001 
Comorbidity    
No 1   
Yes 0.93 (1.05-1.15) p= 0.5045 
    
Stage    
Localised 1 
  
Regional 0.62 (0.43-0.89) 
 
Distant 0.30 (0.22-0.41) 
 
Unknown 0.34 (0.22-0.51) p<0.0001 
    
Histological subtype5    
Serous 1   
Mucinous, endometriod and clear cell 0.91 (0.70-1.18)  
Adenocarcinoma and other specified 
and unspecified histological types 
 
0.31 (0.25-0.39) p<0.0001 
Period of diagnosis    
2000-2004    
2005-2008 1.26 1.05-1.52 p< 0.0169 
    
Method of diagnosis    
Cytology 1   
Clinical 2.88 (1.27-6.55)  
Histological 12.01 (5.89-24.50) p<0.0001 
    
Type of treating hospital    
Public general  1   
Private general 1.65 (1.25-2.17)  
Public GOS  2.37 (1.88-3.01)  
Private GOS 5.85 (4.21-8.12) p<0.0001 
    
Time from diagnosis to surgery (months)    
At diagnosis plus or minus one month 1   
Two-three months 0.40 (0.24-0.65)  
Four-six month 0.15 (0.09-0.27)  
Seven months or greater 0.29 (0.22-0.38) p<0.0001 
1Odds Ratios (OR) and 95% Confidence Intervals (95%CI) 
2 152 women had no procedure 
5Morphology codes were grouped empirically based on similar IARC groupings and similar survival curves. The full list of 
codes is provided in Appendix 1 
6 Appropriate surgery: ICD-10-AM Version 6 MBS-Extended procedure codes are provided in Appendix 1 
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5.9. Appendix 1 Online only text – methods 
5.9.1. Patient characteristics 
The following variables were obtained from cancer registry records: Age at diagnosis was 
treated as a continuous variable for the survival analysis and grouped into five categories for 
the logistic regression, 15-49 years, 50-59 years, 60-69 years, 70-79 years and 80 years and 
older. Country of birth, as notified to the cancer registry and supplemented where unknown 
with the information on the hospital admission data, was grouped into Australian born, born 
in an English speaking country and born in a non- English speaking country and unknown. 
Socioeconomic status was allocated in five categories using the Australian Bureau Statistics 
Index of Relative Socioeconomic Disadvantage (IRSD) based on the 2001 and 2006 Local 
Government Area Census Boundaries, depending on the appropriate diagnostic period. 1 
Smoking history, no recorded history, current or past smoker (any of ICD-10 codes Z86.43, 
Z72.0, Z71.6, F17 in any record). Comorbidities were conditions counted using the Charlson 
index 2 and classified as no comorbidity or any comorbidity because of the small number of 
comorbid conditions. Secondary cancer, most often a code reflecting the stage of the ovarian 
cancer was excluded from the comorbid conditions. : Place of residence at diagnosis was, 
classified as metropolitan, outer metropolitan and rural based on groupings of Local Health 
Districts (2010 boundaries). Order of ovarian cancer was based on whether the ovarian 
cancer was the women’s first cancer or second of subsequent cancer. 
5.9.2. Cancer characteristics 
Histological type of cancer, was summarised using the International Classification of 
Disease of Oncology (ICD-O) version 3 morphology codes3 which were grouped based on 
Cancer Incidence in Five Continents Vol IX4. Histological subtypes were further combined 
into three groups on the basis of similarity of survival as determined in a previous 
publication(5): Serous (84413, 84603-84633, 90143); mucinous, endometriod and clear cell 
carcinoma; (mucinous carcinoma (84703-84903, 90153), endometriod carcinoma (83803-
83833, 85603, 85703), clear cell (83103-83133, 91103) and adenocarcinoma and other 
specified and unspecified histopathological types (adenocarcinoma (81403-81473, 81703-
81903, 82113-82313, 82603, 83843, 84403, 85763), other specified types (80413, 80503, 
80703, 80713, 81203, 82003, 82403, 82463, 83203), unspecified types (80103-80223, 
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80003-80053)). Summary stage (extent of disease) at diagnosis was classified as localised, 
regional, distant or unknown. 6 
5.9.3. Treatment characteristics 
Year of diagnosis was grouped into time periods 2000-2004 and 2005-2008; Method of 
diagnosis whether a woman’s ovarian cancer was diagnosed clinically, cytologically or 
histologically verified as determined by the NSW Central Cancer Registry; Surgery 
undergone for the management of ovarian cancer (see below); Time from diagnosis to 
surgery to which the patient’s management was classified (see below) and A payment status 
of private or a public patient at the treatment admission for a procedure was also included. 
5.9.4. Surgery undergone for the management of ovarian cancer 
The surgical categories were obtained by examining all procedures coded in a separation (up to 50 
allowed), for all public and private inpatient hospitalisations in the linked dataset. Extensive 
surgery: ICD-10-AM Version 6 MBS-Extended procedure codes: one of the following codes 
(35653-03, 35717-04, 35667-00, 35664-00, 35713-11, 35670-00, 35713-07, 35653-02, 
35638-11, 35661-00, 35638-12, 35653-01, 35717-01, 35638-02, 35753-01, 35713-06, 
35753-00, 35638-03, 35653-00, 35717-05, 35638-01, 35673-01, 35638-06, 35638-13, 
35673-00, 35756-02) alone or in conjunction with Staging (30094-06, 35713-14, 35723-01, 
96189-00, 35723-00, 35637-10, 35551-01, 35723-02) or Debulking (35720-00, 30566-00, 
30392-00, 35658-00, 90450-00, 90450-01, 90450-02).Limited surgery or no surgery one of 
the following codes: ICD-10-AM Version 6 MBS-Extended procedure codes (30094-06, 
35713-14, 35723-01, 96189-00, 35723-00, 35637-10, 35551-01, 35723-02, 35720-00, 
30566-00, 30392-00, 35658-00, 90450-00, 90450-01, 90450-02, 30075-37) or no ovarian 
cancer procedure code. 7Chemotherapy and radiotherapy are not reliably recorded in 
separation records and so were not considered for the analysis. 
5.9.5. Time from diagnosis to surgery 
The NSW Central Cancer Registry determined date of diagnosis using International 
Association of Cancer Registries (IACR) rules. In NSW, cancer is a notifiable disease under 
the NSW Public Health Act. Notifications are received from pathology laboratories, 
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hospitals’ outpatient cancer clinics and radiation therapy centres. Coding staff review all 
notifications and the diagnosis date recorded is the date the specimen was taken if there is 
histological or cytological confirmation. In the absence of histological verification then the 
hospital of first admission is given as the date of diagnosis. When a woman is diagnosed at 
death through an autopsy or postmortem, the date of diagnosis is reported as the date of 
death. There were only 42 patients that met this criteria and we excluded them from the 
survival analysis. There were 152 women with a hospital admission but no procedure or 
procedure date for who time from diagnosis to surgery could be calculated. 
5.9.6. Quality of the NSW Central Cancer Registry data and the admitted patient 
data collection 
When compared with other cancer registries internationally, the NSW Central Cancer 
Registry has higher than average histological verification proportions; lower than average 
death certificate only registration percentages and good mortality incidence ratios, that is 1-
ratio compares well to survival figures. 8Hospital data in NSW is subject to data quality 
checking when it is submitted to the Ministry of Health and when it is reported nationally to 
the Department of Health and Ageing. Procedures and diagnoses are incorporated in patient 
administration systems within hospitals to ensure consistent coding and are reviewed 
regularly by the National Centre for Classification in Health.7 
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Chapter 5 Appendix 1 Table 1 Patient, cancer and treatment characteristics and deaths within 8 years of diagnosis in 
3,411 women diagnosed with ovarian cancer in NSW 2000 to 2008 
Characteristics 
Number of women % Number of deaths % 
 3,411 100 1,652 100 
Patient      
     
Minimum distance to a public specialist hospital (Km) 
    0-4.9  740 21.7 344 20.8 
5.0-8.9 672 19.7 333 20.2 
9.0-26.9 657 19.3 295 17.9 
27.0-187.1  711 20.8 348 21.1 
187.5+  631 18.5 332 20.1 
     Age 
    15-49 561 16.4 155 9.4 
50-59 745 21.8 280 16.9 
60-69 742 21.8 337 20.4 
70-79 795 23.3 473 28.6 
80+ 568 16.7 407 24.6 
     
Place of birth 
    Australia  2,221 65.1 1,125 68.1 
English speaking countries 212 6.2 115 7.0 
Non English speaking countries 891 26.1 401 24.3 
Unknown  87 2.6 11 0.7 
     
Socioeconomic status   
  Lowest  488 14.3 272 16.5 
Second lowest  502 14.7 274 16.6 
Middle  748 21.9 357 21.6 
Second highest  748 21.9 339 20.5 
Highest  925 27.1 410 24.8 
     
Smoking history1 
    Non smoker 2,301 67.5 1,163 70.4 
Current smoker 550 16.1 266 16.1 
Previous smoker 297 8.7 116 7.0 
Unknown 263 7.7 107 6.5 
     
Comorbidity (Charlson index) 
    None  2,547 74.7 1,168 70.7 
Any  864 25.3 484 29.3 
     
Region of residence at diagnosis  
    Metropolitan 1,481 43.4 697 42.2 
Outer metropolitan 844 24.7 412 24.9 
Rural 1,086 31.8 543 32.9 
     
Order of ovarian cancer 
    First case of cancer 3,224 94.5 1,589 96.2 
Second or subsequent case 187 5.5 63 3.8 
     
Cancer      
     
Summary stage at diagnosis 
    Localised 643 18.9 80 4.8 
Regional 528 15.5 211 12.8 
Distant 1,898 55.7 1,199 72.6 
Unknown 342 10.0 162 9.8 
     
Histological type2     
Serous 1591 46.6 761 46.1 
Mucinous, endometriod and clear cell 755 22.1 183 11.1 
Adenocarcinoma, specified and carcinoma NOS 1065 31.2 708 42.9 
and unspecified histopathological types     
     
Treatment      
     
Period of diagnosis 
    2000-2004 1,422 41.7 903 54.7 
2005-2008 1,989 58.3 749 45.3 
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Method of diagnosis 
    Clinical only 277 8.1 183 11.1 
Cytology  168 4.9 129 7.8 
Histologically verified 2966 86.9 1,340 81.2 
     
Surgery for ovarian cancer4 
    Limited, biopsy only or no surgery 1,312 38.5 902 54.6
Extensive surgery 2,099 61.5 750 45.4 
     
Time from diagnosis to treatment 
    Plus or minus one month  2,708 79.4 1,154 69.9
Two to six months 190 5.6 129 7.8 
Seven months or greater 361 10.6 248 15.0 
No procedure date 152 4.5 121 7.3 
     
Type of hospital attended 
    Public general  1,075 31.5 635 38.4
Private general  484 14.2 243 14.7 
Public GOC 1,273 37.3 568 34.4 
Private GOC  579 17.0 206 12.5 
     
Payment status     
Public financial status 1,787 52.4 924 55.9 
Private financial status 1,624 47.6 728 44.1 
1Smoking codes (Z86.43, Z72.0, Z71.6,F17) 
5Morphology codes were grouped empirically based on similar IARC groupings and similar survival curves. The full list of 
codes is provided in Appendix 1 
6 Extensive surgery: ICD-10-AM Version 6 MBS-Extended procedure codes are provided in Appendix 1 methods 
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5.9.7. Determining model fit 
To determine model fit we plotted the unadjusted Kaplan Meier survival curves and the adjusted 
survival curves predicted from our model. With the exception time to surgery, which was removed 
from the model because of poor fit, we found very little difference between the survival curves within 
each of the covariates indicating good model fit. 
Chapter 5 Appendix 1 Figure 1 Comparison of Kaplan Meier unadjusted curves with the adjusted survival curves 
predicted using the proportional odds model in stpm2 undertaken to assess model fit 
 
 
The following variables included a time dependent variable – age at diagnosis, major surgery and histological subtype. Age was 
modelled as a continuous variable with a cubic polynomial shape; in addition, there was an interaction between age and stage. 
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6.1. Abstract 
Background: Access to specialist services may influence the stage at which cancer is 
diagnosed and whether or not the cancer is ever adequately staged. We investigated whether 
increasing distance to the nearest accessible specialist hospital (NASH) is associated with a 
higher likelihood of advanced or unknown stage cancer at diagnosis in Australian non-small 
cell lung cancer (NSCLC) patients. Methods: We analysed linked cancer registry and 
hospital records for 11,147 NSCLC patients diagnosed between 2000 and 2008 admitted to 
hospital within 12 months of diagnosis. Distances from patients’ homes to the NASH were 
measured in kilometres using geographical coordinates. Multinomial logistic regression 
analysis examined relationships of distance from the NASH, type of hospital of treatment 
(specialist or general) and other characteristics of NSCLC patients with advanced and 
unknown cancer stage. Results: Odds of advanced stage NSCLC was significantly higher in 
people who lived 100+ km from the NASH, OR 1.29 (95%CI 1.15-1.45), than in those living 
0-39 km from it. Furthermore, odds of unknown stage NSCLC was significantly higher in 
people who lived 40-99km OR 1.29 (1.07-1.55) and those who lived 100 km+ OR 1.58 
(1.27-1.84) from the NASH. The likelihood of both advanced and unknown stage NSCLC 
was significantly higher in patients treated in general hospitals than in specialist hospitals. 
Furthermore, in patients treated in specialist hospitals the odds of unknown stage was 
significantly lower OR 0.63 (95%CI 0.47–0.85). Whereas, patients treated in general 
hospitals had double the likelihood of unknown stage OR 2.13 (1.78-2.54) when they lived 
more than 100km+ from the NASH. These associations were independent of key 
confounding variables, including age, sex, comorbidity and histopathological subtype. 
Conclusions: People living remotely from accessible specialist services may be at greater 
risk of being diagnosed with advanced NSCLC. A higher prevalence of unknown NSCLC 
stage in patients who lived more than 40 km from the NASH and those attending general 
hospitals suggests they are inadequately investigated this limiting their treatment options. 
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6.2. Introduction 
Determining cancer stage at diagnosis is important in ensuring that patients are given stage 
appropriate care 1. Most lung cancer patients present with late stage disease 2; and the 
proportion of patients for whom stage is unknown, at least to cancer registries, tends to be 
higher for lung cancer than for many other common cancers 3, 4. 
UK studies have shown that the greater the distance non-small-cell lung cancer (NSCLC) 
patients lived from a cancer centre the more likely they were to have disseminated disease at 
diagnosis 5-7 and to have no histological verification of their cancer or to be first diagnosed at 
death or autopsy 8. The likelihood of histological verification also diminished with increasing 
deprivation.9, 10 
However, not all relevant studies show a relationship between advanced lung cancer and distance 
to treatment. A number of United States registry based studies found that the odds of presenting 
with advanced stage lung cancer were higher in urban areas and very remote areas, but lower in 
suburbs and outer metropolitan areas 11, 12.These differences in stage at diagnosis appeared to be 
due to higher proportions of young patients and black patients in urban locations. Advanced stage 
lung cancers were found to be more common in younger patients. After adjusting for age and 
ethnicity, patients living outside of cities were less likely to present at an advanced stage. The 
urban-rural differences were accentuated after adjusting for socioeconomic status and access to 
primary care, suggesting that unmeasured factors like awareness of symptoms or diagnostic 
differences were responsible11. 
We know of only one study that has examined the likelihood of unstaged lung cancer with access 
to care. Patients were more likely to be unstaged if they were older, poorer, black, had “other 
histological types of cancer” and resided in rural areas with fewer physicians.13 
We investigated whether increasing distance to a specialist centre was associated with 
advanced or unknown stage at diagnosis. This study considers factors antecedent to and 
plausibly associated with actual stage at diagnosis and subsequent factors that are likely to be 
associated with accuracy and completeness of stage determination and its reporting to the 
Central Cancer Registry (CCR). 
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6.3. Methods 
We included patients registered by the New South Wales (NSW) CCR as diagnosed with 
NSCLC; ICD-O topography codes C33-C34 excluding morphology codes for lung small cell 
cancer, M80413-M80453, M82463) between 2000 and 2008. CCR records for these patients 
were linked to matching records in the NSW Admitted Patient Data Collection. This 
collection records diagnosis and surgical treatment for all separations from NSW public and 
private hospitals. The combined automated and manual record linkage process had an 
estimated false positive rate of 0.4 per cent.14 
6.3.1. Stage 
CCR coders record stage at diagnosis on the basis mainly of hospital notifications (which 
report degree of spread at diagnosis coded as 1, localised to tissue of origin, 2, regional 
spread to adjacent organs and/or regional lymph nodes, 3 distant metastases or 4 – 
unknown). Hospital notifications supplemented by pathology reports (which are obligatorily 
provided), outpatient cancer centres notifications of patients treated with chemotherapy or 
radiotherapy and doctors’ responses to CCR queries. Studies have shown that the “degree of 
spread” categories used provide broadly similar information to other methods of staging.4, 15, 
16 
6.3.2. Distance 
Distance to the NASH (“nearest accessible specialist hospital”, a public hospital with a 
thoracic surgical service) was obtained for each patient by calculating the distance in 
kilometres from the patient’s geocoded address to the geocoded address of the NASH using 
the “Great Circle Distance Calculator”17. This measure of distance is similar to other 
measures of distance over Earth’s surface 18; and UK studies using travel time and straight-
line distance 19 have found them to be highly correlated (R=0.856).We considered distance to 
the NASH to be a measure of access to best care because it encompasses both distance to and 
affordability of specialist care; all Australians are entitled to treatment free-of-charge in 
public hospitals 20. Distance to a patient’s actual hospital of treatment may be a biased 
measure of access because more mobile patients may be referred to hospitals at longer 
distances; in addition it can only apply to those who received treatment. 21 
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Patients were grouped into three categories of distance: 0–39 km, 40–99 km and ≥100 km. 
We plotted the frequency distribution of patients by distance from the NASH in five 
kilometre groupings and found that the progressively diminishing proportion of patients 
plateaued at 40 kilometres and remained constant thereafter. One hundred or more 
kilometres was selected as the lower bound of the most distant category because patients 
living this distance from required care can obtain financial support for travel and 
accommodation through the Isolated Patient Travel Accommodation and Assistance Scheme 
(IPTAAS) 22. 
Patients’ area of residence was also classified broadly as metropolitan, outer metropolitan 
and rural based on the 2010 boundaries of NSW Local Health Districts. 
6.3.3. Hospitals 
Eleven public thoracic surgery hospitals were identified using Canrefer, a web directory of 
public and private cancer services 23; all were in Sydney, the State capital, except for one in 
Newcastle, the State’s second largest city. We classified hospitals in which patients were 
treated as specialist hospitals (public teaching hospitals or private hospitals with a thoracic 
surgical service) or general hospitals (public or private hospitals without such a service). 
Because there was an obvious correlation between distance as defined above and the type of 
hospital in which a patient was actually treated, we created a six-category variable from 
hospital type (specialist and general) and distance from the NASH (0–39 km, 40–99 km, 
≥100 km) for use when both variables were included in models. 
6.3.4. Patient characteristics 
The following patient characteristics were obtained from cancer registry records: sex, age at 
diagnosis (grouped into four categories, 15-59 years, 60-69 years, 70-79 years and 80 years 
and older); country of birth (grouped as Australian born, born in an English speaking 
country, born in a non-English speaking country and unknown); socioeconomic status 
(allocated in five categories using the Australian Bureau Statistics’ Index of Relative 
Socioeconomic Disadvantage 24 from the 2001 or 2006 Census depending on the period of 
diagnosis); and year of diagnosis (grouped as 2000–2004 and 2005–2008). 
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Additional patient characteristics obtained from Admitted Patients Data Collection records 
were: smoking status (non-smoker, past smoker, current smoker based on ICD-10 codes 
Z86.43, Z72.0, Z71.6, F17 in any separation record); any or no comorbidity (any or no 
condition in the Charlson index 25, except secondary cancer, coded as a primary or other 
diagnosis in any record); and any or no history of chronic obstructive pulmonary disease 
(based on relevant four-digit ICD-10 codes in the range J41.0-J44.9 in any separation 
record). 
6.3.5. Tumour characteristics 
In addition to stage at diagnosis (see above) classified by extent of disease as localised, 
regional, distant or unknown, histological subtype of cancer, was coded by the CCR from 
pathology reports using ICD-O version 3 morphology codes 26. NSCLC subtypes were 
combined into four categories, squamous cell carcinoma, adenocarcinoma, large cell, and 
other and unspecified cancers and carcinomas, in accordance with Cancer Incidence in Five 
Continents Vol IX. 27 
6.3.6. Treatment characteristics 
Treatment characteristics were categorised as period of diagnosis (grouped as 2000-2004 and 
2005-2008) andmethod of diagnosis (clinical, cytology or histopathology), which is recorded 
by the CCR because a number of studies have reported it to be a reliable indicator of lack of 
investigation.8 Type of hospital admission (admitted via the emergency department, planned 
admission or other usually outpatients). Time from diagnosis to surgery or admission to 
hospital in the absence of surgery in months was used to subset cases treated within 12 
months of diagnosis. 
6.3.7. Statistical analyses 
Stata 12.1 was used for the statistical analysis. Multinomial logistic regression was 
conducted with stage as the outcome variable in three categories: localised (as the reference 
category), advanced (regional and distant spread) and unknown. Potential predictor variables 
considered for inclusion in multivariate models fell into two groups depending on their 
temporal relationship 28 to stage at diagnosis: (1) variables that were antecedent to and 
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plausibly associated with actual stage at diagnosis (patient and tumour characteristics, 
distance from the NASH); and (2) variables subsequent (not antecedent) to actual stage but 
likely to be associated with accuracy and completeness of determination of stage and its 
reporting to the CCR (type of hospital admission, type of hospital of treatment and time from 
diagnosis to admission). 
Sex, age, comorbidity and history of chronic obstructive pulmonary (all antecedent 
variables) were retained in the final model regardless of their statistical significance because 
of their clinical importance. All other univariable predictors were included in a backward 
elimination model if they had p value of less than 0.2 and retained in the final model if, as a 
result of nested likelihood ratio tests, they had a p value of less than 0.05. 29 Area Health 
Service of Residence had a variance inflation factor of more than three with distance from 
the NASH and was excluded from the model. 
To examine the sensitivity of associations of advanced stage with distance and hospital type 
to presence of unknown stage cancers, we undertook logistic regression analyses with 
unknown stage replaced by stage imputed using multiple imputation methods 30. Multiple 
imputation with chained equations was used because it has been found to be effective in a 
registry setting. 31 
6.4. Results 
There were 23,871 people with NSCLC, of whom 11,147 were included in this analysis. 
These patients were admitted to hospital at or within 12 months after their date of diagnosis 
(Table 1). Patients were excluded from the analysis if they were registered only from death 
certificates (737), or not hospitalised at any time (874), or any time after their diagnosis of 
lung cancer (10,684), or not until 12 months or more after diagnosis (429). We excluded 
these patients because we required contemporary variables from Admitted Patients Data 
Collection records for measurement of key antecedent variables (Chronic Obstructive 
Pulmonary Disease (COPD) and other comorbidity) and all subsequent variables, 
importantly type of hospital of admission. 
 176 
 
People who lived ≥100 km from the NASH were less likely than people who lived 0–39 km 
from the NASH to have localised stage (25.8% vs. 30.5%) and more likely to have unknown 
stage cancer (21.1% vs. 15.5%). After adjustment for other variables antecedent to stage at 
diagnosis, odds of advanced stage and, more strongly, unknown stage cancer increased with 
increasing distance from the NASH (p<0.0001 in each case; Chapter 6 Table 2b). 
Considering other antecedent variables, advanced stage cancer was also more likely in 
males, younger people, people of higher socioeconomic status, people diagnosed in 2000-04 
(rather than in 2005-2008), people without COPD, people with cancers other than squamous 
cell cancers and cancers not verified histopathologically (Chapter 6 Model 1, Table 2b). The 
pattern of associations with unknown stage cancer was similar except that it was not 
significantly associated with sex, age, or socioeconomic status. 
Addition of variables subsequent to stage at diagnosis but possibly associated with clinical 
determination of stage and its reporting to the CCR (Chapter 6 Table 2b Model 2) had little 
impact on the associations of antecedent variables with advanced and unknown stage. 
Considering the main effects of the subsequent variables, patients treated in general hospitals 
had consistently higher odds of advanced stage and, particularly, unknown stage cancer than 
people treated in specialist hospitals (Chapter 6 Table 2b Model 2). For patients who lived 
100km+ from the NASH, the odds of unknown stage was significantly lower in patients 
treated in a specialist hospitals OR 0.63 (95%CI 0.47–0.85) and significantly higher in 
patients treated in general hospitals OR 2.13 (1.78-2.54) than for patients who lived 0-39km 
from the NASH. There was little evidence of a similar pattern for advanced stage cancer. 
Odds of both advanced and unknown stage were highest in patients admitted as emergencies 
and lowest for those with planned admissions. The odds of unknown stage was particularly 
high for patients admitted to hospital more than 6 months after diagnosis compared to those 
admitted within a month of diagnosis ( Chapter 6 Table 2b, Model 2). This pattern was not 
evident in patients with advanced stage. The ORs for advanced stage changed little from 
those shown in Chapter 6 Table 2b Model 2 on repeating the analysis using imputed stage in 
place of unknown stage. Country of birth and smoking status were not significantly 
associated with advanced or unknown stage cancer in the fully adjusted model.  
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Chapter 6 Table 1 Personal, cancer and treatment characteristics of NSW NSCLC patients diagnosed between 2000-
2008 (n=11,147) hospitalised within 12 months 
Characteristics  Total Localised 
 
Advanced Unknown  
  3,240  5,975  1,932   
Distance from the NASH 
 
n % n % n %  
Specialist hospital 0-39.9 5,282 1,757 54.2 2,783 46.6 742 38.4  
Specialist hospital 40-99.9 611 263 8.1 293 4.9 55 2.8  
Specialist hospital 100 plus 858 371 11.5 424 7.1 63 3.3  
General hospital 0-39.9 1,482 306 9.4 868 14.5 308 15.9  
General hospital 40-99.9 828 153 4.7 468 7.8 207 10.7  
General hospital 100 plus 2,086 390 12.0 1,139 19.1 557 28.8 p<0.0001 
        
 
LHD of residence 
       
 
Urban 4,297 1,365 42.1 2,337 39.1 595 30.8  
Outer metropolitan 3,162 904 27.9 1,731 29.0 527 27.3  
Rural 3,688 971 30.0 1,907 31.9 810 41.9 p<0.0001 
        
 
Sex 
       
 
Males 6,983 2,005 61.9 3,748 62.7 1,230 63.7  
Females 4,164 1,235 38.1 2,227 37.3 702 36.3 p<0.0001 
        
 
Age at diagnosis 
       
 
0-59  2,662 662 20.4 1,659 27.8 341 17.7  
60-69  3,414 970 29.9 1,948 32.6 496 25.7  
70-79  3,653 1,176 36.3 1,782 29.8 695 36.0  
80+  1,418 432 13.3 586 9.8 400 20.7 p<0.0001 
        
 
Socioeconomic status 
       
 
Lowest SES' 2,376 670 20.7 1,262 21.1 444 23.0  
Second lowest SES' 2,114 623 19.2 1,071 17.9 420 21.7  
Middle SES' 2,357 694 21.4 1,223 20.5 440 22.8  
Second highest SES' 2,314 672 20.7 1,289 21.6 353 18.3  
Highest SES' 1,986 581 17.9 1,130 18.9 275 14.2 p<0.0001 
        
 
Period of diagnosis 
       
 
2000-2004 5,824 1,588 49.0 3,058 51.2 1,178 61.0  
2005-2008 5,323 1,652 51.0 2,917 48.8 754 39.0 p<0.0001 
        
 
Chronic obstructive pulmonary disease 
      
 
No COPD 8,167 2,147 66.3 4,665 78.1 1,355 70.1  
COPD 2,980 1,093 33.7 1,310 21.9 577 29.9 p<0.0001 
        
 
Comorbidity 
       
 
No comorbidity 7,381 2,035 62.8 4,131 69.1 1,215 62.9  
Comorbidity 3,766 1,205 37.2 1,844 30.9 717 37.1 p<0.0001 
        
 
Histology 
       
 
Squamous  2,478 962 29.7 1,104 18.5 412 21.3  
Adenocarcinoma  4,120 1,214 37.5 2,444 40.9 462 23.9  
Large cell  3,204 692 21.4 1,810 30.3 702 36.3  
Other  1,345 372 11.5 617 10.3 356 18.4 p<0.0001 
        
 
Method of diagnosis         
Cytology 1,204 164 5.1 648 10.8 392 20.3  
Clinical 1,082 144 4.4 490 8.2 448 23.2  
Histologically verified 8,861 2,932 90.5 4,837 81.0 1,092 56.5 p<0.0001 
         
Emergency status 
       
 
Emergency  4,510 730 22.5 2,781 46.5 999 51.7  
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Planned  6,247 2,440 75.3 2,961 49.6 846 43.8  
Other 390 70 2.2 233 3.9 87 4.5 p<0.0001 
Time from diagnosis  
       
 
At diagnosis 8,554 2,600 80.2 4,730 79.2 1,224 63.4  
2-3 months 1,286 409 12.6 717 12.0 160 8.3  
3-6 months 782 154 4.8 347 5.8 281 14.5  
7-12 months 525 77 2.4 181 3.0 267 13.8 p<0.0001 
1Smoking codes: ICD10-AM codes Z86.43, Z72.0, Z71.6, F17. 
2Chronic obstructive pulmonary disease codes: ICD10-AM codes J41.0, J41.1, J41.8, J42.0, 
J42, J43, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.8, J44.9 
3Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, 
Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 Other 80003-80053, 88003, 88013, 88023, 
88053, 88103, 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-
91333, 95403-95813, 88303, 91503. 
 
Chapter 6 Table 2a Stage at diagnosis by distance from the closest public specialist hospital for NSCLC patients 
admitted to hospital within 12 months of diagnosis NSW, 2000 to 2008  
 
 
 
 
 
 
 
 
 
Stage Number 
 0-39 
 
40-99 100+ 
Localised 3,240  30.5 28.9 25.8 
Regional 3,540  32.3 30.3 31.3 
Distant 2,435  21.7 22.6 21.8 
Unknown  1,932  15.5 18.2 21.1 
Total  11,147  6,764 1,439 2,944 
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Chapter 6 Table 2b Odds ratios and 95% confidence limits for advanced and unknown stage (referent to localised stage) in NSCLC patients diagnosed in NSW between 2000-2008) – Patients 
admitted to hospital within 12 months of diagnosis 
 Model I Antecedent variables  Model 2 Antecedent and subsequent stage at diagnosis 
 Advanced stage Unknown stage Advanced stage Unknown stage 
 OR 95% CI pvalue OR 95% CI pvalue OR 95% CI pvalue OR 95% CI pvalue 
             
Distance from the NASH (km)             
             
0-39 km 1   1         
40-99 km 1.10 (0.96-1.27) 
 
1.29 (1.07-1.55) 
 
      
100+km 1.29 (1.15-1.45) p<0.000
1 
1.58 (1.37-1.84) p<0.0001       
             
Distance from the NASH             
and hospital of treatment             
             
Specialist hospital 0-39.9       1   1   
Specialist hospital 40-99.9       0.96 (0.80-1.16)  0.77 (0.56-1.06)  
Specialist hospital 100 plus       1.08 (0.92-1.28)  0.63 (0.47-0.85)  
General hospital 0-39.9       1.33 (1.14-1.55)  1.26 (1.03-1.54)  
General hospital 40-99.9       1.48 (1.21-1.82)  1.97 (1.53-2.52)  
General hospital 100 plus       1.49 (1.29-1.73) p<0.0001 2.13 (1.78-2.54) p<0.0001 
             
             
Sex 
      
      
Males 1 
  
1 
  
1   1   
Females 0.86 (0.78-0.94) p=0.01 0.93 (0.82-1.05) p=0.23 0.88 (0.80-0.96) p=0.01 0.94 (0.82-1.07) p=0.34 
       
      
Age at diagnosis 
      
      
15-60 1 
  
1 
  
1   1   
60-69 0.85 (0.75-0.96) 
 
0.93 (0.78-1.11) 
 
0.87 (0.76-0.98)  0.99 (0.83-1.19)  
70 -79 0.64 (0.57-0.72) 
 
0.96 (0.81-1.15) 
 
0.64 (0.56-0.72)  1.02 (0.86-1.22)  
80+ 0.49 (0.42-0.58) p<0.000
 
1.08 (0.88-1.33) p= 46 0.43 (0.36-0.51) p<0.0001 1.06 (0.86-1.32) p=0.92 
       
      
Socioeconomic status 
      
      
Low SES 1 
  
1 
  
1   1   
Second lowest SES 0.93 (0.81-1.07) 
 
1.12 (0.93-1.34) 
 
0.94 (0.82-1.09)  1.12 (0.93-1.36)  
Middle SES 0.98 (0.85-1.12) 
 
1.07 (0.89-1.28) 
 
1.02 (0.88-1.17)  1.10 (1.00-1.33)  
Second highest SES 1.13 (0.98-1.30) 
 
0.99 (0.82-1.20) 
 
1.23 (1.07-1.43)  1.04 (0.85-1.26)  
Highest SES 1.17 (1.01-1.37) p=0.01 0.99 (0.80-1.23) p=0.650 1.29 (1.10-1.50) p<0.0001 1.07 (0.86-1.33) p=0.77 
       
      
Chronic obstructive pulmonary 
       
      
No 1 
  
1 
  
1   1   
Yes 0.61 (0.55-0.68) 
p<0.000
1 0.83 (0.72-0.95) 
p=0.0082 0.64 (0.57-0.71) p<0.0001 0.90 (0.78-1.04) p=0.17 
       
      
       
      
Comorbidity       
None 1 
  
1 
  
1   1   
Any 0.96 (0.87-1.06) p=0.45 0.93 (0.81-1.06) p=0.26 0.89 (0.80-0.99) p=0.02 0.88 (0.77-1.02) p=0.09 
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Period of diagnosis 
      
      
2000-2004 1 
  
1 
  
1   1   
2005-2008 0.91 (0.83-1.00) p<0.004 0.68 (0.60-0.77) p<0.0001 0.96 (0.88-1.06) p=0.43 0.80 (0.71-0.91) p<0.0007 
       
      
Histology 
      
      
Squamous 1 
  
1 
  
1   1   
Adenocarcinoma 1.57 (1.40-1.76) 
 
0.86 (0.73-1.01) 
 
1.61 (1.43-1.81)  0.88 (0.74-1.05)  
Large cell 1.95 (1.71-2.22) 
 
1.56 (1.32-1.85) 
 
1.66 (1.46-1.90)  1.39 (1.17-1.66)  
Other 1.15 (0.97-1.35) p<0.000
 
1.41 (1.15-1.74) p<0.0001 1.07 (0.90-1.26) p<0.0001 1.34 (1.08-1.66) p<0.0001 
             
Method of diagnosis             
Cytology 1      
1   1   
Clinical 0.94 (0.72-1.22)  0.97 (0.74-1.28)  0.84 (0.65-1.10)  0.97 (0.73-1.28)  
Histologically verified 0.42 (0.35-0.50) p<0.000
 
0.16 (0.13-0.20) p<0.0001 0.59 (0.49-0.72) p<0.0001 0.22 (0.18-0.28) p<0.0001 
             
Type of hospital admission             
Emergency       1   1   
Planned       0.36 (0.32-0.40)  0.57 (0.50-0.66)  
Other       0.82 (0.62-1.10) p<0.0001 0.75 (0.53-1.08) p<0.0001 
             
Time from diagnosis              
to surgery or admission             
At diagnosis       1   1   
2-3 months       1.11 (0.96-1.27)  0.98 (0.80-1.21)  
3-6 months       1.08 (0.88-1.32)  3.70 (2.96-4.62)  
7-12 months       0.91 (0.69-1.20) p=0.39 5.49 (4.16-7.24) p<0.0001 
             
1ORs are relative to specialist hospital 0-39.9 km 
Smoking codes: ICD10-AM codes Z86.43, Z72.0, Z71.6, F17. 
2Chronic obstructive pulmonary disease codes: ICD10-AM codes J41.0, J41.1, J41.8, J42.0, 
J42, J43, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.8, J44.9 
3Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 
Other 80003-80053, 88003, 88013, 88023, 88053, 88103, 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-91333, 95403-95813, 88303, 91503 
88103, 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-91333, 95403-95813, 88303, 91503 
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6.5. Discussion 
Odds of advanced stage and unknown stage NSCLC at diagnosis were higher for people who 
lived 100km or more from the NASH. Odds of advanced stage and of unknown stage cancer 
were also higher in people who attended general hospitals than people who attended 
specialist hospitals for their care; and odds of attending a general hospital increased with 
distance from the NASH. Somewhat paradoxically, perhaps, odds of unknown stage cancer 
in people admitted to specialist hospitals were less the further they lived from the NASH. 
These associations were independent of key confounding variables, including age, sex, 
comorbidity and histopathological subtype. 
Our finding that distance from the NASH influenced stage at diagnosis, is consistent with the 
small number of population based studies that have examined the effect of distance to 
specialist care. Early Scottish registry based studies reported that patients with lung cancer 
were diagnosed with more advanced disease or had higher death rates or poorer survival with 
increasing distance to a cancer centre. 5, 7, 32 Two US registry based studies13, 33 have 
considered straight-line distance and the likelihood of advanced stage lung cancer with 
mixed results. Consistent with our findings, Silverstein et al (Silverstein et al, 2002) reported 
that distance from hospital and the histological subtype of a person’s lung cancer most 
explained the likelihood of advanced stage at diagnosis after adjusting for age, sex, marital 
status, education and place of residence. 13 Scoggins et al measured distance to primary care 
rather than distance to hospital and found no association of it with advanced stage. 33 
A few studies have investigated why people who live remotely are more likely to have 
cancer of unknown stage. Older age 13 3, rural residence and fewer primary care physicians 13 
and lack of investigation 10 appear to be the most common answers. Linkage studies in 
Western Australia have shown that rural lung cancer patients take longer to consult their GPs 
34 and to present with more symptoms, which were associated with later diagnosis and fewer 
treatment options. 34 
Considering factors associated with the accuracy and recording of stage, type of 
presentation, hospital of treatment and time to treatment are most likely associated with later 
or unknown stage at diagnosis. To be diagnosed, people with symptoms of NSCLC must 
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attend their GP or a hospital emergency department. In Australia, GPs are not subject to 
direct government control and can locate surgeries wherever they please 35. People who live 
remotely in NSW have reduced access to primary care due to lower GP ratios per head of 
population than in urban areas 36. Furthermore the GP to population ratios in rural areas are 
declining over time 37. These barriers to primary care probably increase the likelihood that 
people will first present to the emergency department at their local general hospital. We 
found as have others that people eventually diagnosed with NSCLC who attended non-
specialist hospitals were more likely to be emergency admissions than planned admissions 38 
39 40 without a diagnosis or without a chest x-ray or histological confirmation 10 and were less 
likely than other patients to receive specialist care (62% vs 94%)41. 
Advanced stage patients may be admitted to general hospitals because they are unlikely to 
benefit from surgery. However, unknown stage patients will have limited options for 
investigation when referred to general hospitals. Lung cancer patients treated in regional 
public hospitals in the Australian State of Queensland were less likely to have had their 
cancer histologically or cytologically confirmed (7%) than patients treated in specialist 
hospitals (27%). This difference remained after adjusting for age, sex, and comorbidities. 42 
Similarly, UK patients were less likely to be histologically verified when they lived further 
from the closest hospital or thoracic unit; and patients in the most deprived areas the least 
likely to have histological verification of their cancer. 10 8 
Other barriers identified in NSW that may have contributed to a lack of staging at an 
emergency department include the limited availability of radiology and pathology services, 
the reliance on the private sector, the lack of ultrasound services and interventional 
radiologists and the lack of access to cytology and frozen sections, which are all necessary to 
diagnose lung cancer.43 
Patients referred to specialist hospitals were less likely to have unknown stage cancer when 
they lived 100+ km from the NASH. This finding suggests that patients living in remote 
areas who are admitted to a specialist hospital are more highly selected for referral than 
patients who live closer to the NASH. It would also possible that some level of investigation 
has been done prior to referral, perhaps on advice from a consultant at the specialist hospital. 
Stabilising symptoms, encouraging smoking cessation and evaluating functional status are 
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suggested for NSCLC patients prior to their surgery. These factors may assume even more 
significance when travel is required to access staging and surgery.44 Studies of patients who 
attend specialist centres for their treatment show that they are more likely to be appropriately 
staged by a thoracic surgeon and have surgery,45, be reviewed by a multidisciplinary team 40, 
have better survival because of the higher surgical volumes even for patients who were older 
and had comorbidities 46. For people where surgical treatment is not an option, a greater 
likelihood of clinical trial participation occurs when they attend a specialist hospital. 47 
Other factors examined and found to be independently associated with advanced stage 
NSCLC patients were consistent with the existing literature. Males had higher odds of 
advanced stage compared to females, and higher odds with younger age at diagnosis 48, 49 50 
Older patients have been found to have their cancer detected earlier and incidentally as part 
of other investigations 13. The lower likelihood of advanced stage with a diagnosis of COPD 
is consistent with increased monitoring. Patients with COPD are counselled to stop smoking 
and have their lung function monitored. 51Not expected, and contrary to most UK studies 48 13 
that have used deprivation as their measure of socioeconomic status, were the increased odds 
of advanced stage in people of higher socioeconomic status. A plausible explanation for this 
finding is that patients of higher SES were more likely to be investigated and staged, 
although there was not a compensating reduction in odds of unknown stage cancer. The 
reduced odds of unknown stage cancer in patients diagnosed between 2005 to 2008 
compared to the earlier period corresponds to the period after the introduction of the 
Australian National Health and Medical Research Council’s clinical practice guidelines for 
lung cancer, 52 which are likely to have increased the proportion of patients adequately 
staged. 
There was a strong association of unknown stage with increasing delay in hospitalisation. 
Delays in the diagnosis of lung cancer have occurred because of failure to recognise 
abnormal images or complete diagnostic procedures in a timely manner 53 or because of the 
limited access to radiology and pathology diagnostic services as previously discussed. 43 
Unstaged patients may also have been hospitalised at a terminal stage of their disease. 
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6.5.1. Limitations and strengths 
This analysis was limited to linked cancer registry and hospital data. Therefore, we had no 
information on presenting symptoms, whether patients had multidisciplinary team review or 
why they were treated in a general rather than a specialist hospital with increasing distance to 
the NASH. NSW and Victorian lung cancer patterns of care studies have reported high 
proportions of lung cancer patients see at least one specialist 54-57 40 indicating that most 
patients should have had some opportunity to have their cancer staged. Review by a 
multidisciplinary team (MDT) has also been found to be an independent predictor of 
survival.40 Furthermore, seeing three or more specialists have been associated with the 
receipt of guideline based care58. 
While TNM staging was preferred, it was not available. However, there may be an even 
greater difference in the proportion of advanced stage with increasing distance from 
NASH because patients seen at  general hospitals would probably have not had a PET 
scan to stage their disease compared to those treated at specialist hospitals who do. 
Therefore a significant proportion of apparent "localised disease" is upstaged on PET 
scans to "advanced disease." However, a major strength of this study is that unknown stage 
was included in our analysis. The majority of registry based studies exclude unknown stage 
because they assume missing stage is due to poor follow up practices within a registry. 
However, in Australian registries, notifications are from multiple sources legislated by the 
Public Health Act. In addition, registries contact doctors to obtain missing or discrepant 
information as part of the cancer registration process. Therefore, unknown stage in this study 
is most likely due to a lack of investigation or minimal investigation of the patient. A further 
strength of this study is that it is population based with good linkage to all public and private 
hospitalisations.  
6.5.2. Conclusion 
People living remotely from accessible specialist services have an increased risk of being 
diagnosed with advanced and particularly unknown stage NSCLC and are more likely to be 
treated in general hospitals than in specialist hospitals. People who attended general hospitals 
when they live 100km from specialist care had double the likelihood of unknown stage, 
suggesting they are inadequately investigated  thus limiting their treatment options . 
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Furthermore, NSCLC who attended a specialist hospital when they lived 100km or more 
from one had less advanced or unknown stage cancer at diagnosis suggesting selective 
referral of patients may have been occurring because of the requirement to travel. All 
patients require proper staging in order to determine appropriate treatment, regardless of 
distance to specialist care. 
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7.1. Abstract 
Aim: To determine whether increasing distance to the nearest accessible specialist hospital 
(NASH) a public hospital with a thoracic surgical service) increases a patient’s likelihood of 
missing out on curative surgery for localised non small cell lung cancer “(NSCLC)”. 
Method: Population-based study of cancer registry records for 27,033 people with lung 
cancer diagnosed in New South Wales, Australia, between 2000 and 2008 linked to hospital 
admission records. This analysis includes 3,240 patients with localised (NSCLC) admitted to 
hospital within 12 months of diagnosis. Results: Patients who lived 100+km from the NASH 
were more likely to have no surgery (50.6%) than those living 0-39 km away (37.6%) and 
more likely to attend general hospitals for their care (52.2% at 100+km, 14.8% at 0-39 km). 
Relative to patients living 0-39 km from the NASH and attending a specialist hospital for 
their care, the odds ratio of not having surgery was high if patients attended a general 
hospital (adjusted OR 5.99, 95%CI 3.87-9.26, for those 0-39 km distant) and even higher as 
distance from the NASH increased (24.68, 95%CI 12.37-49.13 for 40-49 km and 30.10, 
95%CI 18.2-49.40, for 100+km). For patients treated in specialist hospitals (public or 
private), the trend with distance was opposite: relative to 0-39 km, the OR was 0.29 (95%CI 
0.15-0.50) at 40-99 km and 0.14 (95%CI 0.08-0.26) at 100+km. Conclusions Patients with 
localised NSCLC are most likely to have no potentially curative surgery if they live distant 
from a specialist hospital and attend a general hospital for their care. 
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7.2. Introduction 
In 2008, lung cancer was the fourth most common cancer and the most common cancer 
causing death in Australia.1 Although, patients with small cell lung cancer or distant 
metastases have a poor prognosis,2, 3 those presenting with localised non small cell lung 
cancer (NSCLC) are potentially curable if treated surgically.4 NHMRC guidelines 
recommend surgical resection for patients with early stage NSCLC, with lobectomy the 
preferred procedure.4 Potentially curative surgery has been found to be one of the best 
determinants of cancer survival with a recent UK lung cancer audit of 34,513 NSCLC 
patients reporting a HR of 0.41 (95%CI 0.39-0.44) in patients who underwent surgery 
relative to those who did not after adjusting for age, sex, performance status, stage and 
Charlson index of comorbidity.5 NSCLC patients have better survival if they are treated in 
high volume surgical centres, even if they are older, of low socioeconomic status, or have 
comorbidities.6 In addition, those treated by thoracic surgeons have lower post-operative 
mortality and morbidity and better adherence to established practice standards than patients 
treated by general surgeons.7, 8 
Most studies of the effects of distance to specialist care on treatment of NSCLC have been 
done in the UK. The majority of them have shown that patients’ access to surgical treatment 
is influenced by distance, clinician specialty and hospital of treatment. 5, 9-11 Most studies 
could not take account of effects of lung cancer stage on their conclusions. NSW Cancer 
Registry based studies have shown that the probability of no surgical treatment varies by 
patients’ Local Health District of residence and is higher for patients living in outer 
metropolitan areas.12-14 In this study, we investigate whether increasing distance to the 
nearest accessible specialist hospital (NASH) a public hospital with a thoracic surgical 
service is associated with failure to receive surgical treatment for localised primary lung 
cancer after adjusting for potentially confounding variables. 
7.3. Methods 
The NSW CCR was the primary data source. 15 We included in this analysis all NSW 
patients with NSCLC (ICD topography codes C33-C34 excluding morphology codes 
M80413-M80453, M82463) diagnosed between 2000 and 2008 whose CCR record linked to 
one or more records in the NSW APDC, which details diagnosis and surgical treatment for 
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all separations from NSW public and private hospitals.16 17 The combined automated and 
manual record linkage process had an estimated false positive rate of 0.4 per cent.18 
Summary stage at diagnosis was classified as localised, regional, distant or unknown, based 
on the extent of disease notified to, or determined by, the CCR 19. We included only patients 
with localised stage at diagnosis who were admitted to hospital at or up to 12 months after 
diagnosis. We applied this restriction so the admission records would provide contemporary 
information on chronic obstructive pulmonary disease, smoking, other comorbidities, type of 
hospital and other treatment related variables. 
7.3.1. Distance 
Distance to the NASH was obtained for each patient by calculating the distance in kilometres 
from the patient’s geocoded address to the closest public hospital with a specialist 
cardiothoracic or thoracic surgical service using the “Great Circle Distance Calculator”.20 
We considered this to be a measure of access to best care because it encompasses both 
distance and affordable care; all Australians are entitled to treatment free-of-charge in public 
hospitals. Distance to a patient’s actual hospital of treatment as an alternative measure of 
accessibility may be biased because more mobile patients may be referred to more distant 
hospitals; also, it can only apply to those who received treatment.11 UK studies using travel 
time and straight-line distances 21have found them to be highly correlated (R=0.856). 
Patients were grouped into three categories of distance: 0-39 km, 40-99 km and 100+km. We 
plotted the frequency distribution of distance from the NASH in five kilometre groupings 
and found that it reached a plateau at 40 kilometres. We selected 100 km as the lower bound 
of the most distant category because patients living this distance or further from required 
care can obtain financial support through the Isolated Patient Travel, Accommodation and 
Assistance Scheme (IPTAAS).22 Patients’ place of residence was also classified broadly as 
metropolitan, outer metropolitan and rural based on the 2010 boundaries of NSW Local 
Health Districts. 
7.3.2. Hospitals 
Eleven public specialist hospitals (public hospitals with a cardiothoracic or thoracic surgical 
service) were identified in Canrefer, 23 a Cancer Institute NSW web directory of cancer 
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services. We classified other hospitals as private specialist (private hospitals with a 
cardiothoracic or thoracic surgical service, also identified in Canrefer) or general hospitals 
(public or private hospitals without such a service). 
The “patients’ financial status at admission” was also included in the analysis, because of its 
relevance to which hospitals a person might have access to. The APDC variable was grouped 
into three categories (public financial status treated in a public hospital, private financial 
status treated in a private hospital and private financial status treated in a public hospital). 
Our outcome of interest was whether patients had potentially curative surgery or not within 
12 months of diagnosis. Whether or not patients had their primary cancer treated surgically 
by lobectomy, segmental resection or pneumonectomy (any major surgery) or not (no 
surgery) was determined from procedure codes in APDC records covering the period from a 
month before diagnosis to 12 months after diagnosis. Other characteristics of patients, cancer 
and treatment are available in Appendix 1. 
7.3.3. Statistical analysis 
Stata 12.1 was used for the statistical analysis. Logistic regression analysis was conducted 
with surgery (no or any) as the dependent variable. Univariable predictor variables were 
considered for inclusion in a full multivariable model if, on their own, they were 
significantly associated with no surgery (p<0.2) (Appendix 1 Table 2).They included 
distance to the NASH and hospital type, the primary variable of interest in the analysis, 
which we modelled as a six category composite variable because of a strong statistical 
interaction between distance and hospital type in determining absence of major surgery (p 
for interaction p<0.0001). The six categories were all combinations of hospital type in two 
categories (specialist and general) and distance in three categories (0-39km, 40-99km, 
100+km). 
Sex, age, comorbidity and history of chronic obstructive pulmonary were retained in the final 
model, regardless of their statistical significance, because of their clinical importance. For all 
remaining variables, we conducted a series of nested maximum likelihood ratio tests with a p 
value for retention in the model of less than 0.05. 24 We checked by adding back previously 
discarded variables in the backward elimination model to determine if they improved model 
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fit. We used the Fitstat procedure and compared the AIC and the pseudo R square for each of 
the nested models. 
7.4. Results 
There were 5,456 patients with localised NSCLC diagnosed in 2001 to 2008. From these, we 
excluded 119 with no hospital admission, those whose only linking admissions occurred two 
or more months before (2,013) or more than 12 months after (84) their diagnosis. This left 
3,240 patients who were eligible for these analyses. 
Of the 3,240 patients with localised NSCLC, 40.8% (1,320) did not have major surgery. A 
greater proportion of patients who lived 100km or more from the NASH did not have 
surgery (50.6%) than patients living 0-39km (37.6%) away. This disparity was more 
pronounced for lobectomy than it was for segmental resection or pneumonectomy (data 
available on request). 
The adjusted odds ratio (OR) for not having surgery in patients admitted to a general hospital 
(relative to a value of 1 in patients admitted to a thoracic surgery hospital and living 0-39km 
from the NASH) increased with increasing distance from the NASH: OR 5.99 (95%CI 3.87-
9.26) for those 0-39 km distant, 24.68 (95%CI 12.37-49.13) for 40-49km and 30.01 (95%CI 
18.2-49.40) for 100+km (Figure 1 and Table 1). These ORs were adjusted for all other 
variables independently associated with no surgical treatment in the final model (Table 1). In 
contrast, for patients treated in specialist hospitals the adjusted ORs fell with increasing 
distance from the NASH: relative to the OR of 1 for patients 0-39km distant, the ORs were 
0.29 (95%CI 0.16-0.50) at 40-99 km and 0.14 (95%CI 0.08-0.25) at 100+km (Figure 1 and 
Table 1). 
Other variables in the final model significantly associated with a higher odds of not having 
surgery (Table 1) were, absence of any recorded comorbidity, being a non smoker, if the 
lung cancer was the first cancer diagnosed in the person having a squamous or large cell 
cancer, diagnosis in the years 2000 to 2004 (the earlier half of the period studied), having 
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cancer that was not verified histopathologically, having an emergency presentation to 
hospital, and being a private financial status patient treated in a public hospital. Sex, age, and 
COPD although included in the final model, were not significantly associated with lack of 
surgery. Local Health District was excluded from the final model because it was highly 
correlated with distance from a specialist centre (variance inflation factor of 3). Remoteness 
(p=0.29) was not included in the backward elimination model and socioeconomic status 
(p=0.51) and country of birth (p=0.35) were not retained. Overall, the model had a pseudo R 
square of 81.9. 25 
Distance of residence from the NASH and hospital of treatment made the largest 
contribution to model fit with a pseudo R square of 47.0, followed by emergency 
presentation that increased the pseudo R square to 67.1; effects of other variables explained 
the difference of 14.9 between this value and the overall pseudo R square. 
Given the large number of patients (2,013) who were excluded from the analysis because 
they did not have a hospital admission after diagnosis, we did a supplementary logistic 
regression analysis in which these patients were compared, with respect to as many variables 
as possible included in the model in Table 1with patients who had a hospital admission at or 
up to 12 months after diagnosis but no surgery. The excluded patients were older and more 
likely to be smokers and to have COPD. They are also more likely to live 100+km from the 
NASH (OR 1.26, 95%CI 1.06-1.50) (Appendix 1 Table 3). 
7.5. Discussion 
Our results show that patients with localised NSCLC who attend general hospitals for care 
are much more likely not to have surgery for their cancer than those who attend a specialist 
hospital. In patients who attended a general hospital, the likelihood of not having major 
surgery increased with their distance from the NASH. Somewhat unexpectedly, the opposite 
was true for patients who attended a thoracic surgery hospital; that is, patients living 100+km 
from the NASH had the lowest risk of not having major surgery (i.e. were most likely to 
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have surgery). The type of hospital of treatment and whether the admission was an 
emergency presentation were the strongest predictors of risk of not having major surgery. 
Most studies addressing distance to surgical treatment in patients diagnosed with lung cancer 
were undertaken in the UK or US and did not taken account of stage at diagnosis. UK lung 
cancer patients were less likely to have surgery when they lived further from a specialist 
hospital or cancer centre than when they lived closer to one, after adjusting for age, sex, 
selected tumour pathology characteristics and socioeconomic deprivation. 11 9 However, a 
US study that used a similar measure of distance to ours did not find distance to specialist 
care to be associated with the likelihood of patients having lung cancer surgery after 
adjusting for age, sex, race, stage, and year of diagnosis. 26 This study, was limited to 
patients with Medicaid insurance, and did not take account of type of hospital of treatment, 
which we found to be highly correlated with distance, or other factors potentially important 
factors, like comorbidity. A UK study, which adjusted for stage at diagnosis but did not 
measure distance, found, as we did, that NSCLC patients who were referred to non specialist 
hospitals were less likely to have surgery than those referred to specialist hospitals, after 
adjusting for age, sex, performance status, comorbidity and stage.5 
UK27 and some Australian registry based studies12-14 but not all28 have also shown that 
surgery rates vary by health regions. A UK registry based study showed that lung cancer 
surgery rates varied widely among 26 health authorities.29 Australian lung cancer patterns of 
care studies have shown mixed results for geographical variation in surgery rates. In NSW, 13 
the proportion of patients having surgery varied between 17% and 26% when three area 
health services were compared. In Victoria, there was no significant difference between 
urban residents and rural and regional residents in the proportion having surgery.28 A NSW 
registry based study of NSCLC patients, which reported on surgery by physician provided 
TNM stage, found that patients who lived in outer metropolitan health service areas were 
51% more likely get no treatment than patients who lived in urban area health services.14 
Our observed fall in risk of not having surgery with increasing distance from the NASH in 
patients who attended a specialist hospital was somewhat unexpected. While we know of no 
directly relevant evidence, we believe the most plausible explanation is that more remote 
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patients referred to specialist hospitals are likely to have had a thorough assessment of their 
suitability for surgery including PET before admission to hospital than patients referred over 
shorter distances Whereas patients seen in general hospitals particularly with greater 
distance from NASH are unlikely to have a PET scan to stage their disease, indeed some 
"localised disease" may have been based on chest xray only leading to under  
s taging.  This difference in type of staging (upstaging for patients in specialist hospitals 
and downstaging for patients in general hospitals) will artificially increase the staging 
disparity between hospitals with increasing  distance to the NASH.  
We found a number of factors other than hospital attended and distance that were 
independently associated with not having major surgery. Patients were more likely to have 
no major surgery before 2004 than after it; this difference is probably explained by the 
release in 2004 of the Australian NHMRC guidelines for the treatment and management of 
lung cancer, 4 that recommend surgery for localised lung cancer. Our patients were also less 
likely to have major surgery if their first admission for lung cancer was an emergency. 
Emergency admissions appear to put patients on a suboptimal care pathway; others have 
reported that lung cancer patients who attended emergency departments without a diagnosis 
or without a chest x-ray were less likely than other patients to receive specialist care (62% vs 
94%),30 or to have their lung cancer confirmed pathologically.31 Patients with large cell 
carcinomas were also less likely to have surgery than patients with other types of non small 
cell cancer, perhaps because care decisions are influenced by the often higher grade and 
known poorer prognosis of these cancers.32, 33 Private financial status patients admitted to 
public hospitals were less likely to have major surgery than public patients in public 
hospitals and private patients in private hospitals. Speculatively, this observation may reflect 
a preference for thoracic surgeons to receive sicker patients at public hospitals where, with 
the exception of smaller rural hospitals, medical staff are on-call and on-site 24 hours a day. 
A reduced odds of no surgery for lung cancer patients treated in private hospitals has also 
been found in a WA linkage study.34 
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Unlike previous studies on distance, 10, 11, 34 –the likelihood of no surgery in our study did not 
vary  with age or by socioeconomic status after adjustment for other covariates. The effect of 
socioeconomic status in our study disappeared when type of admission was included in the 
model (730 or 23% of patients had emergency admissions) because most patients having 
emergency admissions did not have surgery. We also found that patients whose NSCLC was 
a second cancer as opposed to their first cancer were less likely to have no surgery, probably 
because of their existing links with expert care. Surprisingly, we found that patients with 
comorbidity were less likely to have no surgery, which is not consistent with other studies.35 
While we have no certain explanation for this finding; it is plausible that patients being 
prepared for surgery have their comorbidities recorded more fully because of their 
preoperative assessment. Unexplained confounding might also have produced it. 
7.5.1. Limitations and strengths 
This study was limited to surgical treatment. We had no information on whether patients 
received chemotherapy or radiotherapy as these are provided in outpatient cancer care 
centres. However, other studies have shown that, like surgery, there is lower use of 
radiotherapy,11 27, 36 chemotherapy9 27 and combined treatment27 with increasing distance to 
specialist treatment and that their use varies depending on the specialty of the hospital9 11 or 
whether a centre with radiotherapy was the first attended.27, 36 We also used a cancer registry 
based definition of localised stage (localised to the tissue or organ of origin); TNM 
definitions32 would have been preferable but were not available. 
The major strengths of our study are its coverage of a whole population; our ability to link 
cancer registry and hospital separation records both public and private; a routinely recorded 
measure of cancer stage, albeit imperfect; use of geocoded data to provide more precise 
measures of distance between patients’ residences and treating hospital; and use of a distance 
measure that related to directly to patients’ access to care at the time referral decisions were 
being made. 
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7.5.2. Conclusions 
The likelihood that patients with localised NSCLC would be treated in a general hospital for 
their cancer increased with distance from the NASH. Patients treated in general hospitals 
were much less likely to have potentially curative surgery for their cancer than those treated 
in specialist hospitals because they were not offered, or they declined, referral to expert care. 
It is urgent that we understand the reasons these patients are not referred and take steps to 
address them. 
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Chapter 7 Table 1 localised non small cell lung cancer patients and the odds of no major surgery in patients admitted to 
hospital within 12 months of diagnosis 
 
  
 
 
 
 
Major 
surgery 
 
No 
surgery 
    
 Characteristics N % N % OR (95% CI) p value 
Total  1,918  100 1,322 100    
Distance of residence from the NASH         
and type of hospital where treated 
 
       
0-39.9km, thoracic surgery hospital 1,225 63.9 532 40.2 1   
40-99.9km, thoracic surgery hospital 241 12.6 22 1.7 0.29 (0.16-0.50)  
100 plus km, thoracic surgery hospital 351 18.3 20 1.5 0.14 (0.08-0.25)  
0-39.9km, general hospital 63 3.3 243 18.4 5.99 (3.87-9.26)  
40-99.9km, general hospital 13 0.7 140 10.6 24.65 (12.37-49.13)  
100 plus km, general hospital 25 1.3 365 27.6 30.01 (18.22-49.40) p<0.0001 
        
Sex        
Males 1,144 61.9 861 65.1 1   
Females 774 38.1 461 34.9 0.87 (0.67-1.13) p=0.2905 
        
Age at diagnosis        
15-59 years 422 20.4 240 18.2 1   
60-69 years 633 29.9 337 25.5 1.07 (0.76-1.52)  
70 -79 years 697 36.3 479 36.2 1.05 (0.75-1.48)  
80 plus years  166 13.3 266 20.1 1.34 (0.85-2.12) p=0.6484 
        
Comorbidity        
No comorbidity 1,184 61.7 851 64.4 1 
  
Comorbidity 734 38.3 471 35.6 0.38 (0.29-0.50) p<0.0001 
        
Chronic obstructive pulmonary disease‡        
no COPD 1,184 62.8 851 64.4 1   
COPD 734 37.2 471 35.6 0.84 (0.63-1.13) p=0.2483 
        
Smoking status†     
   
Non smoker 316 16.5 404 30.6 1   
Previous smoker 888 46.3 483 36.5 0.41 (0.28-59)  
Current smoker  714 37.2 435 32.9 0.39 (0.27-0.56) p<0.0001 
        
Period of diagnosis 
       
2000-2004 733 38.2 855 64.7 1 
  
2005-2008 1,185 61.8 467 35.3 0.39 (0.31-0.51) p<0.0001 
        
Method of diagnosis     
   Cytology 17 0.9 147 11.1  1   
Clinical 7 0.4 137 10.4 0.86 (0.24-3.12) 
 Histologically verified 1,894 98.7 1,038 78.5 0.07 (0.03-0.14) p<0.0001 
        
Cancer         
        
Order of lung cancer        
First cancer 1,771 94.8 1,301 98.4 1   
Second or subsequent cancer 147 5.2 21 1.6 0.39 (0.20-0.78) P=0.0079 
        
Histology§ 
       
Squamous 553 28.8 409 30.9 1 
  
Adenocarcinoma 909 47.4 305 23.1 0.44 (0.32-0.60) 
 
Large Cell 219 11.4 473 35.8 2.29 (1.64-3.21) 
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Other 237 12.4 135 10.2 0.35 (0.22-0.56) p<0.0001 
        
Type of admission        
Emergency 45 44 685 51.8 1 
  
Planned admission 1,857 52.9 583 44.1 0.04 (0.02-0.06) 
 
Referred from outpatients  16 1.6 54 4.1 0.26 (0.11-0.66) p<0.0001 
        
Financial status        
Public financial status treated in public hospitals 971 50.6 950 71.9 1 
  
Private financial status treated in public hospitals 132 6.9 258 19.5 2.48 (1.74-3.52) 
 
Private financial status treated in private hospitals 815 42.5 114 8.6 0.21 (0.15-0.29) p<0.0001 
Odds Ratios (OR) and 95% Confidence Intervals (95% CI) 
†Smoking codes: ICD10-AM codes Z86.43, Z72.0, Z71.6, F17. 
‡Chronic obstructive pulmonary disease codes: ICD10-AM codes J41.0, J41.1, J41.8, J42.0, 
J42, J43, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.8, J44.9 
§Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, 
Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 Other 80003-80053, 88003, 88013, 88023, 
88053, 88103, 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-
91333, 95403-95813, 88303, 91503. 
 
Chapter 7 Figure 1 Odds ratios for having no major surgery for primary non small cell cancer by distance from a public 
thoracic surgery hospital and type of hospital where treated 
 
Adjusted for age, sex, chronic obstructive pulmonary disease and whether a person’s lung cancer was their first or second 
cancer and each other variable in Chapter 7 Table 1 
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7.6. Appendix 1 
7.6.1. Patient characteristics 
The following variables were obtained from CCR records: Sex, age at diagnosis (grouped 
into four categories, 15-59, 60-69, 70-79 and 80 years and older); country of birth (grouped 
as Australian born, born in an English speaking country, born in a non English speaking 
country and unknown); socioeconomic status (allocated in five categories using the 
Australian Bureau Statistics’ Index of Relative Socioeconomic Disadvantage based on the 
2001 and 2006 Census, depending on the period of diagnosis37). 
Additional variables obtained from APDC records were: smoking status (non smoker, past 
smoker, current smoker based on ICD-10 codes Z86.43, Z72.0, Z71.6, F17 in any separation 
record); any comorbidity (any condition, except secondary cancer, in the Charlson index38 
and coded as a primary or other diagnosis in any record); and any or no history of chronic 
obstructive pulmonary disease (based on relevant four-digit ICD-10 codes in the range J41.0-
J44.9 in any separation record). 
7.6.2. Cancer characteristics - histological subtype 
Histological subtype of cancer was coded by the CCR from pathology reports using the ICD-
O version 3 morphology codes, 16 which were grouped in accord with Cancer Incidence in 
Five Continents Vol IX.39Order of lung cancer –whether the lung cancer was the first or 
subsequent cancer diagnosed. 
7.6.3. Treatment 
Period of diagnosis (grouped as 2000-2004 and 2005-2008). Method of diagnosis (clinical, 
cytology or histopathology), which is recorded by the CCR, was also included because a 
number of studies have reported it to be a reliable indicator of lack of investigation.40 Type 
of hospital admission admitted via the emergency department, planned admission or other 
(usually outpatients). Time from diagnosis to surgery or admission to hospital in the absence 
of surgery in months was used to subset cases treated within 12 months of diagnosis. 
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Chapter 7 Appendix 1 Table 1 Characteristics of patients with localised non small cell lung cancer diagnosed between 
2000 and 2008 in NSW and admitted to hospital within the first 12 months after diagnosis 
      
Total 3,240 100 
Patient 
     
Distance from the NASH and hospital of 
treatment 
  Specialist hospital 0-39.9 1,757 54.2 
Specialist hospital 40-99.9 263 8.1 
Specialist hospital 100 plus 371 11.5 
General hospital 0-39.9 306 9.4 
General hospital 40-99.9 153 4.7 
General hospital 100 plus 390 12.0 
Index of remoteness 
  Accessible 3,156 97.4 
Not accessible 84 2.6 
LHD of residence 
  Urban 1,365 42.1 
Outer metropolitan 904 27.9 
Rural 971 30.0 
Sex 
  Males 2,005 61.9 
Females 1,235 38.1 
Age at diagnosis 
  15-59 years 662 20.4 
60-69 years 970 29.9 
70 -79 years 1,176 36.3 
80 plus years  432 13.3 
Country of birth 
  Australian born 2,094 64.6 
Born in an English Speaking country 232 7.2 
Born in a Non English speaking country 772 23.8 
Unknown country of birth 142 4.4 
Socioeconomic status 
  Lowest SES' 670 20.7 
Second lowest SES' 623 19.2 
Middle SES' 694 21.4 
Second highest SES' 672 20.7 
Highest SES' 581 17.9 
Comorbidity 
  No comorbidity 2,035 62.8 
Comorbidity 1,205 37.2 
**Smoking status 
  Non smoker 720 22.2 
Previous smoker 1,371 42.3 
Current smoker  1,149 35.5 
***Chronic obstructive pulmonary disease 
 no COPD 2,035 62.8 
COPD 1,205 37.2 
Cancer 
  Histology 
  Squamous 962 29.7 
Adenocarcinoma 1,214 37.5 
Large cell 692 21.4 
Other 372 11.5 
Order of lung cancer 
  First cancer 3,072 94.8 
Second or subsequent cancer 168 5.2 
Treatment 
  Period of diagnosis 
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2000-2004 1,588 49.0 
2005-2008 1,652 51.0 
Method of diagnosis 
  Cytology 164 5.1 
Clinical 144 4.4 
Histology hospital 770 23.8 
Histology by cancer registry staff  2,162 66.7 
Type of admission 
  Emergency 730 22.5 
Planned admission 2,440 75.3 
Other 70 2.2 
Time from diagnosis to treatment 
  At diagnosis 2,600 80.2 
2-3 months 409 12.6 
3-6 months 154 4.8 
7 to 12 months 77 2.4 
Financial status 
  Public financial status treated in public hospitals 1,921 59.3 
Private financial status treated in public hospitals 390 12.0 
Private financial status treated in private hospitals 929 28.7 
†Smoking codes: ICD10-AM codes Z86.43, Z72.0, Z71.6, F17. 
‡Chronic obstructive pulmonary disease codes: ICD10-AM codes J41.0, J41.1, J41.8, J42.0, 
J42, J43, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.8, J44.9 
§Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, 
Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 Other 80003-80053, 88003, 88013, 88023, 
88053, 88103, 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-
91333, 95403-95813, 88303, 91503. 
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Chapter 7 Appendix 1 Table 2 Patient, cancer and treatment characteristics, chi squared p values and univariable odds 
ratios and 95%Confidence intervals for no surgery in non small cell lung cancer patients diagnosed between 2000 and 
2008 in NSW and admitted to hospital within the first 12 months after diagnosis 
Characteristics 
Any 
Surgery 
n % 
No 
Surgery 
n % p value 
 
Univariable 
 OR and 95% 
confidence 
Intervals 
 
 
 
 
p value 
Total 1,918 100 1,32
 
100.
  
OR 95% CI  
Patient 
     
   
Distance from the NASH and 
   
     
   
0-39.9km, specialist hospital 1,225 63.9 532 40.2 1   
40-99.9km, specialist hospital 241 12.6 22 1.7  0.21 (0.13-0.33)  
100 plus km, specialist hospital 351 18.3 20 1.5  0.13 (0.08-0.21)  
0-39.9km, general hospital 63 3.3 243 18.4  8.88 (6.61-
 
 
40-99.9km, general hospital 13 0.7 140 10.6  24.80 (13.92-
 
 
100 plus km, general hospital 25 1.3 365 27.6 p<0.0001 33.62 (22.14-
 
p<0.0001 
Index of remoteness 
     
   
Accessible 1,873 97.7 1,28
 
97.0 
 
1   
Not accessible 45 2.3 39 3.0 p=0.288 1.27 (0.82-1.95) p=0.288 
LHD of residence 
     
   
Urban 857 44.7 508 38.4 
 
1   
Outer metropolitan 577 30.1 327 24.7 
 
0.96 (0.80-1.14)  
Rural 484 25.2 487 36.8 p<0.0001 1.70 (1.44-2.01) p<0.0001 
Sex 
     
   
Males 1,144 59.6 861 65.1 
 
1   
Females 774 40.4 461 34.9 p=0.002 0.79 (0.68-0.92) p=0.0016 
Age at diagnosis 
     
   
15-59 years 422 22.0 240 18.2 
 
1   
60-69 years 633 33.0 337 25.5 
 
0.94 (0.76-1.15)  
70 -79 years 697 36.3 479 36.2 
 
1.21 (0.99-1.47)  
80 plus years  166 8.7 266 20.1 p<0.0001 2.82 (2.19-3.62) p<0.0001 
Country of birth 
     
   
Australian born 1,215 63.3 879 66.5 
 
1   
Born in an English Speaking country 122 6.4 110 8.3 
 
1.25 (0.95-1.64)  
Born in a Non English speaking country 474 24.7 298 22.5 
 
0.87 (0.73-1.03)  
Unknown country of birth 107 5.6 35 2.6 p<0.0001 0.45 (0.31-0.67) p<0.0001 
Socioeconomic status 
     
   
Lowest SES' 359 18.7 311 23.5 
 
1   
Second lowest SES' 333 17.4 290 21.9 
 
1.01 (0.81-1.25)  
Middle SES' 383 20.0 311 23.5 
 
0.94 (0.76-1.16)  
Second highest SES' 450 23.5 222 16.8 
 
0.57 (0.46-0.71)  
Highest SES' 393 20.5 188 14.2 p<0.0001 0.55 (0.44-0.70) p<0.0001 
Comorbidity 
     
   
No comorbidity 1,184 61.7 851 64.4 
 
1   
Comorbidity 734 38.3 471 35.6 p=0.126 0.89 (0.77-1.03) p=0.126 
Smoking status† 
     
   
Non smoker 316 16.5 404 30.6 
 
1   
Previous smoker 888 45.3 483 36.5 
 
0.43 (0.35-0.51)  
Current smoker  714 37.2 435 32.9 p<0.0001 0.48 (0.39-0.58) p<0.0001 
Chronic obstructive pulmonary 
      
   
no COPD 1,184 61.7 851 64.4 
 
1   
COPD 734 38.3 471 35.6 p=0.882 0.99 (0.85-1.15) p=0.882 
Cancer 
     
   
Histological subtype§ 
     
   
Squamous 553 28.8 409 30.9 
 
1   
Adenocarcinoma 909 47.4 305 23.1 
 
0.45 (0.38-0.54)  
Large Cell 219 11.4 473 35.8 
 
2.92 (2.38-3.58)  
Other 237 12.4 135 10.2 p<0.0001 0.77 (0.60-0.99) p<0.0001 
Order of lung cancer 
     
   
First cancer 1,771 92.3 1,30
 
98.4 
 
1   
Second or subsequent cancer 147 7.7 21 1.6 p<0.0001 0.19 (0.12-0.31) p<0.0001 
Treatment 
     
   
Period of diagnosis 
     
   
2000-2004 733 48.2 855 64.7 
 
1   
2005-2008 1,185 61.8 467 35.3 p<0.0001 0.34 (0.29-0.39) p<0.0001 
Method of diagnosis 
     
   
Cytology 17 0.0 147 11.1 
 
1   
Clinical 7 0.4 137 10.4 
 
2.26 (0.91-5.63)  
Histologically verified 1,894 98.7 1,03
 
78.5 p<0.0001 0.06 (0.03-0.10) p<0.0001 
Type of admission 
     
   
Emergency 45 2.3 685 51.8 
 
1   
Planned admission 1,857 96.8 583 44.1 
 
0.02 (0.02-0.03)  
Other 16 0.8 54 4.1 p<0.0001 0.22 (0.12-0.42) p<0.0001 
Financial status 
     
   
Public financial status treated in public 
 
971 50.6 950 71.9 
 
1   
Private financial status treated in public 
 
132 6.9 258 19.5 
 
2.00 (1.59-2.51)  
Private financial status treated in private 
h i l  
815 42.5 114 8.6 p<0.0001 0.14 (0.12-0.18) p<0.0001 
†Smoking codes: ICD10-AM codes Z86.43, Z72.0, Z71.6, F17. 
  207  
‡Chronic obstructive pulmonary disease codes: ICD10-AM codes J41.0, J41.1, J41.8, J42.0, 
J42, J43, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.8, J44.9 
§Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, 
Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 Other 80003-80053, 88003, 88013, 88023, 
88053, 88103, 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-
91333, 95403-95813, 88303, 91503. 
 
Chapter 7 Appendix 1 Table 3 Multivariable logistic regression model of NSW localised non small cell lung cancer 
patients who did not undergo surgery and were not admitted to hospital after diagnosis relative to those who were 
admitted within 12 months of their diagnosis. 
 
 
Did not have 
 
 
Admitted 
   
Not admitted 
  
 
   
Characteristics   N % N % % % OR (95%CI) P value 
Patient 3,335 1.0 1,322 100.0 2,013 1.0 
   Distance from the NASH 
  
  
     0-39.9km  1,862 55.8 755 57.1 1,087 54.0 1 
  40-99.9km  416 12.5 162 12.3 254 12.6 1.09 (0.85-1.38) 
 100 plus km  1,057 31.7 385 29.1 672 33.4 1.26 (1.06-1.50) p=0.0318 
Sex 
  
  
     Males 2,166 64.9 861 65.1 1305 64.8 1 
  Females 1,169 35.1 461 34.9 708 35.2 1.13 (0.96-1.33) p=0.1635 
Age at diagnosis 
  
  
     15-59 years 430 12.9 240 18.2 190 9.4 1 
  60-69 years 738 22.1 337 25.5 401 19.9 1.34 (1.05-1.78) 
 70 -79 years 1,282 38.4 479 36.2 803 39.9 1.99 (1.63-2.67) 
 80 plus years  885 26.5 266 20.1 619 30.8 3.01 (2.35-4.03) p<0.0001 
Charlson comorbidity index 
  
  
     No 2,005 60.1 851 64.4 1154 57.3 1 
  Any 1,330 39.9 471 35.6 859 42.7 1.16 (0.97-1.37) p<0.0893 
Smoking status† 
  
  
     Non smoker 757 22.7 404 30.6 353 17.5 1 
  Previous smoker 1,325 39.7 483 36.5 842 41.8 1.62 (1.32-1.99) 
 Current smoker  1,253 37.6 435 32.9 818 40.6 2.02 (1.63-2.51) p<0.0001 
Chronic obstructive pulmonary disease ‡ 
  
  
     no COPD 1,930 57.9 878 66.4 1052 52.3 1 
  COPD 1,405 42.1 444 33.6 961 47.7 1.63 (1.37-1.94) p=0.0006 
Cancer          
Order of lung cancer 
  
  
     First cancer 3,121 93.6 1,301 98.4 1820 90.4 1 
  Second or subsequent cancer 214 6.4 21 1.6 193 9.6 5.17 (3.20-8.37) p<0.0001 
Histological subtype§ 
  
  
     Squamous 994 29.8 409 30.9 585 29.1 1 
  Adenocarcinoma 746 22.4 305 23.1 441 21.9 1.12 (0.90-1.39) 
 Large Cell 1,144 34.3 473 35.8 671 33.3 0.98 (0.80-1.19) 
 Other 451 13.5 135 10.2 316 15.7 1.29 (0.98-1.70) p=0.1318 
Method of diagnosis          
Cytology 478 14.3 147 11.1 331 16.4 1   
Clinical 407 12.2 137 10.4 270 13.4 1.23 (0.89-1.70)  
Histology hospital 1,307 39.1 555 42.0 752 37.4 0.88 (0.68-1.14)  
Histology by cancer registry staff  1,143 34.2 483 36.5 660 32.8 0.87 (0.67-1.14) p=0.0599 
Treatment factors 
  
  
     Period of diagnosis 
  
  
     2000-2004 1,455 43.6 855 64.7 600 29.8 1 
  2005-2008 1,880 56.4 467 35.3 1413 70.2 4.08 (3.46-4.74) p<0.0001 
For patients not admitted to hospital after diagnosis the information for COPD, smoking and comorbidity has been obtained 
from admissions two months or more prior to their date of diagnosis and is not contemporaneous. 
†Smoking codes (diagnosis codes Z86.43, Z72.0, Z71.6,F17) 
‡Chronic obstructive Pulmonary Disease (diagnosis codes 
J41.0,J41.1,J41.8,J42.0,J42,J43,J43.1,J43.2,J43.8,J43.9,J44.0,J44.1,J44.8,J44.9 
§Non small cell lung cancer=squamous (80503-80783),large cell carcinoma 80353,83103,80103-80123,80143-80313, 
Sarcoma'88003,88013,88023,88053,88103,88113,88303,88903,89203,90403,90413,91203,91333,91503,95403,88403-
89213,89903-89913,91203-91333,95403-95813,88303,91503Adenocarcinoma 82303-82313, 82503-82603, 81403, 
82113,83233,85763,8246Other =80003-80053 
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8.1. Abstract 
Lung cancer patients have better survival when treated in thoracic surgical (specialist) 
centres. Aims: To determine, whether, outcome of non-small cell lung cancer (NSCLC) 
patients is poorer with increasing distance to the nearest accessible specialist hospital 
(NASH). Methods We linked cancer registry, hospital and death records of 23,871 NSCLC 
patients; 3,240 localised, 2,435 regional and 3,540 distant stage patients hospitalised within 
12 months of diagnosis were analysed. Distance from patients’ residences to the NASH was 
measured using geographical coordinates. Cox proportional hazards models examined 
predictors of NSCLC death. Results: Having a resection of the cancer, which admission to a 
specialist hospital made more likely, substantially reduced hazard of NSCLC death. Distance 
influenced hazard of death through both these variables; a patient was less likely to be 
admitted to a specialist hospital than a general hospital and less likely to have a resection the 
further they lived from the NASH. However, patients who lived distant from the NASH and 
were admitted to a specialist hospital were more likely to have a resection and less likely to 
die from NSCLC than patients admitted to a specialist hospital and living closer to the 
NASH. These patterns varied little with lung cancer stage. Conclusions NSCLC outcome is 
best when patients are treated in a specialist hospital. Greater distance to the NASH can 
affect its outcome by reducing the likelihood of being treated in a specialist hospital. 
Research is needed into patient and health service barriers to referral of NSCLC patients for 
specialist care. 
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8.2. Introduction 
Surgical resection is recommended for early stage non small lung cancer patients; with 
lobectomy the preferred type of surgery.1 Depending on the location of the tumour, surgery 
may also be appropriate for patients with up to stage IIIa tumours.2 Post-operative mortality 
is lower and survival longer when patients are treated by thoracic surgeons in high volume 
centres probably because these surgeons are most likely to adhere to established practice 
standards.3, 4 
Distance to specialist centres is hypothesised to be a barrier to access to specialised medical 
care.5, 6 Most studies of the effects of distance to specialist care on treatment of NSCLC have 
been done in the UK. The majority of these studies have shown that patients’ access to 
surgical treatment is influenced by distance; and by clinician specialty and hospital of 
treatment.5-8 These studies generally could not take account of effects of lung cancer stage on 
their conclusions. 
New South Wales (NSW) Central Cancer Registry based patterns of care studies have shown 
that probability of no surgical treatment varies by a patient’s area of residence.9-11 The five 
year relative excess risk of death for NSW lung cancer patients was found to be significantly 
higher for patients living in accessible and moderately accessible areas regardless of stage.12 
A NSW GP or specialist can refer a patient to hospital as a planned admission, or patients 
can themselves present to the emergency department and be admitted directly to hospital. 
The commonest non-emergency pathway is probably referral by a GP to a specialist and 
referral by the specialist to a hospital for treatment under their care. Chemotherapy and 
radiotherapy are usually provided in outpatient settings. 
In this study, we investigate whether increasing distance to the nearest accessible specialist 
hospital (NASH), the nearest public hospital with a thoracic surgical serviceis associated 
with poorer survival for patients with localised, regional and distant stage primary lung 
cancer after adjusting for potentially confounding variables. 
  215  
8.3. Methods 
The NSW CCR was the primary data source.13 The study population was all patients with 
NSCLC (International Classification of Disease (ICD) topography codes C33–C34 excluding 
morphology codes M80413–M80453, M82463) diagnosed in NSW between 2000 and 2008 
and followed up to the end of 2008. Cancer registry coders based on pathology reports, 
doctor’s letters and other notifications determine stage at diagnosis. It is grouped into four 
categories: localised (confined to the organ of origin), regional (invasion of adjacent organs 
and proximal lymph nodes), distant (invasion distant lymph nodes or distant organs) and 
unknown (not recorded because pathology information was not available). Previous studies 
have shown these extent of disease categories to provide broadly comparable information to 
other methods of staging.14, 15 
A total of 23,871 patients were potentially eligible for this study. Of these, 22,997 patients 
whose CCR13 record linked to one or more records in the NSW APDC, which details 
diagnosis and surgical treatment for all separations from NSW public and private hospitals, 
16 were considered for the analysis. The combined automated and manual record linkage 
process had an estimated false positive rate of 0.4%.17 Patients were excluded if they were 
diagnosed by death certificate only (707) were not admitted to hospital after diagnosis 
(10,684), or were admitted more than 12 months after diagnosis (459); which left 11,147 
patients. Inpatient staging procedures could not have occurred and hospital risk factor and 
treatment information was not available for the patients not admitted to hospital after 
diagnosis.We also excluded (1,932) unknown stage patients except in a sensitivity analysis. 
This left 9,215 in the main analysis. Of these patients, 3,240 patients had localised stage, 
2,435 had regional stage and 3,540 had distant stage cancer. 
8.3.1. Distance 
Distance to the NASH was obtained for each patient by using the geographical coordinates 
of the patient’s address and the NASH, and the “Great Circle Distance Calculator”, a (SAS) 
programme. This algorithm calculates the shortest distance between two points on Earth, 
treating it as a sphere. 18 We considered this distance to be a measure of access to best care 
because it encompasses both distance to and affordability of care; all Australians are entitled 
to treatment free-of-charge in public hospitals. Distance to a patient’s actual hospital of 
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treatment as an alternative measure of access may be biased because patients that are more 
mobile may be referred to hospitals that are more distant. In addition, it can only apply to 
those who received treatment.6 UK studies using travel time and straight-line distance 19 have 
found them to be highly correlated (R = 0.856). 
Patients were grouped into three categories of distance: 0–39 km, 40–99 km and ≥100 km. 
The >100km category was made the most distant category because patients living this 
distance from required care in NSW can obtain financial support for travel and 
accommodation through the Isolated Patient Travel, Accommodation and Assistance 
Scheme.20 Patients’ place of residence was also classified broadly as metropolitan, outer 
metropolitan and rural, based on the 2010 boundaries of NSW Local Health Districts. 
8.3.2. Hospitals 
Eleven public specialist hospitals were identified using Canrefer, 21 a Cancer Institute NSW 
web directory of cancer services. We grouped hospitals in which patients were treated as 
specialist (public and private hospitals with a thoracic surgery service) or general hospitals 
(public and private hospitals without a thoracic surgery service). We selected the hospital of 
treatment as the hospital where patients received their most invasive procedure; in the 
absence of any procedure we selected the first hospital to which the patient was admitted 
after diagnosis. 
Because there was structural correlation between distance to the NASH and the type of 
hospital in which a patient was treated (the specialist hospitals were in Sydney or a large city 
while the general hospitals were distributed more widely throughout the State) we created a 
six category variable of hospital type in two categories, specialist and general, by distance 
from the NASH in three categories, 0–39 km, 40–99 km, ≥100 km. Other covariates are 
described in Appendix 1 Tables 1 and 2. 
8.3.3. Surgery 
Whether or not patients had their primary cancer treated surgically by lobectomy, segmental 
resection or pneumonectomy (referred to hereafter as a resection) was determined from 
hospital procedure codes in APDC records covering the period a month before diagnosis to 
12 months after diagnosis. Other characteristics of patients are found in Appendix 1. 
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8.3.4. Statistical analysis 
Stata 12.1 was used for the statistical analysis. We described cause specific survival from 
NSCLC and its predictors using Kaplan–Meier curves. Univariable Cox proportional hazards 
regression models were fitted for each covariate. Proportionality was examined and time 
varying components were retained if proportionality assumptions failed. Interactions were 
included on an a priori basis. Independent determinants of cause specific survival were 
identified by backward elimination from a full Cox proportional hazards model. A p value 
less than 0.05 in the likelihood ratio test was used to determine whether a variable was 
retained in the final model. Sex, age, comorbidity and history of chronic obstructive 
pulmonary disease were retained in the final model, regardless of their statistical 
significance, because of their clinical importance. The combination of type of hospital and 
distance from the NASH were similarly retained because investigation of the effects of 
distance was the main objective of this study. For all other variables, nested maximum 
likelihood ratio tests compared two models with and without the covariate. We checked 
model fit by comparing unadjusted Kaplan Meier survival curves with adjusted curves for 
each covariate after redoing the model using the Royston and Palmer stpm2 22 command 
and the Predict command in Stata 12.1 (Appendix 1 Figure 1). This model was the source of 
the adjusted survival curves in Figures 1 and 2. A sensitivity analysis was done by repeating 
the Cox modelling after imputing values for unknown stage (data available on request). 
8.4. Results 
Most NSCLC patients were male and Australian born. The mean age was 70 years in males 
and 69 years in females. There was a lower proportion in the highest socioeconomic status 
(SES) group than is found in the general Australian population. Seventy-two per cent were 
recorded as being current or previous smokers, 31% had chronic obstructive pulmonary 
disease and 35% one or more comorbid conditions (Appendix 1 Table 1). 
Of the 3,240 patients with localised cancer, 59.2% (95% CI 57.5–60.9) had resections. A 
lower proportion of patients who lived 100 km or more from the NASH had a resection 
(49.4%, 95% CI 45.8–53.1) compared to patients living 0–39 km (62.5%, 95% CI 60.3–64.4) 
or 40–99 km from it. Conversely, for patients who attended a specialist hospital there was a 
greater likelihood of resection with increasing distance to the NASH (69.7% at 0–39 km, 
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91.6 at 40–99 km and 94.6 at ≥100 km) (Table 1).For patients with regional stage cancer the 
proportion attending a general hospital also increased with distance from the NASH: 14.8% 
at 0–39 km to 51.2 at ≥100 km for localised stage, 15.3% at 0–39 km to 54.4% at ≥100 km. 
Much higher proportions of patients with distant stage than localised or regional stage 
attended general hospitals (Table 1). Overall, there were 3,517 surgical resections, or 16% of 
total NSCLC patients, 95% occurred in specialist hospitals, while only 5% occurred in 
general hospitals (Table 1). 
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Chapter 8 Table 1 The proportional breakdown of NSCLC patients by distance from the NASH by their hospital of treatment whether they had major surgery by stage category, NSW, 2000-
2008 
    Hospital of treatment   Had surgical resection 
 
Distance from the NASH by 
stage at diagnosis  
Specialist General Total Specialist General Total 
  n % n % n n % n % n 
Localised stage 0-39 km 1,757 85.2 306 14.8 2,063 1,225 69.7 63 20.6 1,288 
 
40-99 km 263 63.2 153 36.8 416 241 91.6 13 8.5 254 
  100+ 371 48.8 390 51.2 761 351 94.6 25 6.4 376 
Regional stage 0-39 km 1,244 84.7 224 15.3 1,468 836 67.2 46 20.5 882 
 
40-99 km 208 64.0 117 36.0 325 191 91.8 5 4.3 196 
  100+ 293 45.6 349 54.4 642 267 91.1 10 2.9 277 
Distant stage 0-39 km 1,539 70.5 644 29.5 2,183 166 10.8 7 1.1 173 
 
40-99 km 85 19.5 351 80.5 436 24 28.2 0 0 24 
  100+ 131 14.2 790 85.8 921 46 35.1 1 0.1 47 
    5,891 63.9 3,324 36.1 9,215 3,347 95.2 170 5.1 3,517 
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There was substantial variation in unadjusted survival of NSCLC patients depending on type 
of hospital of treatment and distance from the NASH (Figures 1a-c). Patients attending 
specialist hospitals had better survival while patients attending general hospitals had poorer 
survival for each stage category. Most of these differences, however, diminished greatly on 
adjustment of the survival curves for the covariates that were retained in the backward 
elimination Cox models of hazard of death from NSCLC (Figure 1b). 
Consistently with Figures 1d-f, the fully adjusted, stage specific hazard ratios for death from 
lung cancer did not vary greatly by distance and hospital type particularly in patients with 
regional and distant stage cancer (Table 2). To the extent that individual hazard ratios were 
materially above unity, these increases appeared more consistent with an independent effect 
of hospital type than an independent effect of distance from the NASH, with the poorer 
outcome in patients treated in general hospitals. 
However, since there are strong relationships between distance and hospital type, and 
hospital type and having a lung resection (Table 1), it is likely that resection, which reduced 
the hazard of death from NSCLC (Figure 2, Table 2), mediates most of the effects that 
distance and hospital have on the hazard of death, because only 170 of the 3,517 resections 
were undertaken in general hospitals (Table 1). To explore this possibility, we examined the 
impact of removing resection from the fully adjusted model on the associations of distance 
and hospital type with death from NSCLC (Table 3). With resection excluded from the 
model, there was a strong association with distance from the NASH and a reduced hazard of 
death for patients treated in a specialist hospital regardless of cancer stage. 
Because, with increasing distance from the NASH, patients underwent a resection when they 
attended a specialist hospital (for localised patients 91.6% at 40-99, and 94.6 at 100+Table 
1). Conversely, patients who attended a general hospital were more likely to die from their 
cancer; this increased risk varied little, by the distance patients lived, from the NASH. This 
poorer relative outcome in general hospitals was similar for all stage categories (Table 3). 
Resection was strongly associated with a lower risk of lung cancer death in all three stage 
categories, and this was true for each type of resection – pneumonectomy, lobectomy and 
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segmental resection (Figure 2, Table 2). For localised and regional cancer, this impact 
appeared greater at one year after diagnosis than at five years. 
Women had a lower risk of death for all stage categories (Table 2). As expected, increasing 
age, one or more comorbid conditions, having squamous cell carcinoma and having only a 
clinical diagnosis of lung cancer were strong predictors of a poor outcome. Except for 
comorbidity, these associations appeared weaker with regional and distant disease. Previous 
smokers had a lower risk of death than non smokers or current smokers regardless of stage; 
this might be a consequence of smoking cessation preparatory to resection. Similarly, 
patients with a history of COPD had a better outcome, particularly if they had localised 
disease, perhaps because of better recording of medical history in patients considered for 
resection. Patients with localised disease who had an emergency admission had a higher 
hazard of death at one year (HR 1) than patients who had planned admissions (HR 0.75). 
Patients admitted for resection 2-12 months after diagnosis had a hazard of death at five 
years that was more than double that in patients admitted within a month of diagnosis, and an 
even greater relative hazard if they had distant disease (Table 2). Most patients who had 
resection were admitted to hospital within a month of diagnosis (80.2%). 
The stage specific results in Table 2 were similar when stage was imputed for patients with 
unknown stage (data available on request). 
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Chapter 8 Table 2 Hospital of treatment, distance from the NASH and other variables independently associated with hazard of death from localised, regional and distant primary NSCLC in 
NSW in 2000-2008 
 Localised Regional Distant 
 One year1 Five years1  One year1 Five years1  One year1 Five years1  
 HR 95% CI HR 95% CI P value  HR 95% CI HR 95% CI P value  HR 95% CI HR 95% CI P value  
Hospital of treatment                 
and distance from the NASH                
Specialist hospital 0-39.9 1  1   1  1    1  1   
Specialist hospital 40-99.9 1.32 (0.96-1.82) 1.32 (0.96-1.82)  0.99 (0.79-1.23) 0.99 (0.79-1.23)  0.92 (0.71-1.18) 0.92 (0.71-1.18)  
Specialist hospital 100 plus 0.96 (0.72-1.28) 0.96 (0.72-1.28)  0.93 (0.76-1.13) 0.93 (0.76-1.13)  0.77 (0.62-0.95) 0.77 (0.62-0.95)  
General hospital 0-39.9 1.28 (1.00-1.65) 1.28 (1.00-1.65)  0.92 (0.77-1.10) 0.92 (0.77-1.10)  1.12 (1.01-1.24) 1.12 (1.01-1.24)  
General hospital 40-99.9 1.57 (1.14-2.18) 1.57 (1.14-2.18)  1.03 (0.82-1.30) 1.03 (0.82-1.30)  1.09 (0.96-1.24) 1.09 (0.96-1.24)  
General hospital 100 plus 1.02 (0.80-1.29) 1.02 (0.80-1.29) p<0.022 0.84 (0.71-0.99) 0.84 (0.71-0.99) p=0.2494 
 
1.10 (0.99-1.22) 1.10 (0.99-1.22) p=0.0097 
                
Sex                
Males 1  1    1   1    1   1   
Females 0.84 (0.75-0.94) 0.84 (0.75-0.94) p<0.0019 0.90 (0.80-1.00) 0.90 (0.80-1.00) p< 0.0187 0.80 (0.75-0.87) 0.80 (0.75-0.87) p<0.0001 
                
Age at diagnosis                
50-69 years 1  1    1  1    1  1   
60-69 years 1.31 (1.10-1.55) 1.31 (1.10-1.55)  1.12 (0.97-1.29) 1.12 (0.97-1.29)  1.13 (1.03-1.24) 1.13 (1.03-1.24)  
70 -79 years 1.51 (1.29-1.77) 1.51 (1.29-1.77)  1.44 (1.24-1.66) 1.44 (1.24-1.66)  1.32 (1.20-1.45) 1.32 (1.20-1.45)  
80 plus years  1.91 (1.58-2.30) 1.91 (1.58-2.30) p<0.0064 1.62 (1.32-1.99) 1.62 (1.32-1.99) p<0.0001 1.51 (1.32-1.73) 1.51 (1.32-1.73) p<0.0001 
                
Country of birth                
Australian born  1  1    1   1    1   1   
English speaking  0.99 (0.81-1.20) 0.99 (0.81-1.20)  1.00 (0.82-1.22) 1.00 (0.82-1.22)  1.10 (0.96-1.27) 1.10 (0.96-1.27)  
Non English speaking  0.87 (0.76-0.99) 0.87 (0.76-0.99)  0.85 (0.75-0.96) 0.85 (0.75-0.96)  0.81 (0.74-0.88) 0.81 (0.74-0.88)  
Unknown  0.58 (0.40-0.83) 0.58 (0.40-0.83) p<0.0001 0.51 (0.36-0.73) 0.51 (0.36-0.73) p<0.0002 0.76 (0.60-0.96) 0.76 (0.60-0.96) p<0.0001 
                
Comorbidity                
No comorbidity 1  1        1  1   
Comorbidity 1.15 (1.01-1.29) 1.15 (1.01-1.29) p<0.0258 1.13 (1.00-1.28) 1.13 (1.00-1.28) p=0.0443 1.16 (1.07-1.26) 1.16 (1.07-1.26) p=0.0005 
                
Chronic obstructive                 
Pulmonary disease                
No COPD 1  1        1  1   
COPD 0.85 (0.75-0.96) 0.85 (0.75-0.96) p=0.0110 0.99 (0.87-1.12) 0.99 (0.87-1.12) p=0.8356 0.91 (0.83-1.01) 0.91 (0.83-1.01) p=0.0874 
                
Smoking3                
No smoking 1  1   1  1   1  1   
Previous smoking 0.86 (0.75-0.99) 0.86 (0.75-0.99)  0.84 (0.73-0.97) 0.84 (0.73-0.97)  0.89 (0.81-0.97) 0.89 (0.81-0.97)  
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Current smokers 0.97 (0.83-1.13) 0.97 (0.83-1.13) p=0.0596 0.91 (0.78-1.05) 0.91 (0.78-1.05) p=0.0607 0.93 (0.85-1.02) 0.93 (0.85-1.02) p=0.0367 
                
Method of diagnosis                
Cytology 1  1    1   1    1   1   
Clinical 1.65 (1.25-2.19) 1.65 (1.25-2.19)  1.21 (0.88-1.66) 1.21 (0.88-1.66)  1.17 (1.01-1.35) 1.17 (1.01-1.35)  
Histologically verified 0.97 (0.79-1.10) 0.97 (0.79-1.10) p<0.0001 0.78 (0.64-0.96) 0.78 (0.64-0.96) p< 0.0013 0.79 (0.72-0.88) 0.79 (0.72-0.88) p<0.0001 
                
Histology4                
Squamous 1  1    1  1    1  1   
Adenocarcinoma 0.89 (0.77-1.03) 0.89 (0.77-1.03)  1.20 (1.05-1.38) 1.31 (1.02-1.68)  0.94 (0.80-1.11) 1.02 (0.75-1.39)  
Large cell 1.04 (0.89-1.20) 1.04 (0.89-1.20)  1.31 (1.12-1.54) 1.02 (0.76-1.37)  1.03 (0.86-1.22) 0.85 (0.62-1.18)  
Other 0.47 (0.37-0.61) 0.47 (0.37-0.61) p<0.0001 0.93 (0.72-1.19) 0.63 (0.41-0.98) p<0.0001 1.00 (0.80-1.25) 0.86 (0.57-1.31) p<0.0001 
                
Type of admission                
Emergency  1  1    1  1    1  1   
Planned  0.75 (0.64-0.87) 0.75 (0.64-0.87)  0.85 (0.72-1.00) 1.34 (0.99-1.80)  1.00 (0.89-1.13) 1.66 (1.32-2.09)  
Other 0.93 (0.67-1.30) 0.93 (0.67-1.30) p<0.0001 0.97 (0.68-1.38) 0.99 (0.52-1.88) p<0.0001 1.16 (0.89-1.51) 1.34 (0.83-2.17) p<0.0001 
                
Major surgery5                
No resection 1  1    1  1    1  1   
Pneumonectomy 0.35 (0.25-0.50) 0.74 (0.44-1.25)  0.42 (0.34-0.53) 0.60 (0.40-0.90)  0.28 (0.18-0.42) 0.16 (0.07-0.35)  
Lobectomy 0.14 (0.11-0.17) 0.32 (0.23-0.44)  0.31 (0.26-0.37) 0.54 (0.40-0.73)  0.34 (0.27-0.45) 0.32 (0.19-0.54)  
Segmental resection 0.18 (0.15-0.23) 0.37 (0.25-0.54) p<0.0001 0.32 (0.26-0.40) 0.60 (0.41-0.87) p<0.0001 0.36 (0.25-0.51) 0.24 (0.13-0.48) p<0.0001 
                
Time to surgery                
At diagnosis 1  1    1   1    1   1   
2-3 months 0.96 (0.77-1.19) 1.67 (1.12-2.47)  0.97 (0.82-1.14) 1.51 (1.11-2.04)  1.71 (1.43-2.04) 4.63 (3.23-6.64)  
3-6 months 0.67 (0.50-0.90) 1.74 (1.02-2.96)  1.14 (0.93-1.39) 2.99 (2.01-4.44)  1.44 (1.19-1.76) 7.58 (4.82-11.92)  
7 to 12 months 1.15 (0.97-1.38) 1.74 (1.27-2.37) p<0.0001 0.65 (0.50-0.85) 2.00 (1.25-3.20) p<0.0001 0.89 (0.70-1.13) 12.44 (7.01-22.07) p<0.0001 
1Hazard ratios at one and five years after diagnosis are presented because the effects of some variables in the model were time varying. 
2Chronic obstructive pulmonary disease (diagnosis codes J41.0,J41.1,J41.8,J42.0,J42,J43,J43.1,J43.2,J43.8,J43.9,J44.0,J44.1,J44.8,J44.9 
3Smoking codes (diagnosis codes Z86.43, Z72.0, Z71.6,F17) 
4Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 Other 
80003-80053, 88003, 88013, 88023, 8053 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-91333, 95403-95813, 88303, 91503. 
5Procedure codes Lobectomy (38438-01, 38441-00), Resection (38438-00, 38440-00, 38440-01, 90169-00,90181-00, Pneumonectomy (38441-01,38438-02). 
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Chapter 8 Table 3 Effect of presence or absence of surgery on associations of hospital of treatment and distance from a NASH with hazard of death from NSCLC in patients with localised, 
regional and distant stage disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adjusted for hospital of treatment and distance from a NASH, sex, age at diagnosis, country of birth, comorbidity, COPD, smoking, method of diagnosis, histology, type of admission, and time to 
diagnosis 
       
 HR 95%CI P value HR 95%CI P value 
Hospital of treatment and distance from a NASH       
 Multivariable model including surgery* Multivariable model excluding surgery* 
Localised NSCLC patients (n=3240)       
Specialist hospital 0-39.9 1   1   
Specialist hospital 40-99.9 0.82 (0.64-1.05)  1.32 (0.96-1.82)  
Specialist hospital 100 plus 0.64 (0.51-0.81)  0.96 (0.72-1.28)  
General hospital 0-39.9 1.69 (1.43-2.00)  1.28 (1.00-1.65)  
General hospital 40-99.9 2.01 (1.63-2.48)  1.57 (1.14-2.18)  
General hospital 100 plus 1.82 (1.55-2.13) p<0.0001 1.02 (0.80-1.29) p<0.022 
       
Regional NSCLC patients(n=2,435)       
Specialist hospital 0-39.9 1   1   
Specialist hospital 40-99.9 0.82 (0.66-1.01)  0.99 (0.79-1.23)  
Specialist hospital 100 plus 0.77 (0.63-0.93)  0.93 (0.76-1.13)  
General hospital 0-39.9 1.24 (1.04-1.47)  0.92 (0.77-1.10)  
General hospital 40-99.9 1.58 (1.26-1.98)  1.03 (0.82-1.30)  
General hospital 100 plus 1.23 (1.04-1.45) p<0.0001 0.84 (0.71-0.99) p=0.2494 
 
       
Distant NSCLC patients(n=3,540)       
Specialist hospital 0-39.9 1   1   
Specialist hospital 40-99.9 0.82 (0.64-1.06)  0.92 (0.71-1.18)  
Specialist hospital 100 plus 0.65 (0.52-0.80)  0.77 (0.62-0.95)  
General hospital 0-39.9 1.18 (1.06-1.30)  1.12 (1.01-1.24)  
General hospital 40-99.9 1.21 (1.07-1.38)  1.09 (0.96-1.24)  
General hospital 100 plus 1.23 (1.11-1.36) p<0.0001 1.10 (0.99-1.22) p=0.0097 
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Chapter 8 Figure 1 Kaplan Meier survival curves by hospital of treatment and distance from the nearest accessible specialist hospital (NASH) for patients with primary non small cell lung 
cancer by stage unadjusted and adjusted for confounding variables, New South Wales (NSW), 2000-2008 
A. Localised stage patients (n=3,240)   B. Regional stage patients (n=2,435)    C. Distant stage patients (n=3,540) 
 
D. Localised stage patients (n=3,240)   E. Regional stage patients (n=2,435)    F. Distant stage patients (n=3,540) 
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*Adjusted for sex, age at diagnosis, country of birth, comorbidity, chronic obstructive pulmonary disease, smoking, method of diagnosis, histology, type of admission, major surgery and time to diagnosis –
the effects of age and time to diagnosis were time varying. 
Chapter 8 Figure 2 Kaplan Meier survival curves by surgery for patients with primary non small cell lung cancer by stage unadjusted and adjusted for confounding variables, NSW, 2000-2008 
A. Localised stage (NSCLC) patients (n=3,240)   B. Regional stage (NSCLC) patients (n=2,435)  C. Distant stage (NSCLC) patients (n=3,540) 
 
D. Localised stage (NSCLC) patients (n=3,240)   E. Regional stage (NSCLC) patients (n=2,435)  F. Distant stage (NSCLC) patients (n=3,540) 
*Adjusted for hospital of treatment and distance from the NASH, sex, age at diagnosis, country of birth, comorbidity, chronic obstructive pulmonary disease, smoking, method of diagnosis, histology, type 
of admission, and time to diagnosis 
 227 
 
8.5. Discussion 
Two factors most influenced the hazard of death: attendance at a specialist hospital and 
having a resection of the lung cancer. Both were associated with a lower hazard of death. 
With increasing distance from the NASH, a patient was less likely to be admitted to a 
specialist hospital and therefore less likely to have a resection. To add to the complexity, 
when patients who lived further from the NASH were admitted to a specialist hospital, they 
were more likely to have a resection, probably because patients referred over long distances 
were more carefully selected for operability. Either way, distance and hospital type appeared 
as important determinants of having a resection and, therefore, of outcome of NSCLC. 
We found as have others23, 24 in a number of UK5-7, 25 and US studies26, 27 that patients living 
in proximity to a specialist hospital attended one. In addition, we found this pattern of 
attendance was similar regardless of the stage at diagnosis with 85% of localised and 
regional and 70% of distant stage patients attending specialist hospitals if they lived within 
0-39 km of one. There is evidence, too, that the proximity to hospital and specialty of the 
referring doctor is important. In a study of US SEER registered lung cancer patients with 
linked Medicare records, patients were more likely to attend a NCI Centre if they lived 
within 30 minutes of one and had care from a specialist doctor in the preceding six months.24 
We found that if a patient attended a general hospital, their survival was poorer, because they 
were less likely to have a resection of their cancer. Crawford 7 in a UK registry study also 
found that lung cancer patients whose closest hospital was district hospital were significantly 
less likely to have thoracic surgery than those whose closest hospital was a cancer centre. 
Other, studies of lung cancer patients in the north of England found that both distance from a 
cancer centre and deprivation reduced the likelihood of surgery, and treatment in a cancer 
centre reduced the likelihood of death. 5-7 More recently, the UK lung cancer audit found that 
NSCLC patients first seen at thoracic surgical centres were 51% more likely to have 
resection than those seen in other centres (adjusted OR 1.51, 95% CI 1.16–1.97).8 A recent 
UK study also found better survival in hospitals with higher resection volumes even for 
patients who were older, had lower socioeconomic status or had comorbidities.28 We found 
as have others that regardless of stage at diagnosis and after adjustment for other factors 
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having any resection (pneumonectomy, lobectomy or segmental resection) was the single 
most important factor in reducing the hazard of death. 8, 24 
Most studies of the efficacy of surgical resection of early stage NSCLC have been 
observational, based on routinely collected data or audits.29 However, both US30 and 
Australian 1 guidelines recommend that stage I to stage IIIa NSCLC patients with potentially 
resectable disease have a lung resection, subject to staging that includes systematic lymph 
node sampling or mediastinal lymph node dissection. We could not determine if formal 
staging was undertaken. However, NSW lung cancer patterns of care studies 9-11 report that 
89% of lung cancer patients saw a specialist at some time in their care, with 54% initially 
referred to a respiratory physician. Of these, 90% were referred to either an oncologist or 
cardiothoracic surgeon. Vinod et al.11 found that 49% of stage I patients, 24% of stage II, and 
4% of stage III NSCLC patients would have expected to have their lung cancer resected. 
The outcomes for surgically treated patients we observed are similar to those of Rich et al., 8 
who examined the outcomes for 34,513 NSCLC patients in a lung cancer audit. They found 
that potentially curative surgery was the most powerful overall determinant of survival. 
Relative to patients who did not have surgery, patients who had surgery had an HR of 0.41 
(95%CI 0.39–0.44) after adjusting for age, sex, performance status, stage and comorbidity. 
Apart from the increased likelihood of having a resection, patients referred to specialist 
centres would have access to lung cancer specialists for all their care, PET for operative pre-
staging, guideline based lung cancer treatment,23 and a reduced likelihood of developing 
complications.3 A recent lung cancer audit in Victoria, Australia, found that multidisciplinary 
team management of lung cancer patients, which is most likely to be available in specialist 
centres, was an independent predictor of receiving guideline based treatment and of a lower 
hazard of death.31 Specialised facilities and practices are less likely to be available in general 
hospitals, which tend to be outer urban or rural and to serve smaller, less dense populations.32 
We found, as have others, consistently lower hazard of death in women 5, 8 and a higher 
hazard of death with increasing age. 5, 7, 8 Unlike others5, 6 but consistent with some NSW 
studies 10, 33 but not all, 34 we did not find that socioeconomic status affected the hazard of 
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dying from lung cancer. We also found, as have other Australian 9-11, 31 and UK studies,7 that 
there were higher hazards of death in patients with any comorbidity8, those without 
histological confirmation35 and patients who were admitted through the emergency 
department.36 
8.5.1. Limitations and strengths 
This study was limited to surgical treatment. Other studies have shown that, as for surgery, 
there is lower use of radiotherapy, 6 37 chemotherapy 7 37 and combined treatment 37 with 
increasing distance to a specialist centre. Our study used a cancer registry based definition of 
localised, regional and distant stage; while TNM definitions would have been preferable, 
they were not available. Cancer registry summary staging categories, however, are routinely 
used for international comparisons of survival.14 A recent comparison of lung cancer 
summary staging and TNM staging showed that whereas all metastases are grouped into T4 
category with summary staging extension to adjacent organs (mediastinum, great vessels, 
trachea, oesophagus or carina) is categorised as regional stage.14 However, we do not believe 
that staging error will have an effect on our main findings because results for hospital of 
treatment and distance to the NASH were similar in each stage category. 
The major strengths of our study are its coverage of the whole population and our ability to 
link cancer registry and hospital separation records, both public and private, include 
routinely recorded measures of cancer stage (albeit imperfect), and use geocoded data to 
provide precise measures of distance between patients’ residences and distance to the NASH. 
If patients were being referred to specialist hospitals based on appropriateness for resection 
then the proportion of patients so referred would not vary by distance from the NASH. A 
better understanding of physician referral patterns is needed. A greater understanding of 
patient factors influencing travel to specialist care is also required. 
8.6. Appendix 1 online text - methods 
8.6.1. Other characteristics of patients 
The following variables were obtained from cancer registry records: sex; age at diagnosis 
(grouped into four categories: 15–59, 60–69, 70–79 and ≥80 years); country of birth 
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(grouped as Australian born, born in an English speaking country, born in a non English 
speaking country and unknown country of birth); socioeconomic status (allocated in five 
categories using the Australian Bureau Statistics’ Index of Relative Socioeconomic 
Disadvantage based on the 2001 or 2006 Census depending on the period of diagnosis38) and 
year of diagnosis (grouped as 2000–2004 and 2005–2008). 
Additional variables obtained from APDC records were: smoking status (non smoker, past 
smoker, current smoker based on ICD-10 codes Z86.43, Z72.0, Z71.6, F17 in any hospital 
admission record); any or no comorbidity (any condition in the Charlson index39, except 
secondary cancer coded as a primary or other diagnosis in any record, or no condition); and 
any or no history of chronic obstructive pulmonary disease (based on relevant four-digit 
ICD-10 codes in the range J41.0–J44.9 in any separation record). Because of its relevance to 
which hospitals a person might have access to, patients’ financial status at admission, as 
recorded in the APDC, was also included in the analysis, grouped into three categories: 
public patient in a public hospital, private patient in a private hospital and private patient in a 
public hospital. 
8.6.2. Stage, pathology and treatment 
Summary stage at diagnosis was classified, based on the extent of disease notified to, or 
inferred by, the CCR, as localised, regional, distant or unknown40. Histological subtype of 
cancer was coded by the CCR from pathology reports using the ICD-O version 3 
morphology codes41, which were grouped in accord with Cancer Incidence in Five 
Continents Vol IX42. Method of diagnosis, clinical, cytology or histopathology, which is 
recorded by the CCR, was also included because a number of studies have reported it to be a 
reliable indicator of lack of investigation.35 Time to surgery was recorded in months from 
diagnosis to the procedure. 
8.6.3. Statistical methods: sensitivity analyses 
Sensitivity analyses were conducted by modelling factors associated with the hazard of death 
for patients with unknown stage and those not admitted to hospital after diagnosis. A 
complete analysis was undertaken of all non small cell lung cancer (NSCLC) patients and we 
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applied multiple imputation using the “ice” (imputation by chained equations) command in 
Stata 12.143 to impute unknown stage, creating 10 imputed datasets.(Available on request). 
8.6.4. Determining model fit 
To determine model fit we plotted the unadjusted Kaplan Meier survival curves and the 
adjusted survival curves predicted from our stpm2model after using the Predict command. 
We found very little difference between the survival curves within each of the covariates 
indicating good model fit. 
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Chapter 8 Appendix 1 Table 1 New South Wales, NSCLC patients diagnosed between 2000-2008 distributed by patient, 
tumour and treatment factors 
Characteristics N % 
Total 23,871 100 
Hospital of treatment    
distance from the NASH1   
Specialist hospital 0-39.9 8,247 34.5 
Specialist hospital 40-99.9 769 3.2 
Specialist hospital 100 plus 1,029 4.3 
General hospital 0-39.9 4,837 20.3 
General hospital 40-99.9 2,364 9.9 
General hospital 100 plus 5,573 23.3 
No hospital2 1,022 4.3 
   
Index of remoteness   
Accessible 23,051 96.6 
Not accessible 802 3.4 
   
Area of residence   
Urban 8,572 35.9 
Outer metropolitan 6,493 27.2 
Rural 8,788 36.8 
   
Sex   
Males 15,053 63.1 
Females 8,800 36.9 
   
Age at diagnosis   
15-59 years 4,244 17.8 
60-69 years 6,143 25.77 
70 -79 years 8,418 35.31 
80 plus years  5,036 21.12 
   
Country of birth   
Australian born 15,675 65.7 
Born in an English Speaking country 1,760 7.4 
Born in a Non English speaking country 5,393 22.6 
Unknown country of birth 1,025 4.3 
   
Socioeconomic status   
Lowest SES 4,917 20.6 
Second lowest SES 4,383 18.4 
Middle SES 5,404 22.6 
Second highest SES 4,904 20.5 
Highest SES 4,233 17.7 
   
Period of diagnosis   
2000-2004 9,849 41.3 
2005-2008 14,004 58.7 
   
Comorbidity   
No comorbidity 15,611 65.4 
Comorbidity 8,242 34.6 
   
Smoking status3   
Non smoker 6,547 27.4 
Previous smoker 8,755 36.7 
Current smoker  8,551 35.8 
   
Chronic obstructive pulmonary disease4   
no COPD 16,495 69.2 
COPD 7,358 30.8 
   
Method of diagnosis5   
Cytology 3,355 14.1 
Clinical 3,587 15.0 
Histology coded by hospital 6,730 28.2 
Histology coded by cancer registry  9,474 39.7 
Discovered at autopsy 51 0.2 
Death certificate only 656 2.8 
   
Order of lung cancer   
First cancer 22,336 93.6 
Second or subsequent cancer 1,517 6.4 
   
Histology6   
Squamous 4,808 20.2 
Adenocarcinoma 7,596 31.9 
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Large cell 7,760 32.6 
Other 3,677 15.4 
   
Stage    
Localised 5474 22.9 
Regional  4156 17.4 
Distant  8105 34.0 
Unknown  6136 25.7 
   
Emergency presentation   
Emergency 10,495 44.0 
Planned admission 12,626 52.9 
Other 750 3.1 
   
Major surgery for the primary cancer7   
No admission to hospital2 1,0222 4.3 
Admitted to hospital for diagnostic purposes only 5,912 24.8 
No cancer procedure 13,185 55.3 
Lobectomy 2,224 9.3 
Segmental resections 1,122 4.7 
Pneumonectomies 388 1.6 
   
Time from diagnosis to surgery or admission   
At diagnosis 8,607 36.1 
2-3 months 1,287 5.4 
3-6 months 782 3.3 
7 to 12 months 525 2.2 
More than 12 months 459 1.8 
Admission to hospital before diagnosis 11,189 46.9 
No admission2 1,022 4.3 
   
Financial status   
Public financial status treated in public hospitals 14,231 59.69 
Private financial status treated in private hospitals 5,811 24.37 
Private financial status treated in public hospitals 2,777 11.65 
No admission to hospital 1,022 4.29 
1Nearest accessible specialist hospital. 
2These patients were a combination of New South Wales patients that did not have any hospitalisations because they did not 
link or were patients who were death certificate or autopsy notifications 
3Smoking codes (diagnosis codes Z86.43, Z72.0, Z71.6,F17) 
4Chronic obstructive Pulmonary Disease (diagnosis codes 
J41.0,J41.1,J41.8,J42.0,J42,J43,J43.1,J43.2,J43.8,J43.9,J44.0,J44.1,J44.8,J44.9 
5Histology by cancer registry staff means the record is coded using a pathology report notified to the registry. Histology hospital 
means that hospital staff have coded records from a pathology report. When the cancer registry sights the histology report, 
coding of diagnosis is likely to be more accurate than when it does not. 
6Cancer codes: ICD0-3 morphology codes: Squamous 80503-80783, Large cell 80353, 83103,80103-80123,80143-80313, 
Adenocarcinoma 82303-82313, 82503-82603, 81403, 82113, 83233, 85763, 82463 Other 80003-80053, 88003, 88013, 88023, 
8053 88113, 88303, 88903, 89203, 90403, 90413, 91203, 91333, 91503, 95403, 88403-89213, 89903-89913, 91203-91333, 
95403-95813, 88303, 91503. There are two main morphology codes responsible for 81% of the 15.4% of “other” these are 
morphology code 80003 Neoplasm not otherwise specified (1,375 or 37% of “other”) and 80463 non small cell carcinoma not 
otherwise specified (1,609 or 44% of “other”). 
7Procedure codes Lobectomy (38438-01, 38441-00), Resection (38438-00, 38440-00, 38440-01, 90169-00, 90181-00, 
Pneumonectomy (38441-01, 38438-02). 
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Chapter 8 Appendix 1 Table 2 New South Wales, NSCLC patients diagnosed between 2000-2008 and admitted to hospital within 12 months of diagnosis by patient, tumour and treatment factors and 
localised, regional and distant stage 
 Localised 
stage patients  
Regional 
stage patients  
Distant 
stage patients 
  
 % Died  % 
 
 % Died  % 
 
 % Died  % 
Hospital of treatment  3,240 100 1,384 100 2,435 
 
100 1,461 
 
100 3,540 100 3087 100 
and distance from the NASH             
Specialist hospital 0-39.9 1,757 54.2 628 19.4 1,244 51.1 703 48.1 1,539 43.5 1,313 42.5 
Specialist hospital 40-99.9 263 8.1 71 2.2 208 8.5 100 6.8 85 2.4 67 2.2 
Specialist hospital 100 plus 371 11.5 86 2.7 293 12.0 134 9.2 131 3.7 97 3.1 
General hospital 0-39.9 306 9.4 210 6.5 224 9.2 171 11.7 644 18.2 574 18.6 
General hospital 40-99.9 153 4.7 116 3.6 117 4.8 98 6.7 351 9.9 323 10.5 
General hospital 100 plus 390 12.0 273 8.4 349 14.3 255 17.5 790 22.3 713 23.1 
             
Sex 
    
        
Males 2,005 61.9 927 28.6 1,527 62.7 965 66.1 2,221 62.7 1,953 63.3 
Females 1,235 38.1 457 14.1 908 37.3 496 33.9 1,319 37.3 1,134 36.7 
             
Age at diagnosis 
    
        
50-69 years 662 20.4 225 6.9 606 24.9 342 23.4 1,053 29.7 895 29.0 
60-69 years 970 29.9 368 11.4 825 33.9 463 31.7 1,123 31.7 979 31.7 
70 -79 years 1,176 36.3 528 16.3 792 32.5 505 34.6 990 28.0 877 28.4 
80 plus years  432 13.3 263 8.1 212 8.7 151 10.3 374 10.6 336 10.9 
     
        
Country of birth             
Australian born  2,094 64.6 924 66.8 1,557 63.9 946 64.8 2,223 62.8 1,965 63.7 
English speaking  232 7.2 113 8.2 164 6.7 114 7.8 254 7.2 223 7.2 
Non English speaking  772 23.8 315 22.8 626 25.7 369 25.3 970 27.4 826 26.8 
Unknown  142 4.4 32 2.3 88 3.6 32 2.2 93 2.6 73 2.4 
             
Comorbidity             
No comorbidity 2,035 62.8 831 60.0 1,633 67.1 974 66.7 2,498 70.6 2,169 70.3 
Comorbidity 1,205 37.2 553 40.0 802 32.9 487 33.3 1,042 29.4 918 29.7 
             
Smoking             
Non smoker 720 22.22 349 25.22 529 21.7 353 24.2 1,065 30.1 934 30.3 
Previous smoker 1,371 42.31 557 40.25 986 40.5 580 39.7 1,209 34.2 1,040 33.7 
Current smoker 1,149 35.46 478 34.54 920 37.8 528 36.1 1,266 35.8 1,113 36.1 
             
Chronic obstructive pulmonary disease             
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no COPD 2,147 66.3 864 62.4 1,712 70.3 1,013 69.3 2,953 83.4 2,562 83.0 
COPD 1,093 33.7 520 37.6 723 29.7 448 30.7 587 16.6 525 17.0 
             
Method of diagnosis             
Cytology 164 5.1 107 3.3 150 6.2 122 8.4 498 14.1 452 14.6 
Clinical 144 4.4 100 3.1 78 3.2 63 4.3 412 11.6 378 12.2 
Histologically verified 2,932 90.5 1,124 93.7 2207 90.6 1276 87.3 1,241 35.1 1,121 36.3 
             
Histology3 
    
        
Squamous 962 29.7 459 14.2 658 27.0 380 26.0 446 12.6 390 12.6 
Adenocarcinoma 1,214 37.5 394 12.2 1,051 43.2 588 40.2 1,393 39.4 1,169 37.9 
Large cell 692 21.4 431 13.3 522 21.4 383 26.2 1,288 36.4 1,162 37.6 
Other 372 11.5 100 3.1 204 8.4 110 7.5 413 11.7 366 11.9 
     
        
Type of admission 
    
        
Emergency  730 22.5 558 17.2 566 23.2 455 31.1 2,215 62.6 1,983 64.2 
Planned  2,440 75.3 778 24.0 1,804 74.1 961 65.8 1,157 32.7 958 31.0 
Other 70 2.2 48 1.5 65 2.7 45 3.1 168 4.7 146 4.7 
             
Major surgery             
No surgery 1,322 40.8 994 30.7 1,080 44.4 885 60.6 3,296 93.1 2,940 95.2 
Pneumonectomy 113 3.5 50 1.5 219 9.0 113 7.7 46 1.3 27 0.9 
Lobectomy 1,185 36.6 211 6.5 812 33.3 318 21.8 119 3.4 74 2.4 
Segmental resection 620 19.1 129 4.0 324 13.3 145 9.9 79 2.2 46 1.5 
             
Time to diagnosis             
At diagnosis 2,600 80.2 1,090 78.8 1,831 75.2 1,107 75.8 2,899 81.9 2,546 82.5 
2-3 months 409 12.6 152 11.0 344 14.1 177 12.1 373 10.5 314 10.2 
3-6 months 154 4.8 92 6.6 168 6.9 110 7.5 179 5.1 150 4.9 
7 to 12 months 77 2.4 50 3.6 92 3.8 67 4.6 89 2.5 77 2.5 
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Chapter 8 Appendix 1 Figure 1 Testing model fit: a comparison of unadjusted Kaplan Meier survival curves with adjusted survival curves using stpm2 for primary localised NSCLC treated within 12 
months of diagnosis, New South Wales, 2000-2008 
 
When the unadjusted Kaplan Meier curve and the adjusted survival curve obtained from the model show little difference to one another then this variable is considered to have good fit  
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9.1. Discussion 
This thesis has presented a series of studies that have examined the impact of distance to 
surgical care on cancer survival after adjusting for patient, tumour and treatment factors. 
First, an overview of the international literature highlighted the relationship between 
increasing distance from services and poorer patient outcomes.  Varying results in outcome 
in the non-cancer setting depends on the type of presenting problem and the availability or 
otherwise of a service. Distance from outpatient care, the type of service and compliance 
with treatment were important for patients with mental health, drug abuse, depression and 
eating disorders. - For patients with myocardial infarction results were mixed with some 
finding no effect because services were in close proximity while others found poorer 
survival was due to less intensive treatment and reduced access to expert care. 
In the particular context of cancer care, previous studies of straight line distance have been 
dominated by studies in women with breast cancer. A consistent pattern of mastectomy 
instead of breast conserving surgery was found with increasing distance to radiotherapy 
services. In many - Scottish and UK studies,  for the majority of cancer sites examined, the 
hazard of death increased with increasing straight-line distance to a cancer centre. 
Depending on the cancer site and factors examined, a number of studies have found that 
attendance at a cancer centre rather than distance explained the hazard of death. Most studies 
were undertaken to appreciate the policy impact of the specialisation and centralisation of 
cancer services on access for people who live more remotely.   In Australia, most services 
are located in cities, and distances travelled are greater than the international studies 
examined. With increasing trends towards sub-specialisation and greater centralisation of 
cancer services in NSW, the further investigation of the relationship between distance from 
specialist cancer surgical services and outcome, as undertaken in this thesis, could inform 
policy development in this area.   
The early part of this thesis focused on issues of measurement, including measures of 
distance (Chapter 2) and cancer survival (Chapter 3). The remaining chapters (4-8) discuss 
the findings of studies that use linked cancer registry and hospital data and apply the 
distance and cause specific survival methods previously validated in chapters 2 and 3.  
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Bladder cancer was the first study in this thesis to use the cause specific survival method and 
to measure distance to actual surgical care in patients undergoing a cystectomy or bladder 
resection while adjusting for a wide range of patient, tumour and treatment factors (Chapter 
4). The study of distance from and access to specialist hospitals for women diagnosed with 
ovarian cancer also investigated predictors of general hospital care and the receipt of surgery 
(Chapter 5). The three remaining chapters investigated the impact of distance to the nearest 
accessible specialist hospital (NASH) and hospital of treatment for patients with non small 
cell lung cancer (NSCLC) living in New South Wales (NSW) after adjusting for patient 
tumour and treatment factors. The first study of NSCLC examines predictors of advanced or 
unknown stage (Chapter 6), the second, predictors of no surgery (Chapter 7) and finally 
cancer survival (Chapter 8). This final chapter summarises the unique contributions of this 
thesis to the literature previously discussed in detail in the earlier chapters. Emphasis is 
given to common findings for bladder, ovarian and lung cancers.  Possible reasons for 
disparities observed in this thesis are discussed, along with limitations, strengths and key 
implications of the research for future research. Recommendations for changes in clinical 
practice provide a consolidated understanding of the impact of distance to specialist care in 
NSW. 
9.2. Unique contributions of this thesis to the literature 
9.2.1. Measuring distance 
Reporting and explaining variability in patterns of cancer incidence, mortality and survival 
by time at diagnosis for small geographic areas is common to all cancer registries and 
necessary for evaluating cancer control efforts. The NSW Central Cancer Registry (CCR) 
was geocoded to replace the current method (National Locality Index (NLI) encoder) of 
allocating geographic regions in the CCR. However, validating whether this new method 
produced the same results as the old method was necessary. One benefit of geocoded address 
data is that an algorithm called the Great Circle Distance Calculator could be applied to 
geocoded coordinates to measure straight line distance. This algorithm was applied to all 
patient's addresses on the CCR (living within an LGA) to a designated hospital (RPA) to 
measure the straight-line distance (in kilometres). This method had not been used in NSW, 
before. Therefore, checking whether the distances calculated were correct and consistent 
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with known distances was necessary. The number of cancer cases associated with each 
geocoded LGA compared to the number of cases allocated using the NLI coder was similar 
providing reassurance the new method produced the same result. Furthermore, the distance 
in kilometres for every case of cancer used to calculate the median value of distance from 
the LGA to a single hospital RPA was plausible, therefore, providing further reassurance 
that distance was being calculated correctly (Chapter 2). 
9.2.2. Measuring survival 
A comparison of different methods of measuring cancer survival, the primary outcome of 
interest, and, therefore, central to this thesis, was undertaken to determine whether cause 
specific was a practical alternative to the more traditional relative or the new net survival 
methods. Three methods of survival were calculated for two registry populations (the NSW 
CCR and the Northern and Yorkshire Registry) for cancers of the lung, breast, prostate and 
colorectal cancer. In NSW, regardless of survival method, cancer survival at monthly 
intervals, up to one year and yearly intervals, up to eight years after diagnosis, for each 
cancer site, produced almost identical results. This finding was important to this thesis 
because it provided reassurance that cause specific survival in NSW was an acceptable 
method to undertake the subsequent analyses in chapters 4 to 9. Cause specific survival 
depends on the quality of the cause of death data used to determine the final cause of death. 
This study allocated the cause of death to Northern and Yorkshire registry subjects using 
NSW rules. For the good survival cancers of prostate and breast similar survival estimates 
were obtained for cause specific survival compared to other survival methods. However, 
cause specific survival estimates of lung cancer and bowel cancer in Northern and Yorkshire 
were 2.3% and 3.8% higher than the relative or net survival estimates. There was little 
difference between cause specific, relative, and net survival estimates when addition cancer 
specific deaths mentioned in part two of the death certificate were  included in the final 
determination of cause of cancer death. In NSW, the cause of death is more likely to be 
correct as all notifications determine the final cause of death. The second aim of this study 
investigated differences in survival rates for each cancer site between NSW and Northern 
and Yorkshire. Survival estimates in NSW were 5-10% higher than Northern and Yorkshire 
(depending on the site) even after taking account of the cause of death allocation. Therefore, 
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the higher survival estimates in NSW, routinely reported in International studies of cancer 
survival, would appear to be real and not related to the methods used to calculate survival or 
differences in allocating the cause of death (Chapter 3). 
9.2.3. Bladder cancer survival and distance to surgical care 
This study of people diagnosed with bladder cancer between 2000 and 2008 and living in 
NSW was the first study in this thesis to use linked cancer registry and hospital data. In 
addition, distance and cause specific survival methods were applied. This study extended 
previous analyses of predictors of bladder cancer survival and further examined why 
survival was poorer in women1 and considered whether distance to the hospital of surgical 
treatment was a predictor of survival after cystectomy or surgical resection. After adjustment 
for a wide range of variables, there was little impact on women’s higher risk of death from 
bladder cancer following cystectomy. The variable(s) principally contributing to the 
weakening of the association of female sex with risk of death in cystectomy patients were in 
order of strength: summary stage, age at diagnosis, distance from treatment facility, the 
presence of haematuria, country of birth and time to cystectomy. With increasing distance 
from a person's home to their hospital of cystectomy,  people with bladder cancer were less 
likely to die. As this study was the first in this thesis to examine the distance to surgical care 
in retrospect, it may have been preferable to group hospitals into specialist and non-
specialist rather than public and private. However, many urologists operate in the private 
sector and in the absence of guidelines for bladder cancer this approach seemed reasonable. 
It is most likely that patients who travelled further, and who underwent a cystectomy were 
receiving their care in specialist hospitals. The most significant finding in this study, 
however, was the interaction of sex with a history of cystitis in influencing death after 
cystectomy: Hazard Ratio (HR) was 1.55, 95% CI 1.15-2.10, in women with a history of 
cystitis. No such interaction was evident in women who underwent resection. 
9.2.4. Ovarian cancer survival and distance to specialist care 
Australian,2 NSW 3 and International Guidelines4, 5 recommend that women with epithelial 
ovarian cancer should undergo optimal surgical debulking by gynaecological oncologists 
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and be treated in specialist centres. Long term survival from ovarian cancer depends strongly 
on whether residual disease remains after surgery.6 7, 8  
The most important finding of the paper presented in Chapter 5, was that women were more 
likely to be admitted to a general hospital for their care and less likely to have surgery with 
increasing distance to a Gynaecological Oncology Surgical (GOS) hospital. There was an 
increasing trend in the unadjusted risk of death due to distance from the GOS hospital, 
however, after adjustment for patient, tumour and treatment factors distance to the GOS 
hospitals was no longer significant because of the strong association of distance with type of 
treating hospital. Women treated in general hospitals were less likely to have surgery and 
more likely to die. 
In contrast, women treated in GOS hospitals (public and private) or private general hospitals 
were 30-50 per cent less likely to die. Furthermore, women who had surgery for their 
ovarian cancer also had a 65 per cent lower hazard of death at five years after adjustment for 
hospital type and other factors.   
Campbell, 9 in Scotland, used straight-line distance to treatment and found the hazard of 
death for women with ovarian cancer was greater with increasing distance to a cancer centre. 
Whereas distance from a woman’s home to her closest hospital or family doctor examined in 
UK registry studies 10 11 did not appear to be important; only treatment in a cancer centre 
showed a significant reduction in the hazard of death after adjustment for age and 
deprivation. A higher proportion of unknown stage at diagnosis for women treated in general 
hospitals and a lower likelihood for those in specialist hospitals suggests selection of patients 
is occurring with increasing distance. Others have found that women with unstaged disease 
were less likely to receive care from a gynaecological oncologist or to receive recommended 
treatment. 12 
The results reported in Chapter 5 are similar to other large registry based studies of ovarian 
cancer survival. Women treated in teaching hospitals were found to have a lower risk of 
death than women treated in non teaching (general) hospitals, 10, 13even after adjusting for 
extensive surgery and chemotherapy. 14 
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9.2.5.  Predictor of advanced or unknown stage NSCLC with increasing distance 
from the NASH 
The findings in the next three papers on lung cancer in NSW extend and build on the work 
undertaken for ovarian cancer. Lung cancer, similar to ovarian cancer, is a poor survival 
cancer, usually detected at a late stage. In contrast, provided the tumour is located in a part 
of the lung that is operable and the tumour is localised to the lung, surgery can be curative in 
lung cancer patients. Australian15 and International16 guidelines recommend surgery for 
patients with localised NSCLC and  for some later stage patients with survival better for 
those treated in a specialist centres. 
The key question of interest in this study was whether people who lived further from the 
NASH were more likely to have advanced or unknown stage NSCLC at diagnosis or not 
when admitted to hospital within 12 months of diagnosis.  People who lived 100km or more 
from the NASH were less likely to have localised stage and more likely to have advanced 
(regional and distant stage) or unknown stage at diagnosis. After adjustment for other 
factors, the likelihood of presenting with advanced stage was significantly higher in people 
who lived 100 km from the NASH relative to those who lived less than 39 kilometres from 
the NASH. When factors subsequent to diagnosis of stage (e.g. hospital of treatment, 
histological verification, type of admission), were added to the model, people treated in 
general hospitals had higher odds of advanced stage or unknown stage cancer regardless of 
distance from the NASH. In contrast, a lower likelihood of advanced or unknown stage 
NSCLC was observed among people who attended a specialist hospital with increasing 
distance from the NASH.  
This study illustrates three important issues. Firstly, patient selection would appear to be 
occurring for people with lung cancer in NSW. With increasing distance from the NASH  
patients attended general hospitals for their care, which was associated with a greater 
likelihood of advanced or unknown stage. Secondly, the determination of advanced stage 
suggests that some diagnostic investigations had occurred, with patients with advanced stage 
considered unsuitable for surgery and therefore admitted to a general hospital. However, a 
person having a tumour of unknown stage suggests that full diagnostic assessment with 
clinical, radiological and histological assessment had not occurred. Thirdly, people who 
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attended specialist hospitals were significantly less likely to have advanced or unknown 
stage with increasing distance from the NASH, suggesting some diagnostic investigation and 
suitability for surgery had occurred prior to referral and staging that was more extensive 
after admission to hospital. 
A plausible explanation could be that with increasing distance from the NASH perhaps 
stabilisation of symptoms or assessment of suitability for surgery (in patients who had some 
staging) influenced the referral to specialist hospitals. In NSW, lung cancer patterns of care 
studies report that 83 per cent of patients see at least one specialist17-20 21 at some time for 
their care indicating that most patients would have had some opportunity for investigation. 
However, it may be that patients who live more remotely delay visiting their GPs and 
thereby present at an advanced stage reducing treatment opportunities. Well documented in 
NSW are the low GP to population ratios found in rural areas 22, 23 and limited after hour 
services. 24, 25 Studies of lung cancer patients living in Western Australia (WA) report that 
rural patients took longer to consult their GPs, presented with more symptoms and had 
longer waits for specialist consultation.26 More generally, a lack of awareness of the 
importance of symptoms may also be a factor causing delay. 27  
This study (Chapter 6) is only the second study of straight line distance to examine 
predictors of advanced and unknown stage NSCLC.  The greater likelihood of advanced and 
unknown stage NSCLC with increasing distance from the NASH combined with a reduced 
likelihood of histopathological diagnosis, and higher likelihood of an emergency admission 
or attendance at hospital six or more months suggests a pattern of disadvantage. 
9.2.6. Predictors of no NSCLC surgery with increasing distance from the NASH 
This study focused on people diagnosed with localised NSCLC admitted to hospital within 
12 months of diagnosis and investigated whether they were less likely to receive surgery 
with increasing distance from the NASH. Australian15 and International16 guidelines are 
unequivocal in recommending curative surgery as the best treatment option for this group. 
The most significant finding of this study was that with increasing distance to the NASH, 
patients with localised NSCLC were more likely to attend general hospitals for their care 
and not have potentially curative surgery. In contrast, patients who did travel longer 
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distances to attend a specialist hospital had a lower likelihood of not receiving surgery than 
patients who lived closer to the NASH. These findings are consistent with the findings in the 
previous study (Chapter 6); that is, with increasing distance from the NASH people referred 
to a specialist hospital are less likely to have tumours of advanced or unknown stage and 
more likely to have curative surgery (Chapter 7). Two factors explained much of the 
variation in receipt of surgical resection, namely the hospital of treatment and admission via 
the emergency department rather than a planned admission. Most studies of the effects of 
distance to specialist care on surgery of NSCLC have been done in the UK. The majority of 
them have shown that patients’ access to surgical treatment is influenced by distance, 
clinician specialty and hospital of treatment. 10, 11, 28, 29 Emergency admissions appear to put 
patients on a sub-optimal care pathway. Others have reported that lung cancer patients who 
attended emergency departments without a diagnosis or without a chest x-ray were less 
likely than other patients to receive specialist care (62% vs 94%),30 or to have their lung 
cancer confirmed pathologically.31 
9.2.7. Lung cancer survival in people with NSCLC and distance from the NASH 
The final study of lung cancer in NSW examined distance from the NASH, hospital of 
treatment and cancer survival by stage at diagnosis. With increasing distance from the 
NASH, the univariable hazard of death increased in people treated in general hospitals and 
declined for those treated in specialist hospitals. After adjustment, having surgery for lung 
cancer was the most significant predictor and thoroughly explained the survival advantage 
regardless of the stage at diagnosis.  With increasing distance from the NASH, NSCLC 
patients were admitted to a general hospital and when so admitted were less likely to 
undergo surgery. Therefore, attendance at a specialist hospital determined whether surgery 
occurred. People with localised NSCLC, who had surgery (lobectomy, pneumonectomy or 
resection), relative to those that did not, had 60-80 per cent reduction in the hazard of death 
at one year and 26-68 per cent reduction at five years (depending on the surgical procedure). 
Similar risk of death reductions occurred for people diagnosed with regional and distant 
stage NSCLC who had surgery. 
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Potentially curative surgery has been found to be one of the best determinants of cancer 
survival with a recent UK lung cancer audit of 34,513 NSCLC patients reporting a HR of 
0.41 (95%CI 0.39-0.44) in patients who underwent surgery relative to those who did not 
after adjusting for age, sex, performance status, stage and Charlson index of comorbidity.29 
NSCLC patients have better survival if they are treated in high volume surgical centres, even 
if they are older, of low socioeconomic status, or have comorbidities.32  This study and the 
UK lung cancer audit have shown strong evidence of the survival benefits of potentially 
curative lung cancer surgery. It is of concern that people who live more than 100km from the 
NASH are more likely to attend  general hospitals for their care be diagnosed with advanced 
stage, have double the likelihood of being unstaged  and therefore not receive potentially 
curative surgery. 
9.3. Common findings in this thesis 
With increasing distance from the nearest specialist hospital, admission to a general hospital 
was more likely for both women diagnosed with ovarian cancer and people diagnosed with 
lung cancer. Attendance at a specialist hospital and undergoing major surgery independently 
reduced the likelihood of death for women with ovarian cancer. Furthermore, having surgery 
for NSCLC (that only occurred if admitted to specialist hospitals) explained the better 
survival outcomes for patients regardless of the stage at diagnosis. Therefore, what are the 
common factors? 
Women with ovarian cancer and people with lung cancer treated in general hospitals were 
more likely to be emergency department admissions and to have a reduced likelihood of 
histological verification. Increasing age at diagnosis, any comorbidity and no histological 
verification were factors, which increased the risk of death in people with bladder, ovarian 
and lung cancer.  
These findings are consistent with other studies that have found that the hazard of death 
increases with age, comorbidity29  and in those without histological confirmation. 33 Patients 
admitted via the emergency department are also less likely to receive specialist care. 34 
Alternatively, a lack of histological confirmation could perhaps indicate poor general health 
or comorbidity.  The patient may not be well enough to undergo the further tests and 
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biopsies, or their general health was too poor for cancer surgical treatment; therefore, 
histological verification of stage may not have affected their management. Recent lung 
cancer guidelines for GPs recommend that a patient is immediately referred to the 
emergency department if they have symptoms indicative of advanced stage that is massive 
haemoptysis (coughing up blood) or stridor (difficult noisy breathing). 35 
Another common finding was the reduced likelhood of advanced stage and particularly 
unknown stage, the greater likelihood of for women with ovarian cancer and people 
diagnosed with lung cancer who attended specialist hospitals. 
The considerable survival advantage conferred by surgical resection for women with ovarian 
cancer and people with lung cancer relative to other factors was also a common finding in 
this thesis further highlighting the importance of diagnosis and referral to a specialist 
hospital. Women undergoing surgery for ovarian cancer were 65 per cent less likely to die at 
five years. To our knowledge, this is the first population based study to report survival due 
to surgical resection while adjusting for patient, tumour and treatment factors.  In addition, 
to our knowledge, this is the first study to provide survival estimates for people with NSCLC 
by type of lung surgery, for each category of stage and to have used cause specific rather 
than all cause or relative survival. 
Histological subtypes within each cancer significantly affected survival with a higher hazard 
of death observed in bladder cancer patients with transitional cell carcinoma, women 
diagnosed with serous epithelial ovarian carcinoma and people diagnosed with 
adenocarcinoma and large cell NSCLC. These findings are also consistent with the literature 
previously discussed in the introduction to this thesis. While it is not possible to modify a 
person’s prognosis due to the histological subtype, molecular profiling, may provide 
opportunities for targeted therapies in the future. 
The time from diagnosis to surgery or hospital admission for those who did not have surgery 
was relatively short for most patients. The majority or 75 per cent of NSW patients who had 
a cystectomy did so within the recommended three-month or 12 weeks from diagnosis. Most 
women (86 per cent) diagnosed with ovarian cancer were treated within six months of 
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diagnosis. About 10 per cent were admitted to hospital seven months or more after 
diagnosis. Similarly, admission to hospital within a month of their date of diagnosis (80.2 
per cent) occurred for most people with NSCLC. It would appear that time from diagnosis to 
surgery or admission was short for most patients. However, a higher hazard of death 
occurred in patients with increasing time from diagnosis to hospitalisation for all three 
cancer sites. 
These results suggest differential referral of patients to specialist hospitals, with those with 
earlier stage disease (i.e., most amenable to treatment) more likely referred.  However, a 
more standardised approach, particularly given the high proportion of patients with unstaged 
cancer, is required to ensure equity of access for all who may be suitable for curative 
surgery.  
Presented below are potential reasons for the disparities observed in this thesis, factors that 
may explain a delay between symptom awareness and diagnosis, potential risk prediction 
tools and referral pathways (Multidisciplinary Team Meeting (MDTs) and Cancer Care 
Coordinators (CCC) that may assist to ensure that all patients have access to early diagnosis, 
appropriate staging and specialist care. 
9.4. Possible reasons for disparities observed in this thesis 
Common to all three types of cancer studied in this thesis was the inability to measure the 
time from symptom awareness to diagnosis. Given, that most bladder, ovarian and lung 
cancer patients were treated within a relatively short time after diagnosis, it is possible, that 
the delay is occurring between symptom awareness and attending the GP.  This could 
explain why, with increasing distance, patients are presenting with advanced or unknown 
stage attending general hospitals for their care and missing out on surgery. 
Recently UK and Denmark have initiated strategies36 37 38 that focus on reviewing factors 
that cause a delay in diagnosis. Two factors best indicated delay; these were the number of 
days from symptom onset to diagnosis and the proportion of patients diagnosed with late 
stage. The National Awareness and Early Diagnosis Initiative36 was introduced in 2008 in 
the UK to examine pathways to a delayed diagnosis of cancer. A risk factor for delay 
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identified across all cancer types was non-recognition of the seriousness of symptoms. 
Patients who adopted a wait and see attitude often contributed to delay. Not associated with 
delay were lower levels of social support, low socioeconomic status or age at diagnosis 
were. 36 
9.4.1. Factors associated with delay in people diagnosed with bladder cancer 
The most common presenting symptom of people diagnosed with bladder cancer is painless 
haematuria (blood in the urine). Other less common symptoms include urgency, dysuria 
(pain on urination) and in, more advanced tumours, pelvic pain and symptoms related to 
urinary track obstruction. 39  Recently, the American Urological Society has published 
guidelines that anyone with microscopic haematuria (defined as three or more blood cells) 
should be followed up clinically and subsequently with a biopsy because approximately 5% 
of patients will have a urinary tract malignancy.40 
Factors associated with delays prior to diagnosis for bladder cancer include female sex and 
non-white ethnic origin. Compared to men, delayed diagnosis is more common in women 
who have haematuria because other factors like post menopausal bleeding are often 
investigated first.41 Delay was shorter in men who presented with bleeding and longer with 
pain or when symptoms were vague or non-specific. 36 Haematuria in men 42 and cystitis in 
women43 were factors that reduced delay. Practitioner delay was shorter for younger 
urological patients and increased when health symptoms not related to cancer were present. 
Therefore, risk prediction tools in a general practice setting would be welcomed in an 
Australian context particularly given the poorer survival in women compared to men.36 It is 
unknown whether GPs or urologists use risk prediction tools to assist them to diagnose 
people suspected of bladder cancer in NSW.  
9.4.2. Factors associated with delay in women diagnosed with ovarian cancer and 
potential risk prediction tools 
Reasons given for the delay in diagnosing women suspected of ovarian cancer, range from 
the misattribution of symptoms, due to stress or menopause, or attributing symptoms to 
previously benign conditions, for example, irritable bowel syndrome. 46 Presenting 
symptoms of women influence GP referral patterns. GPs referred women with 
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gastrointestinal symptoms to a gastroenterologist while women who presented with bleeding 
to a gynaecologist.44, 45Currently, there is no screening test to detect ovarian cancer. 46 
Women eventually diagnosed with ovarian cancer often present with suspicious ovarian 
masses; a definitive diagnosis may not be possible, until a tumour is removed, and 
histopathology undertaken. A risk of malignancy index may be calculated that takes into 
account a woman’s menopausal status, ultrasonic scan and CA125 levels which collectively 
can be used to triage and refer women suspected of ovarian cancer to a gynaecological 
oncologist.47  
In Australia where large distances to specialist centres occur, triaging is particularly 
important.47 Jacobs48 who first reported this index in 1990 recorded a sensitivity of 85% and 
specificity of 97% in differentiating malignant from benign disease.  More recently, the 
sensitivity and specificity of a symptom index developed by Goff 49 and Rossing 50 was 
applied to age specific numbers of patients with confirmed ovarian cancer identified through 
the Australian Epithelial Ovarian Patterns of Care Study.51 This study calculated a positive 
symptom index (based on numbers of symptoms, clinical history and risk factors) of 
between four and 16 times in women with confirmed ovarian cancer. The authors concluded 
that while not adequate as a screening tool, it may be a useful risk prediction tool to prompt 
referral for diagnostic testing. 51  
9.4.3. Factors associated with delay in people diagnosed with NSCLC and risk 
prediction tools to assist with earlier diagnosis 
Most people with lung cancer present at a late stage with survival differences varying greatly 
internationally by stage at diagnosis.52, 53 A lung cancer tumour can take up to 8-10 years to 
be clinically detectable.54 People with lung cancer may not  recognise their symptoms or 
ignore them for a variety of reasons including stigma and high psychosocial distress.55 
Recently, a number of risk prediction tools have been developed that may assist GPs to 
detect lung cancer. The CAPER studies56 developed in the UK examined the risk of 
detecting lung cancer using combinations of symptoms. Haemoptysis in combination with 
weight loss had a PPV of 9.2%. However, the model was more predictive when stratified by 
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patient age ranging from 8.4% in those aged less than 55 to 20% for those aged 85 years or 
older.56 Another model called the Q Cancer lung model57 included risk factors as well as 
symptoms. This model found that haemoptysis, appetite loss, weight loss, cough, body mass 
index, deprivation score, smoking status, chronic obstructive airways disease, anaemia and 
prior cancer (females only) explained 72% of the variation in the model. The 10% of 
patients with the highest predicted risks included 77% of all lung cancers diagnosed over the 
subsequent 2 years.57  
Delays in diagnostic testing were found to occur for rural lung cancer patients in WA 
leading to more advanced stage at diagnosis and limited opportunity for surgery. 26 
According to Salomaa, a multidisciplinary approach and rapid access to carefully planned 
investigations58 increases the likelihood of timely diagnosis in lung cancer patients. In 
addition, multidisciplinary team review was found to be an independent predictor of lung 
cancer survival in the recent Victorian patterns of care study.21 
9.4.4. Availability of primary care in rural areas 
Improving rural patients access to primary care is currently a National Priority.59 Patients 
who live in rural areas or further from specialist hospitals could be presenting at an advanced 
stage or unknown stage because of their limited access to primary care physicians. Patients 
living in rural areas in Australia22 and the US 60 have a reduced number of primary care 
physicians per head of population. In a US study that considered predictors of unknown 
stage lung cancer, people were more likely to have their cancer unstaged if they were older 
and resided in low income rural areas with fewer primary care physicians per 10,000 
population.60 In Australia, the average ratio of full-time equivalent doctors to patients is 0.71 
per 100061 with ratios below this found in rural and remote areas and outer metropolitan 
areas in capital cities. In addition, Brown et al. 62 reported that women who live in rural and 
remote areas had significantly fewer visits to GPs and specialists (P < 0.001) than women 
living in urban areas.  
 256 
 
9.4.5. Multidisciplinary team review  
Lack of multidisciplinary team (MDT) participation in rural areas (41%) was nominated  by 
the Clinical Oncological Society of Australia as an issue that required specific attention. 
people living in rural areas.63 MDTs may be seen as part of the cancer coordination pathway 
or may exist alone.  
Specific issues identified in patients from rural and remote populations were a lack of 
available specialist health care. This is seen as a major factor in delayed diagnosis. 
64Inconsistent, delayed or incomplete communication particularly between family physicians 
and specialists inhibit the delivery of coordinated care for patients.64 A number of success 
factors of MDTs and referral pathways were identified as part of a literature review 
commissioned by Cancer Australia. These were, determining a clear vision, developing a 
statement of purpose , a structure and strategy for linking with existing organisations, 
consideration of geographic and demographic issues, governance models as well as tracking 
and measuring of outcomes.65 To date the effectiveness of the CanNet (Cancer network 
strategy) mainly relates to process measures. Those include the service directory, Canrefer, 
(developed in NSW and used to identify specialist hospitals in this thesis) the monitoring of 
the number and specialty of MDTs, the funding of clinical nurse consultants and the 
education sessions provided to clinical staff.  
A number of CanNet pilot projects in NSW aim to improve referral patterns for cancer 
patients in rural areas. However, these projects are in progress and are yet to report. One 
project developed referral pathways between the Northern Sydney, Central Coast, Hunter 
New England and North Coast Area Health Services. 65 The second project commissioned 
by the Cancer Institute NSW as part of phase 2 of the CanNET project is developing primary 
care referral guides.66 Lastly, Cancer Australia has funded a Lung Cancer Demonstration 
Project run by Catalyst and based at Sydney LHD and Lifehouse. 67This project aims to 
document pathways from Orange and Dubbo to RPA and St Vincent’s. Memorandums of 
Understanding (MOU) will be eventually be signed by all participants in this referral 
pathway. 67 
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9.4.6. Cancer care coordination 
Few studies have examined the effectiveness of cancer care coordination (CCC) on patient 
outcomes. A literature search of the term “cancer care coordination” revealed there were 
eight studies, 64, 68-73 of these, three were undertaken in NSW.64, 69, 70 One study evaluated a 
questionnaire 70, another attempted to define cancer care coordination and concluded that 
there was not an agreed definition69 and the last study was a small qualitative study (n=20 
patients and 29 clinicians) that considered barriers.64 Only one study evaluated the timeliness 
of care 68 and this study had its limitations: it was small (n=352); a single health facility and 
a retrospective cohort.  However, after establishment of CCC, the proportion of early stage 
non-small lung cancer patients increased from 32% to 48% (p=0.006).68 No studies have 
evaluated the impact of cancer care coordination on outcome. 
The Cancer Institute NSW funded a number of CCC positions and undertook an evaluation 
of the program in 2011.  In urban areas most cancer care coordinators where tumour specific 
whereas most rural cancer care coordinators were community based and worked across 
multiple tumour streams including palliative care.64 Cancer care coordinators in urban areas  
also  reported seeing more than 80% of tumour specific patients, whereas regional and rural 
coordinators only saw between 20 to 46%.74 The main barriers reported include lack of time, 
lack of administrative and IT support, limited links to metropolitan specialist centres and the 
private sector.  
Most CCCs expressed difficulty in obtaining referrals from surgeons and GPs. An increase 
in GP referrals and CCC had occurred in those who sent letters to the GPs and updated them 
on the progress of their patients. Some of the CCCs had developed proformas to inform GPs 
about the MDT discussions and the patient’s treatment plan. In addition, CCCs in rural areas 
had developed referral pathways to CCCs in metropolitan hospitals.74  
Most patients (88%) believed that CCCc were an essential part of cancer care and those who 
received assistance (86%) from a CCC were satisfied with the communication and 
information provided on their care from the MDT. 74 Patients also reported that they were 
also more likely have their support needs assessed such as transport and be referred to 
psychosocial and other support services.74  
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The Cancer Council, NSW has also recommended in the 2014 budget estimates document 
that additional CCCs,  palliative care physicians and nurses be funded for people in rural 
areas.75 
9.4.7. Cost of transport and out of pocket expenses 
The only proxy that related to cost in this thesis were the studies undertaken on lung cancer 
where factors predictive of advanced and unknown stage, no surgery and survival for 
NSCLC who lived 100km or more from the NASH.  .  
In NSW, patients who have a car and travel over 100 kilometres are partly subsidised and 
can apply for Isolated Patient Transport and Accommodation Scheme (IPTAAS) funding to 
cover transport and accommodation costs. This policy does not include the expense of meals 
and incidentals (road tolls, parking, booking fees) which are not reimbursable and other out 
of pocket items.76  
In a study of out of pocket expenses in Queensland, cancer patients who live more than 
100km from a specialist hospital had five times the out of pocket expenses ($7,752 
compared to $1,481) compared to those that lived less than 100km. Not surprising, out of 
pocket costs increased with distance. 77 Therefore, travel burden and cost may be influencing 
the hospital of treatment. Travel burden, cost and employment status predicted whether 
NSW and Victorian patients travelled and lived away for their cancer treatment. People in 
the paid workforce were half as likely (OR=0.48) to live away for treatment, than those who 
were retired or were pensioners. 78 
Currently there are a number of budget initiatives that the Cancer Council has suggested for 
inclusion in the NSW State budget for 2014/2015 that will have a direct impact on access to 
specialist care for cancer patients.75 Specifically, these included the increase in funding for 
the transport for health program to $11.4 million annually as well as amending the IPTAAS 
scheme to cover travel and accommodation for patients who participate in clinical trials.75 
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9.4.8. Characteristics of rural patients 
In NSW in 2006, the percentage of households with gross weekly income less than $500 per 
week increased with remoteness, while the percentage of households earning at least $2,000 
per week decreased with increasing rurality and remoteness. In major cities, 10.7% of 
households reported gross weekly income of less than $500 compared with 17.7% of outer 
regional and remote households. In contrast, 25.6% of households in major cities reported 
gross weekly income of at least $2,000 compared with only 9.1% of households in outer 
regional and remote areas. 24 
Regional Australians reported substantially lower levels of private health fund membership. 
In 2001, 50.2% of people living in capital cities were covered by private health insurance 
compared with 43.5% living outside capital cities. 79 
In NSW, a significantly higher proportion of adults in 2012 in rural health areas (33 %) than 
urban health areas (11.7 %) experienced difficulties getting access to health care in the past 
12 months with the proportion increasing  since 2002 (24.8% Rural and  9.3% Urban). 24 
Furthermore, people in rural NSW present with more complex medical conditions and 
comorbidities due to stoicism and reluctance to ask for help.80, 81 
A systematic review examined the psychosocial well-being and supportive care needs of 
cancer patients living in urban and rural areas and found that rural patients had higher 
psychosocial morbidity and poorer quality of life.81 Phone based counselling or internet chat 
rooms may overcome barriers to the provision psychosocial help. 81 Most of the studies in 
the review were breast cancer patients with more research recommended in other areas. 
Other barriers included travelling daily and staying away from home. Families reported 
financial, emotional and relationship issues associated with travel. The Australian 
Longitudinal Study of Women’s Health also reported higher hazards of death particularly for 
women with lung cancer and chronic obstructive pulmonary disease, with little or no 
difference in smoking rates.82 
According to Underhill, access may not be the only explanation for rural disparities because 
some patients may choose not to have treatment, but improvement in access is still required. 
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83The new regional cancer centres of excellence will provide MDT, support, educational 
services and mentoring by major metropolitan centres as well as links to smaller more 
remote areas. Coordination of government funded travel and accommodation schemes as 
well as telemedicine is important if this initiative is to work.83 
9.5. Strengths of the studies in this thesis 
Major strengths of the studies in this thesis include factors relating to the design of studies, 
as well as the methods and measures used. Each of these issues in discussed below. 
All studies undertaken in this thesis were population based with very few cases that did not 
link to the APDC.  In addition, inclusion and exclusion criteria were identified and 
explained.  Furthermore, patients with unknown stage at diagnosis were included in the 
analysis of predictors of advanced and unknown stage NSCLC (Chapter 6). Few cancer 
registry studies include patients with unknown stage at diagnosis, because of their concerns 
about data quality or lack of follow up. However, because notification to the registry is 
mandatory in NSW, and registry staff follow up missing or discrepant stage information, 
missing stage is most likely due to a lack of investigation rather than a data quality issue. US 
studies of distance were limited to categories of patients.  
To be consistent with other survival analyses for ovarian cancer patients, unknown stage was 
excluded in this study and a complete analysis undertaken. However, a sensitivity analysis 
was undertaken where the analysis was repeated after imputing unknown stage. Similarly, 
multiple imputation was also undertaken as a sensitivity analysis for predictors of advanced 
and unknown stage (Chapter 7) and lung cancer survival (Chapter 8). 
Cause specific survival estimates in NSW produced similar results to those of the more 
widely accepted relative survival and newly developed net survival method. Modelling of 
cause specific cancer survival was possible after adjustment for a wide range of patient, 
tumour and treatment factors. Most US and UK studies of distance to cancer treatment could 
not measure stage, comorbidity or measure cause specific survival. Those that did measure 
survival used all cause survival instead of cause specific survival because the cause of death 
was not available. 
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This thesis compared existing methods of modelling survival, for example, Cox proportional 
regression modelling with new methods of survival analysis such as stpm2. The inclusion 
of time-varying effects and directly adjusted survival curves to the studies in this thesis is 
novel. The comparison of covariate-adjusted survival curves with unadjusted Kaplan-Meier 
survival curves using the stpm2 method of survival allowed determination of model fit.  
Unique to this thesis is was the measure of straight line distance to hospital of surgical 
treatment (bladder) and distance to specialist care (ovary and lung) which provided a 
measure of access to specialist cancer care. Previous studies of distance in Australia have 
used the Accessibility and Remoteness index of Australia (ARIA) that considers distance to 
generic service centres based on the size of the population only. 
There has been no investigation in Australia previously of distance to specialist care and 
survival outcomes by hospital of treatment and surgery. Selection of specialist hospitals 
occurred from a directory of cancer services reviewed and regularly updated. The studies in 
this thesis also considered Australian and NSW clinical and service guidelines that 
documented management of people with lung and ovarian cancer. 
9.6. Limitations of the studies in this thesis 
There are a number of limitations to the work in this thesis. In particular, no information on 
the impact of costs was available apart from taking account of the IPTAAS for the analysis 
of distance to specialist care for patients with lung cancer. No information was available on 
access to primary care or specialists. However, for the ovarian and lung cancer studies 
undertaken in this thesis a number of comparisons with NSW patterns of care were possible. 
Similar numbers of women were referred to gynaecological oncologists as those who 
presented at specialist hospitals.45 Although, unknown, is whether the specialists were the 
most appropriate or whether patients had a multidisciplinary review. No information on why 
proximity to a hospital influenced choice of hospital, although distance to a specialist 
hospital, as well as care from a specialist doctor, were found to be issues with lung cancer 
patients.84 
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We had no information on whether patients received chemotherapy or radiotherapy as these 
services are provided in outpatient cancer care centres and we did not have access to this 
data. However, other studies have shown that, like surgery, there is lower use of 
radiotherapy,11 85, 86 chemotherapy28 85 and combined treatment85 with increasing distance to 
specialist treatment with greater access in specialist hospitals.28 11 
Not investigated, in this thesis, was the competing risk method of survival analysis. More 
recently, a number of studies have suggested that competing risks analyses87 may be an 
alternative to the cause specific hazard analysis combined with the cumulative incidence 
function88 (the probability of failure from a particular cause). However, one study compared 
the “cause specific” failure rate, the “relative” failure rate, and the cumulative incidence in 
the presence of competing risks at five years for the same dataset of colorectal cancer 
patients and found identical failure rates regardless of the method used.89 Therefore, a 
similar result would have most been likely in the studies in this thesis. 
9.7. Key implications of the research for future research 
People who live in rural and remote areas of NSW will continue to need to travel to 
specialist surgical care for cancers of the bladder, ovary and lung, which is appropriate if 
they are to receive the best care. The physical size and population of NSW does not support 
specialist centres in rural areas. Therefore, the studies in this thesis support the literature that 
access to appropriate staging, multidisciplinary review, and surgical treatment by specialists 
in specialist centres will result in the best survival outcomes for everyone regardless of 
where they live. 
The main implication for bladder cancer patients in NSW is an urgent need to consolidate 
urological surgical services. The reduction in the hazard of death with increasing distance 
for patients undergoing cystectomy suggests that bladder cancer patients were attending 
specialist hospitals. Only one study, (US linked Surveillance Epidemiology and End Results 
(SEER) and Medicare data) has examined increasing distance to specialist care for bladder 
cancer patients who had a cystectomy. 90 Longer distance to an available surgeon resulted in 
a decreased odds of having surgery and overall survival was higher for those who had a 
cystectomy compared to those who did not. Currently, 27 hospitals in NSW provide 
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urological surgery. Treatment is recommended in a smaller number of specialised centres.91 
Organised referral pathways, MDT review and CCC involvement would also be of benefit to 
rural patients. The poorer survival from bladder cancer in women remains largely 
unexplained. That a history of cystitis in women diagnosed with bladder cancer and treated 
by cystectomy may contribute to this poorer outcome merits further investigation. 
Considerable debate exists as to whether the histological subtype of ovarian cancer or the 
extensive surgical removal of all residual tumour most influences ovarian cancer survival.6 
The reality is that extensive surgical debulking is the only factor within the surgeon’s 
control. Therefore, the significant survival advantage of attending a specialist GOS hospital 
is demonstrated in this thesis as providing women with the best chance of survival.  
Provision of specialist care to all women diagnosed with ovarian cancer is essential 
regardless of where they live. To achieve timely diagnosis and surgery for women who live 
more remotely, development of strategies for each barrier is required. Documented barriers 
for women suspected of ovarian cancer include recognising symptoms and the influence of 
the type of presenting symptom on GP referral patterns. 
According to the Australian ovarian cancer patterns of care study 60 per cent of Australian 
women were eventually referred to a gynaecologist or gynaecological oncologist.45 
Unknown is whether gynaecologists on-refer patients to gynaecological oncologists. The 
only prognostic factor that a surgeon can alter for women with ovarian cancer is the amount 
of residual disease that remains after surgery. Cytoreductive surgery to less than 1.0 cm of 
residual disease undertaken by gynaecological oncologists has been shown to confer a 
greater survival advantage in a number of single institution studies than cytoreductive 
surgery with more than 1.0cm of residual disease.6    It was clear from the study in this thesis 
that surgery and treatment in either a public or private gynaecological oncology centre 
confers a considerable survival advantage. Therefore ensuring that women themselves are 
aware of this finding is necessary. Most recently, Cancer Australia have published 
information for women called “Five things you should know about ovarian cancer.” The 
fourth thing and the most important piece of information for women is that they should be 
referred to a gynaecological oncologist to obtain the best surgical outcomes.92  
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The main implications for lung cancer patients who live further from specialist centres is to 
develop strategies to encourage presentation at an early stage to increase the likelihood of 
surgery in specialist centres. In the last few years in Australia and NSW a number of 
initiatives and strategies have been developed that should increase community and GP 
awareness of lung cancer. The recent Cancer Australia guidelines for general practitioners 
were developed to assist GPs detect symptoms of lung cancer and to provide them with 
information on appropriate referral. 35 The Cancer Institute NSW has also developed 
treatment algorithms for the management of lung cancer that are stage specific. 93 The most 
important pre-treatment assessment is to confirm the stage, assess the patient’s fitness for 
treatment by undertaking a multidisciplinary team (MDT) assessment (that includes at least 
a surgeon and a respiratory physician) and stabilise other conditions first. Recommended is a 
clinical cancer care coordinator or lung cancer nurse to ensure that a treatment plan and 
access to surgery is organised and communicated. In addition, a video translated into a 
number of different languages provides people with practical advice on symptoms. 94 There 
is enough evidence for all these suggestions, with MDT review found to be an independent 
predictor of cancer survival.21, 95 
It is noteworthy that the proportion of NSCLC patients undergoing lung cancer surgery in 
Australian cancer registry studies is similar with 20% reported in WA in 1996,96 and 21% in 
2007,97 19.1% in Victoria,21 and 20% in 1996 and 19% in 2002 in NSW.17 However, this 
proportion varies between regions, 17% to 26% in NSW,18 when three areas are compared 
and as this thesis has found depends on whether the patient lived in proximity to a specialist 
hospital. Therefore, the challenge is to ensure that everyone has the same opportunities. 
Compared to SEER data for the same region more localised stage and better survival 
occurred after implementing a community-based lung cancer program. This program 
included weekly MDT meetings, nurse coordinators, thoracic surgeons skilled in VATs 
surgery, treatment guidelines and CT screening of former smokers. Cancer survival in the 
community based program increased steadily from 15% in 1983 to 30% in 2006.95 
Therefore, monitoring the proportion of people diagnosed with early stage lung cancer 
should increase the proportion of patients who have potentially curative surgery. 
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9.8. Recommendations for changes in clinical practice 
The NSW Surgical Services Taskforce developed a strategic plan for surgery in Greater 
Sydney91 and for Rural Surgery for the period 2011-2021. 98 The emphasis of these plans is 
the development of concentration of surgical centres particularly for cardiothoracic, 
gynaeconcology and urology. The plan recommends consolidation of existing specialist 
cardiothoracic surgical units to fewer units than currently available. Recommendations for 
gynaecological surgery include reducing the number of specialist centres to ensure that an 
experienced MDT supports all women. 
Co-located, high volume, comprehensive services with experienced staff with the intent of 
improving clinical outcomes for patients is the vision articulated in the most recent NSW 
Surgery Futures plan for Greater Sydney. 91 Comprehensive services include a full range of 
surgery, oncology, radiotherapy, specialised nursing and allied health.  Currently, the Cancer 
Institute NSW is reviewing surgical procedures and outcomes for the upper Gastro Intestinal 
(GI) cancers (pancreatectomy and oesophagectomy ) to ensure that only specific centres can 
perform these procedures.99, 100  
However, for other types of cancer it is said that “further planning for cancer surgery needs 
to be undertaken with the Cancer Institute and the Cancer plan before these changes can be 
fully implemented.” 91 
The Rural Surgery Futures plan has identified a number of key recommendations. The first 
recommendation suggested networking of small hospitals around a major regional or base 
hospital and improved access to specialist clinics in specialist hospitals. Rural clinicians 
have expressed concern that timely access to specialist clinics in specialist hospitals is only 
possible when a surgical specialist provides outreach to the local town. 98, 101 
Another recommendation is to link long-term clinical service plans in rural areas to capital 
works programs. Rural clinicians are often uncertain about the long term future of their 
service or hospital. Other barriers include the difficulty in attracting and retaining 
experienced clinical staff, the shortage of GP proceduralists, and the lack of access to 
ongoing education and training for perioperative nursing, the deficiencies in succession 
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planning and the lack of support from specialist hospitals. 53 Credentialing or the formal 
process of ensuring clinical staff have the relevant training and experience could be more 
efficient. Currently, there are separate processes required between towns and clinical 
services. Identified as a barrier to diagnosis was the limited access to new technologies, 
radiology and pathology services. The majority of pathology service providers in rural areas 
were from the private sector. Rural health staff were concerned about the cost to patients and 
the variable quality of providers. 53  Furthermore, a number of rural hospitals did not have 
access to cytology or frozen sections, which is obviously essential, for pathological 
investigation and diagnosis of a suspected tumour. Lack of access to histopathology may 
explain the increased likelihood of unstaged NSCLC with increasing distance from the 
NASH. 
Furthermore, a survey of NSW staff working in rural areas reported that 43% did not have 
access to the system to plan surgery, which may explain the high proportion of emergency 
admissions for people with NSCLC. Most identified that advanced imaging and 
interventional radiology to assist with diagnosis were the most important future investments 
in rural areas. 98, 101 
Recommended also is the development of Australian clinical practice guidelines for bladder 
cancer and the consolidation of urological services into specialist centres. The 55 per cent 
greater hazard of death from bladder cancer in women who had a history of cystitis needs to 
be investigated further using clinical trial data. 
Regardless of distance to a specialist hospital, referral of all women suspected of ovarian 
cancer should occur to enable surgical treatment by a gynaecological oncologist in a 
specialist hospital so that MDT review is available. Clearly, if appropriate referral to 
specialist hospitals was occurring, then the proportion of patients would not vary by distance 
to specialist care. Further understanding of other patient factors apart from cost78 is required 
to determine why some patients decide not to travel to specialist care. 
Clinicians need to refer and patients need to be encouraged to attend specialist thoracic 
hospitals to ensure that appropriate staging and treatment options are available to all lung 
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cancer patients regardless of where they live. Importantly, all patients regardless of where 
they live should be treated in accordance with the recently updated National Health and 
Medical Research Council (NHMRC) lung and ovarian cancer guidelines. 
Outlined in the National Strategic Framework for Rural and Remote Health were systemic 
issues that require attention to improve health outcomes for rural and remote Australians. 
Issues identified include access, appropriate models of care, sustainable workforce, 
development of collaborative partnerships and strong leadership and performance.65, 102  
In the 2009/2010 Australian Federal budget 560 million dollars103 was provided to build ten 
regional cancer centres. The new or enhanced services ranged from radiotherapy bunkers, 
linear accelerators, Computer Assisted Topography (CAT), MRI and Positive Emission 
Topography (PET) scanners. Funded also is much needed additional patient accommodation 
in three NSW regional cancer centres.104 These centres are in the process of being built and 
will provide much needed diagnostic services and will improve the provision of 
chemotherapy and radiotherapy locally. However, surgery in specialist centres will continue 
to be a requirement for most cancer patients. Therefore, it is important that people who live 
more remotely have equal access to specialist surgical care. 
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